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Abstract  
Inkjet printing is a technology that is witnessing many applications across 
numerous areas of research. This technology is adopted here to address some 
challenges in medicine and pharmaceutical science. A thermal inkjet (HP 
5940) was modified and used for this work; the robustness of the modified 
printer was confirmed afterwards. With printing of bacteria as a theme in this 
thesis, an initial assessment of the effect of ink jetting on the viability of 
bacterial cells was conducted and the damage was found to be negligible. 
 An analytical application of ink jetting in antimicrobial susceptibility testing was 
conducted. A model was developed whereby varying antibiotic concentrations 
were printed onto agar-coated glass slides; a fixed bacterial population was 
then printed onto the varying antibiotic concentrations. The concentration of 
printed antibiotic exhibiting no bacterial growth after incubation was then 
computed based on an initial cartridge characterisation using HPLC. Minimum 
inhibitory concentrations obtained for antibiotics tested, using the designed 
model, when compared with standard broth microdilution technique were 
within an acceptable range, i.e., one doubling dilution apart. 
The inkjet printing technology was also applied in formulating probiotics. 
Probiotics for site-specific delivery into the lower small intestines or colon were 
formulated by printing the probiotic strain (Lactobacillus acidophilus LA 5) onto 
edible starch paper and encapsulating organisms in PhloralÒ pre-coated 
capsules to protect organisms from the harshness of stomach fluids. The 
encapsulated formulation exhibited over 40% recovery at sites of interest with 
78.3% of the administered strain adhering to intestinal cells. The formulation 
was able to eliminate completely a population of E. coli when co-incubated. 
The potential of ink jetting in formulating probiotic oro-dispersible films (ODFs) 
was also explored. ODFs containing Streptococcus salivarius and xylitol were 
prepared and the benefits in managing dental caries were assessed. The 
probiotic ODFs reduced Streptococcus mutans numbers by 2.86 log cycles.  
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Impact Statement 
The use of inkjets despite the increasing interest has generally involved 
piezoelectric inkjets mainly because of the perceived effect of the high 
temperature accompanying droplet formation in thermal inkjets. This work, 
therefore, utilised a thermal inkjet and demonstrated the negligible effect of the 
process of bubble formation using live cells. It is intended this will dispel such 
doubts and increase the use of thermal inkjets in research.  
Antimicrobial resistance (AMR) is a major public health issue currently; testing 
the efficacy of antibiotic therapies against infections is one of the ways of 
addressing this, i.e., via antimicrobial susceptibility testing (AST). Manual 
determinations of AST are accompanied by a heavy workload, automated 
determinations are also limited by the expensive nature of the equipment. 
Considering the global nature of AMR, it is important that such tests could be 
conducted anywhere without cost being a problem. An inexpensive model for 
AST using inkjets was developed here to address the heavy workload of 
manual determinations and the cost element of automated determinations. 
A major challenge with current probiotic formulations is the loss of viability of 
products upon storage. This has resulted in most commercial products having 
reduced numbers when assessed. With inkjets proved as useful tools for 
personalising medicines, the concept was adapted in formulating probiotics.  
An on-demand method of formulating probiotics for targeted delivery to 
intestines and locally in the mouth was demonstrated in this thesis; this will 
eliminate the need for long-term storage of probiotics. The ease of 
manufacture will also aid further research into probiotic science and help verify 
some of the health claims attributed to probiotics. 
With lots of research into the gut microbiota and its role in disease prevention, 
mapping the presence or absence of certain organisms to diseases will be 
possible soon. At such a time, this model of printing probiotics would have 
progressed and be useful in formulating tailored probiotics at the point of care.  
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Chapter 1 General Introduction 
1.1 Gut Microbiota 
Microbes colonise all the surfaces of the human body that are exposed to the 
environment. The gastrointestinal tract (GIT) represents the largest surface 
area exposed to the external environment and contains most of these microbes 
(Unger et al., 2015, Clemente et al., 2012). The intestinal microbiota (i.e., 
microorganisms living in a particular environment) is composed of a complex, 
dense, and diverse bacterial community of several species with bacterial 
numbers as high as 1014 cells and an approximate weight over 1 kg (Nicholson 
et al., 2005, Chassard and Lacroix, 2013, Scott et al., 2008). The entire length 
of the GIT is colonised by bacteria, which increase in number, complexity and 
diversity down the tract with the colon being the most diverse part (Power et 
al., 2014). It has been reported that there are ten times more bacterial cells 
than human cells and 150 times more bacterial genes than the human genome 
in the human body (Unger et al., 2015). The microbiota plays a major role in 
gut health and the general well-being of humans such that it has occasionally 
been referred to as “the forgotten organ” or “the neglected organ” (Scott et al., 
2008, Clarke et al., 2014, O'Hara and Shanahan, 2006). It is of such 
importance that large-scale projects like the US Human Microbiome Project 
and the European Metagenomics of the Human Intestinal Tract have been 
initiated to characterise the human microbiota and understand the symbiotic 
relationship between microbes and their host (Human Microbiome Project, 
2012, Qin et al., 2010, Lozupone et al., 2012). 
The GIT is a muscular tube that runs from the mouth to the anus and is 
composed of four main specialised regions; the oesophagus, stomach, small 
intestine, and large intestine (Figure 1-1). The GIT is approximately 6 m in 
length with a varying diameter along this length. The oesophagus, the first 
specialised region, acts as a channel to move materials into the stomach and 
has a pH between 5 and 6. The stomach serves as a temporary storage for 
ingested materials and reduces materials into a uniform consistency. The 
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stomach has a pH between 1 and 3, mainly due to hydrochloric acid secretion. 
Other secretions into the stomach include pepsin and gastrin. The small 
intestine, the longest section of the GIT, consists the duodenum and ileum. 
The small intestine receives Brunner’s glands, biliary, and pancreatic 
secretions with bicarbonate which neutralises the acidic outflow of the stomach 
resulting in a pH between 5 and 7.5. The small intestine completes digestion 
and is highly specialised for absorption with a surface area of 200 m2.  The 
large intestine is important for water and electrolyte exchange as well as 
storage and compaction of faeces and has a pH between 6 and 7.5 (Betton, 
2013, Iannitti and Palmieri, 2010, Jandhyala et al., 2015, Ashford, 2013).  
 
Figure 1-1: Anatomy of the gastrointestinal tract showing various parts and organs (adapted 
from Iannitti and Palmieri, 2010). 
 
 
   22 
1.1.1 Composition of the gut microbiota 
The composition of the intestinal microbiota is very diverse. Some argue that 
the intestines are colonised at birth whilst others claim colonisation of the 
intestines starts in-utero since microorganisms have been isolated from 
meconium (the earliest infant faeces) (Fuller, 1989, Jimenez et al., 2008, 
Nicholson et al., 2012, Clemente et al., 2012). The infant microbiota is more 
variable day-to-day in its composition and is less stable over time compared 
with that of the adult (Unger et al., 2015). Colonisation continues until around 
2 - 3 years of age when the gut microbial communities have developed a 
richness and diversity that is characteristic of a healthy adult gut (Derrien and 
van Hylckama Vlieg, 2015).  The earliest gut colonisers are either aerobes or 
facultative anaerobes e.g., enterococci (Enterococcus faecalis) and 
enterobacteria (Escherichia coli), and then strict anaerobes mainly 
bifidobacteria as well as clostridia and bacteroides. These arise as a result of 
eventual oxygen depletion in the gut, with the bifidobacteria population 
occurring mainly due to breastfeeding (Isolauri, 2012, Walsh et al., 2014). 
Bacteria in the gut can be grouped according to their degree of pathogenicity 
as beneficial, potentially pathogenic (opportunists), and pathogenic. The 
beneficial organisms (e.g., lactobacilli and bifidobacteria) help maintain the gut 
health and overall human well-being whereas the pathogenic organisms (e.g. 
clostridia and klebsiella) result in infections and inflammation. The potentially 
beneficial organisms (e.g., Escherichia coli, streptococci) are part of the 
normal flora of the gut, however, these become pathogenic once their numbers 
become high (Westerbeek et al., 2006). More than 1,000 bacterial species 
have been identified in the adult gut with the most abundant species in the 
healthy gut being members of the phyla Firmicutes and Bacteroidetes (Walsh 
et al., 2014, Unger et al., 2015). The Firmicutes are the largest bacterial 
phylum in the gut with more than 200 genera, including Lactobacillus, 
Mycoplasma, Bacillus, and Clostridium; the Bacteroidetes, the second most 
dominant has about 20 genera including Bacteroides as shown in Table 1-1.  
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Table 1-1: An illustration of the dominant genera at different regions in the gastrointestinal 
tract (adapted from Tappenden and Deutsch, 2007).  
Region Dominant Genera/ Species 
 
Stomach Candida albicans  
Helicobacter pylori 
Streptococcus spp. 
Lactobacillus spp. 
Duodenum Candida albicans 
Streptococcus spp. 
Lactobacillus spp. 
Bacteroides spp. 
Jejunum Bacteroides spp. 
Candida albicans 
Lactobacillus spp. 
Streptococcus spp. 
Ileum Bacteroides spp. 
Clostridium spp. 
Lactobacillus spp. 
Veillonella spp. 
Enterococcus spp. 
Enterobacteriacae 
  
   24 
Region Dominant Genera/ Species 
 
Colon Bacteroides spp. 
Peptostreptococcus spp. 
Bacillus spp. 
Clostridium spp. 
Enterococcus spp. 
Bifidobacterium spp. 
Fusobacterium spp. 
Eubacterium spp. 
Streptococcus spp. 
Ruminococcus spp. 
Microbial load varies along the GIT (Figure 1-2), with about 105 – 108 cells per 
gram in the mouth, 101 – 103 cells per gram in the stomach and duodenum, 
and 104 – 107 cells per gram in the jejunum and ileum. Most of the organisms 
in the intestinal microbiota are in the large intestine with bacterial numbers as 
high as 1011 – 1012 cells per gram in the colon. More than 70% of all the 
microbes found in the body and gut are in the large intestine (Schippa and 
Conte, 2014, Jandhyala et al., 2015, Derrien and van Hylckama Vlieg, 2015, 
Power et al., 2014, Tappenden and Deutsch, 2007, Vrieze et al., 2010). 
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Figure 1-2: An illustration of the bacterial load in the gastrointestinal tract (adapted from 
O'Hara and Shanahan, 2006). 
 
1.1.2 Factors affecting gut microbiota composition 
The composition of the microbiota despite its diversity and complexity is 
influenced by many factors. These factors affect either the early colonisation 
of the gut or modify the already colonised gut. 
The mode of childbirth is the first factor that affects the gut microbiota. It is 
known that babies delivered vaginally and via caesarean section have 
variations in the type of bacteria that colonise their gut. Babies delivered 
through the vagina are exposed to vaginal and faecal bacteria of maternal 
origin, mainly lactobacilli, prevotella, and atopobium. Infants born by 
caesarean section have an initial exposure to environmental bacteria from 
equipment, air, other infants, and nursing staff with staphylococci being a 
dominant early member (Nicholson et al., 2012, Fallani et al., 2010). 
The type of diet one eats also affects the microbiota composition.  Diet 
provides nutrients for both the host and bacteria in the GIT (Power et al., 2014). 
In infants, the intestinal microbiota is mainly bifidobacteria when they are fed 
on breastmilk whereas, the microbiota is more diverse with bifidobacteria, in 
addition to bacteroides, clostridia, enterobacteria, and streptococci when they 
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are fed on formula food. This, however, does not imply that formula food is a 
better alternative since breast milk also contains several bioactive compounds 
that are not available in formula feeds. Breastmilk also has the advantage of 
meeting the nutritional and physiological demands of the infant. Breastmilk 
contains antimicrobial components and growth factors that stimulate the 
development and maturation of the intestinal mucosa (Jandhyala et al., 2015, 
Westerbeek et al., 2006, Iannitti and Palmieri, 2010). In adults, diet can have 
a significant impact on the gut environment such as influencing gut transit time 
and pH. Also, the intake of carbohydrates, fats, and proteins has a direct 
impact on gut microbiota (Scott et al., 2013). Intake of a diet rich in fruits, 
vegetables, and fibres is claimed to result in a higher richness and diversity of 
the gut microbiota (Jandhyala et al., 2015). 
Antibiotics, especially broad-spectrum antibiotics, although intended for their 
bactericidal and bacteriostatic activity against pathogens, usually have effects 
on the gut microbiota (Modi et al., 2014, Jandhyala et al., 2015). Antibiotic 
treatment leads to a reduction in the diversity of the gut ecology (Jandhyala et 
al., 2015). Some bacterial communities are quite resilient and can revert to a 
pre-treatment state within weeks after withdrawal. Other alterations, however, 
persist for a long period following the withdrawal of the treatment; some 
members of the microbial community fail to return or take several months to 
return to pre-treatment levels whilst others may even be lost from the 
community indefinitely (Power et al., 2014, Jandhyala et al., 2015). In these 
instances, there is reduced resistance to colonisation resulting often in the 
dominance of foreign microbes that can out-populate commensal and 
symbiotic bacteria eventually leading to changes in microbiota and diseased 
states (Clemente et al., 2012, Modi et al., 2014). 
Other factors such as the age of gestation and geography, indirectly affect the 
bacterial community as well. It is not known whether prematurity itself affects 
the bacterial population, however, most preterm babies have an immature 
immune system and are vulnerable to several opportunistic infections. These 
infections generally require antibiotic treatments and could result in changes 
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in the microbiota (Westerbeek et al., 2006). Also, individuals in different 
geographical locations have different feeding habits and lifestyles. For 
instance, lower breastfeeding rates and early weaning are reported in Scotland 
as compared to Scandinavian countries (Fallani et al., 2010). Western diets 
have also been reported to be high in fat and simple carbohydrates as 
compared to African diets that are low in fat and high in complex 
carbohydrates, and these result in variations in intestinal microbiota 
geographically (Magnusson et al., 2015, de Filippo et al., 2010). 
 
1.1.3 Role of gut microbiota 
The role of the gut microbiota can be broadly categorised under three main 
headings: metabolic, protective, and structural functions. 
The metabolic capacity of the gut microbiota is one that is highly recognised 
and reported to have an activity similar to the liver (Scheline, 1973). The 
metabolic activities include the breakdown of non-digestible dietary residue to 
generate short chain fatty acids – which are sources of energy – in the process 
(Janssen and Kersten, 2015).  Gut microbiota have even been reported to play 
a role in the metabolism of drugs. Olsalazine, a medication for treating 
inflammatory bowel disease, has been broken down into two molecules of the 
locally effective 5-aminosalicylic acid in animal models by gut bacteria (Knoll 
et al., 2012). Loperamide oxide has also been metabolised by gut bacteria to 
loperamide  (an antidiarrheal) in animal models (Lavrijsen et al., 1995). The 
synthesis of some vitamins (K and B) has been attributed to gut microbiota as 
well (Hill, 1997, Tappenden and Deutsch, 2007). The gut microbiota, 
especially, in the colon has been of interest for some time as a site for drug 
delivery. The ability of these organisms to metabolise carbohydrates is taken 
advantage of by drug delivery systems like COLAL-PREDÒ – made with 
ethylcellulose and a specific form of amylose – to deliver prednisolone to the 
colon. Non-drug specific techniques like Phloral® (made with starch and 
Eudragit S) are also known (Shukla and Tiwari, 2012, Ibekwe et al., 2008). 
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Gut microbiota exhibit protective functions through the release of antimicrobial 
materials known as bacteriocins; these are proteinaceous molecules that are 
synthesised and can interfere with the growth of most pathogenic bacteria 
(O'Hara and Shanahan, 2006). These have bactericidal action and are 
selective for prokaryotes. Gut microbiota also compete with pathogens for 
nutrients and attachment sites resulting in pathogen displacement. Beneficial 
gut organisms, especially the lactic acid bacteria, are known to utilise both 
carbohydrate and protein sources for energy production and in effect reduce 
nutrients available for other potentially harmful organisms in the gut (Isolauri, 
2012, Pessione, 2012, Tappenden and Deutsch, 2007, O'Hara and Shanahan, 
2006). 
The structural function of the gut microbiota is exhibited through barrier 
fortification and apical tightening of tight junctions. Short chain fatty acids, from 
the metabolic activities of intestinal microbiota, have been noted to have a role 
in regulating cell proliferation and apoptosis (Bartholome et al., 2004). The 
commensal microbiota appears to be very important in maintaining intestinal 
cell proliferation, differentiation, and function which are necessary for 
maintaining critical structural attributes. The gut microbiota is also involved in 
the degradation of mucus glycoproteins produced by the epithelium (Falk et 
al., 1998, O'Hara and Shanahan, 2006, Tappenden and Deutsch, 2007).  
 
1.1.4 Dysbiosis and restoration 
A healthy microbiota is one in which there is a balanced composition of 
symbionts (organisms with known health-promoting functions), commensals 
(permanent residents which provide no benefit or detriment to the host), and 
pathobionts (permanent residents of the microbiota with the potential to induce 
pathology) (Round and Mazmanian, 2009). Dysbiosis is a condition in which 
there is a deregulation of the normal homeostasis of the intestinal microbiota 
usually with a reduction in the number of symbionts or an increase in the 
number of pathobionts (Figure 1-3). This is often involved in the pathogenesis 
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of various diseases and characterised by a decrease in bacterial diversity 
(Louis et al., 2014, Suvorov, 2013). Dysbiosis usually results in a lack of 
immune regulation and breakdown in tolerance to commensal microorganisms 
(Ferreira et al., 2014). Dysbiosis has been linked with important human 
diseases like autoimmune and auto-inflammatory disorders (e.g., allergies), 
obesity, inflammatory bowel disease, gastric ulcers, and colon cancer. The list 
of diseases associated with dysbiosis keeps increasing even though the 
pathogenesis of most of these diseases is not clearly understood (Nicholson 
et al., 2012, Schippa and Conte, 2014). 
A few approaches have been suggested for replenishing the gut microbiota 
after dysbiosis, one such method is faecal microbial transplant. This involves 
introducing faecal bacterial communities from a healthy individual to a recipient 
whose microbiota has been disrupted or altered (Walsh et al., 2014). It has 
advantages as providing the full spectrum of microbial organisms from a 
healthy individual. 
 
 
Figure 1-3: Illustration of a healthy gut microbiota showing (a) a balance between symbionts, 
commensals, and pathobionts and (b) when there is a shift in this system, i.e., dysbiosis 
(adapted from Round and Mazmanian, 2009). 
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Challenges with this approach include the introduction of any resistant strains 
that are present in the donor to the recipient. This approach also appears 
slightly unattractive to most patients as the mode of delivery could be either 
oral consumption, nasogastric intubation into stomach or intestine, or the use 
of enemas into the colon (de Vos, 2013, Borody et al., 2014). Another 
approach is the introduction of non-digestible food ingredients into the gut e.g. 
inulin, polydextrose, lactulose, and maltodextrins. These are known as 
prebiotics and they beneficially affect the host by selectively stimulating the 
growth and/or the activation of one or a limited number of health-promoting 
bacteria in the intestinal tract (Collins et al., 1998, Oliveira et al., 2009, 
Marzorati et al., 2010). The introduction of probiotics, which are live 
microorganisms that when administered in adequate amounts confer a health 
benefit on the host, is another approach and elaborated further in the next 
section (FAO/WHO, 2002). 
 
1.2 Probiotics  
The concept of probiotics emerged from the early 20th century when the 
Russian immunologist Elie Metchnikoff observed that Bulgarian peasant 
farmers had long life-spans. He suggested this was due to the consumption of 
large quantities of fermented milk rich in lactobacillus (Dixon, 2002). 
Metchnikoff suggested that pathogens present in the intestine released toxins 
which were poisonous to the body and the consumption of fermented milk 
helped alleviate the effects of these pathogens and their toxins (Fuller, 1991, 
Vasiljevic and Shah, 2008). With progress in the field, better understanding of 
the concept has been gained; this can be observed in the modification in the 
definition of probiotic over the years. In the mid-twentieth century, it was 
suggested that microbial imbalance arising due to antibiotics could be restored 
by a probiotic-rich diet (Vergin, 1954). This partly led to the probiotics being 
referred to as the opposite of antibiotics. The origin of both words; probiotics 
meaning ‘for life’ and antibiotics, ‘against life’ in Greek also contributed to this 
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inference  (Hamilton-Miller et al., 2007a, Reid et al., 2003). The definition was 
modified in the 1960’s to substances secreted by one organism which 
stimulate the growth of another (Lilly and Stillwell, 1965). Probiotics were later 
defined as organisms and substances that contribute to intestinal microbial 
balance (Parker, 1974).  
One common trend in most of the earlier definitions of probiotics was the fact 
that little attention was placed on the ‘live’ nature of the cells. However, with 
further understanding in the field, definitions proposed in the late 1980’s and 
beyond accorded emphasis to the state of the cells. Fuller (1989), defined 
probiotics as live microbial feed supplements which beneficially affect the host 
animal by improving its intestinal microbial balance. Salminen also defined 
probiotics as live microbial culture or cultured dairy products which beneficially 
influence the health and nutrition of the host (Salminen, 1996).  Following 
heightened interest in probiotics, a joint committee made up of the Food and 
Agriculture Organisation of the United Nations and the World Health 
Organisation suggested the definition of probiotics as live microorganisms that 
when administered in adequate amounts confer a health benefit on the host 
(FAO/WHO, 2002). This definition was also recommended by the International 
Scientific Association for Probiotics and Prebiotics (Rijkers et al., 2011). 
Probiotics are composed of organisms mainly from the genera Lactobacillus 
and Bifidobacterium. L. acidophilus is reported to be the first identified probiotic 
species (Anusha et al., 2015). Other genera like Streptococcus and 
Enterococcus and some yeasts (particularly Saccharomyces boulardii) have 
also been documented as probiotics. Lactobacilli and Bifidobacteria are, 
however, dominant because of their ‘generally recognised as safe’ (GRAS) 
status (Shah, 2007, Fuller, 1991).  
Not every microorganism can be considered as a probiotic, though research 
into probiotics is still relatively rudimentary, certain criteria have been reported. 
A key and very important requirement for an organism to be considered a 
probiotic is that it must be an organism known to be safe, i.e., have a GRAS 
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status. Pathogenic organisms do not meet this requirement, hence, cannot be 
considered as candidates for probiotics (Collins et al., 1998). 
The organism must be a normal inhabitant of the intestine. Since most 
probiotics exert their effect in the GIT, it is prudent to consider only organisms 
that are known to be normal inhabitants of the intestine as candidates for 
probiotics intended for delivery into the intestine. Such probiotics exert their 
effects by attaching to and colonising the intestine (Vasiljevic and Shah, 2008). 
For an organism to be considered as a probiotic, it must have been 
documented to have a health benefit. It is important to clarify that although 
some live viruses have been used in vaccines and are known to have health 
benefits they are not considered as probiotics. Vaccines with viruses as active 
ingredients are classified as drugs and not probiotics (Sanders, 2009). Health 
claims attributed to probiotics are also strain specific, hence, the selection 
should not be based only on the species as there are instances that the desired 
effects of probiotics are not shared by all strains within that particular species 
(Douglas and Sanders, 2008).  
There are no hard and fast rules about the minimum number of cells needed 
in probiotic formulations. This is mainly because different cells have different 
properties in terms of colonisation of the gut; probiotics are also efficient at 
different concentrations (Sanders, 2009). Minimum numbers of 106 CFU/g, 107 
CFU/g, and 108 CFU/g have all been recommended to be present at the point 
of consumption. The FAO/WHO, however, recommends that the minimum 
viable numbers of each probiotic strain in a product at the end of the product’s 
shelf-life should be indicated on the product label (Shah, 2007, Krishnakumar 
and Gordon, 2001, Douglas and Sanders, 2008, FAO/WHO, 2002). 
A few terms have been associated with probiotics. Probiotics that have been 
formulated in combination with prebiotics, are known as synbiotics. Others use 
pharmabiotics, to refer to formulations containing microorganisms with positive 
health effects (Shah, 2007, Broeckx et al., 2016). Probiotic formulations have 
also been referred to as neutraceuticals, i.e., dietary substances that deliver a 
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concentrated form of a bioactive substance in quantities that exceed what can 
be obtained from food (Cook et al., 2012, Govender et al., 2014). 
 
1.2.1 Clinical uses  
The probiotic market and the science supporting probiotics is one that is rapidly 
expanding; the increasing health benefits attributed to probiotics is a major 
contributing factor (Sanders, 2009). Probiotic products can be broadly 
subdivided under foods and dietary supplements based on the carriers. 
Probiotics delivered as foods are predominantly delivered as yoghurts. The 
probiotics market has expanded to an extent that other vehicles as smoothies, 
cheese, chocolates, cereals, and infant formulae have been used (Vasiljevic 
and Shah, 2008, Sanders et al., 2007). Probiotics packaged as dietary 
supplements, which is the focus of this work are usually packaged as tablets, 
capsules, dried powders in sachets or as liquid formulations in bottles (Iannitti 
and Palmieri, 2010).  
The recent increased interest in probiotics also stems from the greater 
awareness of the human microbiome and its potential applications. Also, an 
increased realisation of the need for alternatives for antibiotics has contributed 
to this. Antibiotics have been around for over 50 years, yet, hospital infection 
rates are not declining and multi-drug resistant bacteria continue to emerge 
creating a major public health problem as a result  (Broeckx et al., 2016, 
Teughels et al., 2011). There is accumulating clinical data supporting the role 
of probiotics in human health. Some of the health claims attributed to probiotics 
are highlighted briefly below. 
The prevention of antibiotic-associated diarrhoea is one of the main proposals 
for the use of probiotics. It has been suggested that antibiotic therapy usually 
results in the elimination of beneficial gut bacteria and the dominance of other 
indigenous non-beneficial microbes especially, Clostridium difficile. These 
microbes and the toxins they release usually lead to diarrhoea and other 
complications. The consumption of probiotics has been proposed to help 
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stabilise the numbers of these beneficial microbes especially when taken 
concurrently with antibiotic treatment and continued for a period after the 
treatment (Tung et al., 2009, Vasiljevic and Shah, 2008). 
Probiotics have also been suggested as a remedy for lactose intolerance. 
Lactose intolerance occurs when lactose is not hydrolysed into glucose and 
galactose by the enzyme lactase. These enzymes are usually present in 
breast-fed infants, however, after weaning, the enzyme disappears making 
hydrolysis of lactose – mainly from consumption of milk and other dairy 
products – an issue. Symptoms of lactose intolerance include bloating, 
flatulence, nausea, abdominal pain, and diarrhoea (Vasiljevic and Shah, 2008, 
Fuller, 1991). The rate of lactose transit into the large intestine is known to 
have an effect on lactose intolerance; lactose metabolism by lactobacillus 
strains have also been shown to alleviate lactose malabsorption (Gismondo et 
al., 1999). 
Inflammatory bowel disease (IBD) is a complex condition with unknown 
aetiology although environmental, immunologic, and genetic factors have been 
suggested to have a role (Dotan and Rachmilewitz, 2005, Bai and Ouyang, 
2006). The terminal ileum and colon of the gut which have the most abundant 
flora are the sites where IBD usually occurs. The location of the condition in 
addition to the fact that antibiotic therapy can be used in treatment has led to 
the assumption that bacteria could have a role in the aetiology of the disease 
(Ewaschuk et al., 2006). Others suggest IBD occurs as a result of an overly 
aggressive cell-mediated immune response to commensal enteric bacteria in 
a genetically susceptible host (Podolsky, 2002, Sartor, 2004). IBD mainly 
encompasses Crohn’s disease and ulcerative colitis (Bai and Ouyang, 2006). 
Treatment is generally with corticosteroids, aminosalicylates, and antibiotics 
(Podolsky, 2002, Sartor, 2004, Kato et al., 2004). Remission of disease after 
treatment is a major clinical challenge. The role of probiotics in maintaining 
and prolonging remission of the disease has been investigated by some 
researchers and there are reports of probiotics reducing the recurrence of IBD 
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after treatment (Guslandi et al., 2003, Mimura et al., 2004, Chermesh and 
Eliakim, 2006, Vilela et al., 2008). 
Studies have been conducted whereby probiotics have been used in the 
prevention of infectious complications after surgery for digestive organs 
(Rayes et al., 2002b, Rayes et al., 2002a, Kanazawa et al., 2005). Usually, 
after such procedures, use of antibiotics at a high dose for long periods is 
avoided because of the possibility of developing resistance to antibiotics from 
such actions (Nomoto, 2005). Probiotics, therefore, have a potentially useful 
role in controlling infections after such procedures. The incidence of infectious 
complications like sepsis and peritoneal abscess were decreased in 
individuals who had undergone hepatectomy, extra-hepatic bile duct resection, 
or reconstruction of the biliary tract in patients with highly invasive biliary tract 
cancer who were given probiotic and prebiotic combination (Kanazawa et al., 
2005). A significantly lower incidence of infection was also noted in patients 
who had undergone liver transplant and were given probiotics post-operation 
(Rayes et al., 2002b). 
Bacterial vaginosis is a condition arising due to alteration of vaginal flora and 
microenvironment. This usually arises when faecal microbes come into contact 
with the vaginal tract. Patients normally complain of a grey, malodorous fishy-
smelling vaginal discharge whilst a substantial proportion are asymptomatic 
(Barrons and Tassone, 2008, Sanders et al., 2007). Bacterial vaginosis is 
usually a risk for sexually transmitted infections as well as complications in 
pregnancy (Potter, 1999). Treatment is usually done with oral metronidazole 
or topical clindamycin, however, recurrence after treatment is common 
(MacDermott, 1995). Lactobacilli in the vagina of healthy females constitute 
the normal bacterial flora and have a physiological role in maintaining a low pH 
(< 4.5) and protecting against invasion by other microorganisms (Eriksson et 
al., 2005). Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 
have been used to some success to prevent recurrence of the infection 
(Marcone et al., 2010, Anukam et al., 2006a, Anukam et al., 2006b). 
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Probiotics have also been reported to have a role in immunostimulation. L. 
acidophilus TMC 0356 has been reported to stimulate macrophages to secrete 
both inflammatory and anti-inflammatory cytokines in-vitro (Morita et al., 2002). 
Probiotics through immunomodulation have also been found to have a role in 
treating atopic dermatitis (Kim et al., 2014, Michail et al., 2008). This approach 
appears more convenient as other treatment options like the use of topical 
steroids and systemic corticosteroids often result in non-adherence due to the 
unpleasant accompanying side effects of therapy. In-vitro production of 
interleukin-12 and interferon-gamma, which are vital cytokines for antitumor 
and antimicrobial immunity have also been demonstrated after stimulation with 
Lactobacillus casei strain Shirota (Kato et al., 1999).  
Probiotics especially certain strains of L. acidophilus and some bifidobacteria 
have been suggested to have anti-carcinogenic properties. This is exhibited 
by the removal of pro-carcinogens like nitrosamine, heterocyclic amines, 
phenolic compounds, and ammonia (Shah, 2007, Goldin and Gorbach, 1984). 
Some strains of B. lactis and L. gasseri have also been demonstrated to 
release biologically active amounts of hydroxycinnamic acids (caffeic, ferulic 
and p-coumaric acids) which have potential anti-carcinogenic action in the 
colon (Couteau et al., 2001). Most of these anticancer studies, however, have 
only been demonstrated in animal models. 
Probiotics have been reported to have a role in managing obesity. Obesity 
results from an excess caloric intake relative to energy expenditure. Obesity 
can arise due to many factors including environmental and genetic origins 
(Tennyson and Friedman, 2008). Some animal studies have demonstrated the 
potential of probiotics in reducing glucose levels in diabetic mouse models after 
probiotic administration as well as a delay in development of glucose tolerance 
(Tabuchi et al., 2003, Matsuzaki et al., 1997). 
It has been demonstrated that probiotics like Bifidobacterium longum BL1, L. 
acidophilus RP 32, L. brevis NR1C1684, and L. acidophilus ATCC 4962 can 
deconjugate bile salts resulting in lower cholesterol concentrations (Pereira 
and Gibson, 2002, Klaver and Meer, 1993). Deconjugated bile salts are not 
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rapidly absorbed in the intestinal lumen as compard to their conjugated 
counterparts (Shah, 2007, Klaver and Meer, 1993, Liong and Shah, 2005, Xiao 
et al., 2003, Pereira and Gibson, 2002). Xiao et al. (2003) found a significant 
reduction in total serum cholesterol, low-density lipoprotein cholesterol, and 
triglyceride concentrations after consumption of milk products.  
Caglar et al. (2005) highlighted the use of probiotics in aeronautics and space 
technology. With intestinal problems being a major health problem of 
astronauts, the National Aeronautics and Space Administration (NASA) has a 
project named Lacmos (‘Lac’ is Latin for milk and ‘Mos’ for ‘Cosmos’) 
researching into probiotic food products to address these intestinal problems 
and enable humans to live in space. 
 
1.2.2 Challenges of probiotic science  
Regulation of probiotics is a major challenge in probiotic science. Probiotics 
are classed under food and nutritional supplements rather than drugs, yet there 
are various obstacles to overcome with regulation. Cross-border differences in 
terms of what can be passed as a probiotic is a major obstacle. Regulation in 
Europe is conducted by the European Food Safety Authority (EFSA), whilst 
the Food and Drugs Authority (FDA) is the regulatory body in the United States 
of America. The main challenge arises from how health claims are 
substantiated. A health claim implies a relationship between a specific food 
and maintenance of a good health status, or that a given food can reduce the 
risk of a particular disease (van Loveren et al., 2012).  In Europe, EFSA 
requires all health claims to be supported by trials in a target human population 
(e.g., pregnant women, the elderly, etc.). The implication is that every new 
strain or combination of strains should be subjected to costly and lengthy 
clinical studies in humans to substantiate the health claim (Rijkers et al., 2011, 
Salminen and van Loveren, 2012). In the USA, claims relating to normal body 
functioning, i.e., structure/function claims do not require FDA approval. The 
result is the flooding of the market with probiotic foods and supplements with 
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various structure or function claims making it difficult to differentiate between 
products that are scientifically backed from those with little evidence. The 
downside is that most products on the market are ineffective. In Japan, health 
claim approval can be granted with animal studies (Reid, 2008, Donovan et 
al., 2012, van Loveren et al., 2012). Regulatory science needs to bridge the 
gap between probiotic product development and the science that ensures 
product safety and functionality to advance probiotic science (Rijkers et al., 
2011).  
Probiotic science also faces many product development challenges during 
manufacture/production, storage, and delivery of probiotics. Targeting of 
probiotics to their main site of action will be ideal in the evaluation of health 
claims attributed to probiotics. This will enhance consumer and scientific 
confidence in probiotics. Solid dose probiotics are currently produced in the 
dried form mainly by microencapsulation via freeze-drying or spray-drying. 
These processes impart extreme stresses on the microbial cells (Sanders, 
2009, Douglas and Sanders, 2008, Chandramouli et al., 2004, Cui et al., 2000). 
This is elaborated further in the next section. 
Another challenge is maintaining probiotic viability and product stability over 
the shelf life. The physical parameters of the final product matrix play an 
important role in product stability. Loss of cell viability during storage is noted 
to be more drastic than during processing in most cases (Jankovic et al., 2010). 
Two major biological barriers that probiotics must overcome to reach the lower 
part of the gastrointestinal tract in a viable state to exert biological activity are 
gastric acidity and bile secretion in the small intestine. Probiotic 
microorganisms vary considerably in their tolerance to low pH and bile salts 
(Chassard et al., 2011).The ability of a probiotic formulation to overcome these 
barriers contributes to the effectiveness of the formulation. 
Oxygen tolerance is another challenge probiotics encounter; especially since 
most of these beneficial organisms are either microaerophilics or strict 
anaerobes. Probiotics lack the mechanism to completely convert oxygen to 
hydrogen peroxide and the catalase to convert hydrogen peroxide to water, 
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hence, the presence of oxygen results in cell loss. It is important in the 
production design, storage, and product use to keep exposure to oxygen 
minimum (Vasiljevic and Shah, 2008, Broeckx et al., 2016, Miller et al., 2002). 
 
1.2.3 Current techniques for formulating probiotics  
Formulating probiotics is very challenging since product viability must be 
maintained during formulation and after consumption by consumers. 
Formulating products that can withstand the harshness of the GIT and target 
them to the intestines is currently receiving great interest as are formulation 
processes that are not deleterious to organisms (Kailasapthy, 2002, 
Mortazavian et al., 2007). Cryopreservation is one of the standard ways of 
preserving bacterial viability over long periods. The high energy costs in 
maintaining sub-zero conditions during transport and storage is a major 
commercial drawback (Broeckx et al., 2016). Many approaches have been 
documented in formulating both liquid and solid dosage formulations 
(Kailasapthy, 2002, Dianawati et al., 2015, Kim et al., 1988, Burgain et al., 
2011).  
Most consumers, however, find solid dosage forms of probiotics more 
convenient over liquid formulations (Dianawati et al., 2015). Ideally, a probiotic 
formulation should be able to withstand the conditions of the GIT, especially, 
the stomach and be released at its target site often the small and large 
intestines (Rokka and Rantamäki, 2010, Gilliland, 1989). Approaches for 
formulating solid dose probiotics will be elaborated upon due to relevance to 
this work. 
Earlier research on probiotic formulation has been centred on immobilising 
cells in a matrix. This concept has evolved with time and most of the current 
work is based on microencapsulation of cells (Kailasapthy, 2002). 
Microencapsulation is a process in which the cells are retained within an 
encapsulating matrix or membrane (Krasaekoopt et al., 2004). 
Microencapsulation of probiotic bacteria has been a promising technology to 
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ensure bacterial stability during the drying process and to preserve their 
viability during storage. Microencapsulation is reported to impart functional 
properties like acid and bile tolerance as well as the controlled release of 
contents based on the excipients added (Dianawati et al., 2015, Poncelet, 
2006, Cui et al., 2000).  
The two frequently used methods for microencapsulation are freeze-drying 
and spray-drying, although, other techniques like vacuum desiccation and 
fluidised bed drying are available (Dianawati et al., 2015, Efiuvwevwere et al., 
1999, Kim et al., 1988).  
Freeze-drying is a procedure based on sublimation under high vacuum and 
occurs in three phases, i.e., freezing, primary drying, and secondary drying. It 
involves cells being first frozen at -196 °C and then dried by sublimation under 
high vacuum (Meng et al., 2008, Santivarangkna et al., 2007). A schematic 
overview of a freeze-dryer is shown in Figure 1-4. Freeze-drying has 
advantages like a relatively mild operational temperature (Dianawati et al., 
2015). Freeze-drying produces concentrated cultures that can be stored at 
ambient temperatures (Palmfeldt et al., 2003). A major drawback with the use 
of freeze-drying is the cost of equipment, use of freeze-dryers on a commercial 
scale is expensive and this restricts its use (Peighambardoust et al., 2011). 
Freeze-drying is also a time-consuming procedure partly because drying via 
sublimation is a slow process. This prolonged procedure aggravates other 
adverse conditions like the formation of intracellular ice crystals and 
macromolecule denaturation which result in loss of viability (Johnson and 
Etzel, 1995, Zayed and Roos, 2004, Patist and Zoerb, 2005). 
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Figure 1-4: A schematic overview of freeze-dryer (adapted from Broeckx et al., 2016). 
Spray-drying, on the other hand, is a more economical process (Kailasapthy, 
2002).  It is rapid and involves the injection of the spray-drying medium at high 
velocity at temperatures up to 200 °C, which then blasts through a nozzle 
leading to the formation of granules (Meng et al., 2008). A schematic overview 
of a spray-dryer is shown in Figure 1-5. The operational temperature is a major 
drawback; the inlet and outlet temperatures of spray-dryers usually result in 
reduced viability from simultaneous dehydration and thermal inactivation of 
microorganisms (Anal and Singh, 2007). 
 
Figure 1-5: A schematic overview of spray-dryer (adapted from de Vos et al., 2010). 
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1.2.4 Formulating probiotics using inkjet printing 
Several reports have highlighted the lack of viable organisms in packaged 
probiotics; other commercial products have also been noted to contain less 
than the stated number of strains (Hoa, 2000, Fredua-Agyeman and Gaisford, 
2015, Hamilton-Miller, 2002, Temmerman et al., 2003, Hamilton-Miller et al., 
2007b, de Vos et al., 2010, Huff, 2004, Masco et al., 2005). Fredua-Agyeman 
and Gaisford (2015) also observed tolerance issues with solid products to 
intestinal fluids when analysed relative to liquid formulations. This problem can 
in part be attributed to the fact that most of these solid formulations were 
manufactured via freeze-drying and the stress imposed by the manufacturing 
procedure usually results in the loss of viability. Also, most of these products 
don’t have any protective mechanism against the harshness of some sections 
of the GIT (Broeckx et al., 2016, de Vos et al., 2010, Burgain et al., 2011). 
Most consumers, however, prefer dehydrated probiotic formulations due to 
convenience (Dianawati et al., 2015). Also, with probiotics being oxygen 
intolerant, the deleterious effect of oxygen on probiotics is greater on liquid 
formulations used over a period due to oxygen penetration. An ideal product 
will, therefore, be a solid formulation with improved viability and delivery 
mechanism (Vasiljevic and Shah, 2008, Dianawati et al., 2015).  
Inkjet printing (IJP) is a promising technique for on-demand production of 
medicines with many recent applications. With solid dosage forms being more 
preferred by consumers, this work focusses on exploiting the possibility of ink 
jetting probiotics on-demand to eliminate the need for long-term storage and 
accompanying reduction in viability upon storage. Another advantage of using 
IJP in formulation is the fact that long hours of drying will be eliminated since 
droplets are generally small and drying can be achieved under more tolerable 
conditions (Buanz et al., 2015, Preis et al., 2015). This will also boost 
consumer confidence since formulations will be made on-demand by the local 
chemist or hospital pharmacy, the current target group for this model.  
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1.3 Inkjet Printing 
Inkjet printing (IJP) –  a technique that has been around for over half a century 
–  can be described as a non-contact technique capable of reproducing digital 
image data on a substrate using picolitre ink droplets. IJP had initially been 
restricted to paper printing in commercial printing and publishing units, day-to-
day printing in offices, and privately in homes. However, inkjet printers are very 
powerful machines that can serve varied purposes (Ferris et al., 2013, Le, 
1998). 
IJP can be applied to many procedures that require nano-manipulation but are 
limited by an inability to position precisely very small drops of liquid, e.g., 
microdosing (Derby, 2008). In recent years, IJP has been applied in fields like 
electronics, where the technique has been used in the production of transistor 
circuits as well as in medicine and drug developments. Interesting work has 
also been done in ceramics and polymer engineering (Sirringhaus et al., 2000, 
Mott et al., 1999, Kim et al., 2010).  
Advancements in IJP has resulted in the evolution of the usual two-
dimensional printing to a three-dimensional (3-D) format. 3-D printing employs 
an additive manufacturing process whereby products are built on a layer-by-
layer basis, through a series of cross-sectional slices (Berman, 2012). 
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1.3.1 Types of inkjet printing 
Continuous inkjets and drop-on-demand inkjets are the two main types of ink 
jetting. In continuous ink jetting, as the name implies, there is a continuous 
stream of droplets flowing through a nozzle as a result of fluid instability. These 
droplets are charged upon generation and are either deflected by an electric 
field onto a substrate to form an image or recirculated back for reuse. In drop-
on-demand ink jetting, the ink is produced only when needed via a pressure 
pulse generated in a fluid-filled chamber. The risk of contamination associated 
with the recirculation of inks in continuous inkjets is a major disadvantage in 
comparison to drop-on-demand inkjets and a reason it is less commonly used 
in research. Inkjet printers are very accurate in delivery and a positional 
accuracy of less than 30 µm has been documented (Derby, 2008, Ferris et al., 
2013). Drop-on-demand inkjets are classified as either thermal inkjets or 
piezoelectric inkjets. A third type, solenoid inkjets - utilises gas or hydraulic 
pressure to aid droplet ejection - was highlighted by Lemmo and colleagues 
(1998), however, there is very limited information about this technology in 
literature. 
In piezoelectric inkjet printers, voltage mediated actuation of a piezo-crystal 
creates a pressure pulse that results in droplet ejection as shown in Figure 1-6. 
In piezoelectric inkjets, the printhead consists of a piezoelectric layer attached 
to a single crystal silicon substrate which causes ink to be ejected when 
vibrated. The printhead in piezoelectric printers are located on the printer 
(Figure 1-7). With piezoelectric printers, there is no temperature change 
involved in the printing process. Manufacturers of piezoelectric inkjets include 
Epson and Brother (Allain et al., 2004, Ferris et al., 2013). 
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Figure 1-6: A schematic illustration of droplet formation in a piezoelectric inkjet (adapted from 
Kolakovic et al., 2013). 
 
 
Figure 1-7: A piezoelectric inkjet printer with four printheads (adapted from Allain et al. 
2004). 
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In thermal inkjet printers, also known as bubble-jet printers, rapid localised 
heating results in bubble formation within the ink chamber and eventually 
results in droplet formation as shown in Figure 1-8. Thermal inkjets have the 
printheads located on the cartridge (Figure 1-9), an advantage it has over 
piezoelectric inkjets. This configuration allows greater ease of cleaning and 
loading of thermal inkjet cartridges. Thermal inkjets can deliver droplets in the 
range of 8-95 pL and these can be formed in less than 3 ps. Manufacturers of 
thermal inkjet printers include Canon, Hewlett-Packard, Lexmark, Compaq, 
and NEC (Allain et al., 2004, Merrin et al., 2007). 
 
Figure 1-8: A schematic illustration of droplet formation in a thermal inkjet printer (adapted 
from Kolakovic et al., 2013). 
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Figure 1-9: A thermal inkjet cartridge showing printhead (adapted from Allain et al., 2004). 
 
1.3.2 Applications of inkjet technology in bio-medicine  
New technologies such as IJP are being explored to transform the 
pharmaceutical production process and the end-to-end supply chain. This is 
can be partly attributed to the expensive research costs, high-risk, and capital-
intensive scale-up in traditional centralised batch manufacturing (Daly et al., 
2015). 
IJP, as a versatile technique, has many applications in medicine. Mammalian 
cells have been printed successfully using this technique (Mironov et al., 
2006). This technique has a potential use in drug development where it can be 
applied in drug screening and preparation of pharmaceutical co-crystals 
(Buanz et al., 2013, Lemmo et al., 1998, Scoutaris et al., 2016b).  
Inkjets can also be used in clinical settings in the preparation of personalised-
dose medicines for patients. Buanz and co-workers used the technique to 
prepare personalised doses of salbutamol sulphate on oral films (Buanz et al., 
2011). 
IJP has applications in biomedical device manufacture. Orthopaedic surgeons 
have replaced lost limbs with prosthetic limbs made by ink jetting. Medical 
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devices with anti-bacterial properties have also been fabricated using IJP. 
These were, however, produced using the more advanced three-dimensional 
(3D) printing technique (Mertz, 2013, Sandler et al., 2014). In 3D printing, 
sequential layers of material are deposited and objects of any shape or 
geometry can be created. A computer-aided design model is used in the 
production; many 3D printing technologies exist including stereolithography, 
sintering, melting, and fused deposition modelling. This printing technology 
has been used in other areas of medicine including fabrication of tablets as 
well as modified-release drugs (Preis et al., 2015, Goyanes et al., 2014, 
Goyanes et al., 2015).  
IJP has been used in micro-particle printing. Excipient-free salbutamol 
sulphate and terbutaline sulphate for inhalation have been successfully 
formulated by ink jetting into liquid nitrogen to produce freeze-dried porous 
particles. This production process was a relatively simplified approach 
compared to spray-drying or micronisation (Mueannoom et al., 2012, Sharma 
et al., 2013). 
Thin film coating of medical devices is another application of IJP. Slow-release 
active pharmaceutical ingredients (API’s) can be applied to surfaces 
accurately. Coronary stents, for example, require coatings to ensure 
immunosuppression and prevent coagulation and clogging. Microneedles – 
narrow needles of the order of microns with lengths up to 1 mm which can 
pierce through the stratum corneum, but will not penetrate deep enough into 
the skin to stimulate nerve receptors – have also been coated via ink jetting for 
transdermal delivery of actives. Anticancer agents like 5-fluororacil, curcumin 
and cisplatin have been demonstrated for transdermal delivery after ink jetting. 
Insulin microneedles have also been coated via ink jetting (Uddin et al., 2015, 
Yu et al., 2015, Daly et al., 2015, Scoutaris et al., 2016a, Ross et al., 2015, Gill 
and Prausnitz, 2007).  
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1.3.2.1 Bio-printing      
Bio-printing, defined as the use of material transfer processes for patterning 
and assembling biologically relevant materials – molecules, cells, tissues, and 
biodegradable biomaterials – with a prescribed organisation to accomplish one 
or more biological functions (Mironov et al., 2006). In bio-printing, it is important 
that the selected printing method is neither toxic nor irreversibly damaging for 
cells and their deoxyribonucleic acids (DNA) (Mironov et al., 2006). Biologicals 
including bovine serum albumin and smooth muscle cells from rats have been 
successfully printed (Wilson and Boland, 2003, Roth et al., 2004). Okamoto 
and colleagues (2000) worked on printing DNA and they developed a method 
for fabricating DNA microarrays using IJP onto a glass surface.  
Another area with great potential for clinical application is tissue and organ 
engineering. Tissue and organ engineering seeks to fabricate viable 
replacement body parts (Xu et al., 2005). It is documented that on any given 
day in the United States about 60,000 people are waiting for kidney 
transplants, 3,000 for heart transplants, and 17,000 for liver transplants 
(Mironov et al., 2007). It will be a massive advancement in science if organs 
and tissues can be 3-D printed successfully from an individual’s own cells as 
this will eliminate the current problem of incompatible donors. Most of the 3-D 
bio-printing work done involve natural hydrogels like alginate, gelatin, and 
chitosan, however, variations that occur within batches make reproducibility an 
issue. This is a major challenge with 3-D bio-printing; however, as a relatively 
new technique, with research on-going, there is the possibility of many 
applications in future (Fischer, 2013). 
One area in which very little work has been done is the printing of bacteria and 
the microbiological applications of IJP. Bacterial colony arrays have been 
successfully printed onto substrates and the printing of colony arrays using 
inkjets offers a relatively cheaper alternative to obtaining these arrays for the 
construction of genomic and expression libraries (Zheng et al., 2011, Xu et al., 
2004). 
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1.3.3  Advantages of inkjet printing 
A fundamental advantage derived from the use of IJP is the inexpensive nature 
of inkjet printers. The myriad of applications to which these printers can be put 
and the relatively low cost makes the technology good value for money – some 
inkjet printers cost as little as £20. The ink jetting technique has been described 
as cheap, yet, one that affords extremely fine control of liquid droplets (Buanz 
et al., 2011).  
The ability of some inkjet printers to work with as little as 20 µL of ‘ink’ makes 
the technique useful in drug discovery. Scientists can obtain outcomes with 
little material, especially, when materials being investigated at this stage are 
limited. Also, because materials are delivered exactly where they are needed, 
there is reduced wastage of materials (Allain et al., 2004, Derby, 2008). 
IJP, as a non-contact technique, offers the added advantage of reduced 
contamination as the printhead and the substrate do not interact physically. 
This, eventually, leads to more work being done within a given time as a 
decontamination process is reduced for most procedures (Ferris et al., 2013, 
Daly et al., 2015, Scoutaris et al., 2016c). 
IJP provides a high-throughput option for conducting scientific experiments. 
The speed of the technique allows a broader range of studies to be conducted 
within a short period. This is of importance in drug screening and development 
(Wilson and Boland, 2003, Lemmo et al., 1998). 
Reproducibility of sample volume is also guaranteed under controlled 
environments. With IJP being an automated technique coupled with the 
robustness of ink jetting, the risk of errors is reduced since the amount 
deposited is constant, provided the printhead is in a good condition. Inkjets 
have been described as inexpensive robots that can dependably dispense 
minuscule amounts of growth factors and other proteins and even whole cells, 
in any pattern, gradient, or grid that can be drawn (Alper, 2004, Scoutaris et 
al., 2016c). Inkjets have been reported to deliver picolitre droplets with a 
positional accuracy less than 30 µm (Derby, 2008). 
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1.3.4 Challenges 
The main challenge associated with the use of thermal inkjet printers is the 
blocking of the nozzles of the cartridge. The nozzles are vital, especially in 
thermal inkjet printers, because of the role played in droplet formation. 
Blockage can occur through drying of the ‘ink’ at the nozzle leading to either 
complete or partial blockage of the cartridge. Also, the salts found in culture 
media and physiological solution can also deposit at the nozzles and result in 
clogging (Burg et al., 2010). To minimise the effect of this challenge, some 
researchers include ethylene diamine tetra-acetic acid	 (EDTA) to their 
formulations because of its chelating properties. Though this approach 
extends the lifetime of the cartridge printhead, the impact on cell viability is not 
known. Sonicating cartridges in water after use also helps clear blockages 
(Parzel et al., 2009).   
Another challenge posed by IJP is the limitation in dose fabrication. Although, 
IJP enables on-demand manufacturing and the flexibility of tailor-making 
medicines to suit patients’ needs. It works best for very potent and small dosed 
formulations. Buanz et al. (2011) needed a large surface area (13 – 26 cm2) to 
reach the required dosage of salbutamol sulphate at the highest feasible drug 
loading. 
Ensuring repeatable droplet formation is another challenge especially with 
pharmaceutical printing. A slight change in excipient may have significant 
effects on droplet formation. This can be checked by optimising print settings 
and ink formulation. Printing under controlled environments also helps ensure 
droplet reproducibility since it controls droplet in-flight deviation due to 
aerodynamic effects which can result in poor placements (Daly et al., 2015). 
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1.4 Aims and Objectives 
The main aims and objectives of this thesis are: 
• To modify an inkjet by substituting the paper feeding mechanism with 
printing onto a stationary stage.   
• To evaluate the potential of inkjets as tools in antimicrobial susceptibility 
testing. 
• To evaluate the potential of inkjets as tools in formulating probiotics for 
targeted delivery. 
• To evaluate the potential of inkjets as tools in formulating probiotic oro-
dispersible films. 
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Chapter 2 Modification of an Inkjet Printer and an Evaluation 
of its Potential in Antimicrobial Susceptibility Testing 
2.1 Introduction  
Inkjet printers have been used in various applications in recent times. 
Depending on the intended application, these printers are either modified 
extensively (Pardo et al., 2003, Wilson and Boland, 2003, Zheng et al., 2011, 
Mueannoom et al., 2012) or with little or no modification (Genina et al., 2013, 
Buanz et al., 2011). Inkjets are very sensitive pieces of equipment; hence, 
alterations can easily result in non–functionality i.e., printer not working. 
Extensive care is therefore needed in the modification of an inkjet. A Hewlett-
Packard (HP) 5940 Deskjet (USA), a thermal inkjet (Figure 2-1) was used for 
this work. This model was chosen partly because as an older generation of HP 
printers, it provided greater ease of modification as compared with the 
relatively newer versions. Also, the cartridge properties of this printer model 
permit the printer to function with just one cartridge present (i.e., the ink-backup 
mode). This printer model is also relatively inexpensive, therefore a good 
model for product development (Hewlett-Packard, 2005). 
 
Figure 2-1: HP 5940 thermal inkjet printer, out-of-box configuration 
After any modification process, it is essential to ascertain functionality and 
precision of the procedure, this was hence done for this printer model. A 
printer, aside from its complexity and sensitivity, is just a device that deposits 
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solution accurately based on a designed template. The potential of the 
modified printer as an automated pipette was therefore explored in 
antimicrobial susceptibility testing. 
2.1.1 Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing (AST) is an evaluation of the performance 
of an antimicrobial against microbes. Minimum inhibitory concentration (MIC) 
is described as the ‘gold standard’ for determining the susceptibility of 
organisms to antimicrobials and is used to judge the performance of all other 
methods of AST (Lamy et al., 2004). MIC is defined as the lowest concentration 
of an antimicrobial agent that will inhibit the visible growth of micro-organisms 
after overnight incubation (this period is extended for anaerobes which 
generally require longer incubation). MIC differs from minimum bactericidal 
concentration (MBC), which is the lowest concentration of antimicrobial agent 
that will prevent the growth of organism after sub-culture onto antibiotic-free 
medium (Andrews, 2001). Standards for these tests are set by regulatory 
bodies such as The Clinical and Laboratory Standards Institute (CLSI), The 
European Committee on Antimicrobial Susceptibility Testing (EUCAST), The 
British Society for Antimicrobial Chemotherapy (BSAC), and The French 
Society for Microbiology (SFM) (Galani et al., 2008). MIC tests are performed 
on disease-causing organisms, particularly if the organism belongs to a 
species resistant to frequently used antimicrobial agents (Lamy et al., 2004, 
Galani et al., 2008, Andrews, 2001). MIC determinations are also performed 
when there are severe infections (e.g., meningitis) and during unexpected 
treatment failure. When new antibiotics are discovered, MIC determinations 
are conducted to assess efficacy. These determinations are conducted for 
uncommon microorganisms as well (Acar and Goldstein, 1996). 
MIC can be determined by methods like agar dilution, broth dilution, and broth 
microdilution. Agar dilution involves the incorporation of doubling 
concentrations of antimicrobial into molten growth medium then applying a 
known number of bacteria onto the agar plate (Andrews, 2001). EUCAST 
describes broth dilution as a technique in which containers holding identical 
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volumes of broth with an antimicrobial solution in geometrically increasing 
concentrations are inoculated with a known number of bacteria. Broth 
microdilution denotes performing broth dilution in microdilution plates with a 
capacity ≤ 500 µl (EUCAST, 2003).  
The difficulty and workload involved in obtaining varying drug concentrations 
is a major drawback with these techniques resulting in most of these tests not 
being performed routinely in clinical settings (Smith and Kirby, 2016). Most 
clinical labs, therefore, resort to reference labs to perform these tests resulting 
in a delay in obtaining test results. Others use preformulated antimicrobial 
dilution panels or the E-test strip; however, due to the rapid emergence of 
antimicrobial resistance and multidrug-resistant bacteria, there is usually the 
need to test new or combination of antimicrobial therapies. In such instances, 
where preformulated concentration gradients are not available there is a 
clinical challenge (Wexler et al., 1991, Smith and Kirby, 2016). Automated 
approaches like the spiral gradient endpoint technique and HP D300 digital 
dispenser have been used as alternatives for manual determination of MIC 
(Smith and Kirby, 2016, Pong et al., 2010, Hill and Schalkowsky, 1990).  
MIC determinations via spiral gradient endpoint are done using the spiral plater 
(Figure 2-2). This instrument was originally designed to replace traditional 
serial dilution broth methods for bacterial enumeration. A syringe-driven 
dispensing pen deposits samples onto a rotating agar plate. The pen moves 
from the near-centre outwards while the plate rotates; this results in a spiral 
pattern as shown in Figure 2-3. If movements are done with a constant speed, 
a higher concentration of material is deposited at the centre and a relatively 
lower concentration at the periphery of the plate. This concept has been 
modified and is applied in the determination of MICs, whereby an antibiotic 
solution is deposited in a decreasing gradient from the centre towards the edge 
of agar in petri dish in a spiral manner (Hedderich et al., 2011, Wallace and 
Corkill, 1989, James, 1990). 
In MIC determination, this instrument has the advantage of being automated, 
hence easing the obtainment of different drug concentrations and replacing 
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the workload of serial dilutions in effect. A few challenges are, however, 
associated with the technique, the first being the restrictive cost of the 
instrument making it an issue in resource-challenged settings (Wexler, 1991). 
Also, the difficulty in determination of the final endpoint and the fact that test 
inocula may have to be applied manually make the technique unappealing to 
some scientists (Wallace and Corkill, 1989). 
 
Figure 2-2: A model spiral plater (Image obtained from Autoplate user guide). 
 
 
Figure 2-3: An illustration of the spiral plating process (adapted from Wikimedia commons). 
The HP D300 digital dispenser (Figure 2-4), however, presents an opportunity 
for obtaining serial dilutions in well-plates. This has general advantages of 
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inkjet printers like the accurate and precise dispensing of volumes from 
picolitres to microliters and the elimination of carryover because it is a non- 
contact technique. As an automated technique, there is minimal delay and 
work from manual pipetting. The major drawback here as with the spiral plater 
is the cost – the digital dispenser costs around $40,000 and a standard 
microplate reader, $8,000 – which limits such an important technique (Smith 
and Kirby, 2016, Hewlett-Packard, 2016).  
 
Figure 2-4: HP D300 digital dispenser (Image obtained from HP D300 digital dispenser data 
sheet). 
Due to the challenges of manual susceptibility testing and the benefits of 
automated AST, the potential of inkjets as inexpensive devices in automated 
antimicrobial susceptibility testing was explored to facilitate in-house MIC 
determinations. 
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2.2 Aims 
• To modify a thermal inkjet printer whilst maintaining key functionality. 
• To evaluate the robustness of the modified printer. 
• To design a sterilisation protocol for the ink jetting technique. 
• To determine whether thermal ink jetting reduces viability of bacterial 
cells. 
• To use the modified printer as a tool in antimicrobial susceptibility 
testing.   
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2.3 Materials and Methods  
2.3.1 Reagents and growth media  
Iso-sensitest agar, MRS (de Man, Rogosa and Sharpe) agar and broth from 
Oxoid were the growth media used. Fast Green dye was purchased from Alfa 
Aesar, USA. ¼ Ringer’s solution tablets, acetonitrile, glycerol, and phosphate-
buffered saline tablets were from Fisher Scientific, UK. The antibiotics used, 
pure amoxicillin, tetracycline, doxycycline, and ampicillin (92.5 – 100.5% 
purity), were from Sigma-Aldrich, UK. 
 
2.3.2 Printer and cartridge modification 
The printer was modified such that rather than the substrate (generally, paper 
in the unmodified printer) passing through the printer’s rollers during operation, 
printing was done onto a stage mounted underneath the cartridge printhead. 
The modification process is described briefly. The printer’s external paper trays 
(intake and output trays) located in front of the printer were removed by 
disengaging the internal hinges (Figure 2-5). 
 
Figure 2-5: Printer with external paper trays removed. 
The rear access door of the printer was then removed by means of existing 
handles (Figure 2-6). The rear access door, together with the intake paper tray 
provide a pathway for paper and since the paper feeding mechanism was not 
needed, they were removed.  
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Figure 2-6: Printer with rear access door removed. 
The printer lid was opened and surrounding security screws and the plastic 
case removed (Figure 2-7). Extra attention was paid to avoid damage to the 
electrical circuits operating the printer. 
 
Figure 2-7: Image showing one of the removed surrounding screws.  
The metal protecting case covering the paper guide was unscrewed and 
removed carefully (Figure 2-8). 
 
Figure 2-8: Removal of metal protecting case 
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The secondary rollers attached by gears to the main rollers were disengaged 
carefully (Figure 2-9) to prevent any damage to the main rollers’ sites of 
interaction with the other mechanical workings of the printer. 
 
 
Figure 2-9: Secondary rollers after being disengaged. 
The upper plastic paper guide and the foam covering the lower plastic paper 
guide were then removed (Figure 2-10). 
 
Figure 2-10: Upper paper plastic guide after removal. 
The lower plastic paper guide was removed manually with a dremel drill to 
create an opening for the stage to be mounted (Figure 2-11). 
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Figure 2-11: Image of printer after cutting through lower paper guide. 
An important part of the modification process was the identification of key 
sensors that needed activation for the printer functionality to be maintained. 
The lid sensor (Figure 2-12) and the paper feed sensor (Figure 2-14) required 
manual activation for the modified printer to work. The lid sensor detects when 
the printer’s lid is opened and since this had been removed, manual activation 
was required to mimic the presence of the lid. This must, however, be 
disengaged (Figure 2-13) before insertion and removal of cartridges. For the 
paper feed sensor, since the paper feeding mechanism had been eliminated, 
manual activation was required to prevent the printer detecting absence of 
paper. 
 
     
Figure 2-12: Image of printer’s lid sensor and the engaged bar when the lid is closed. 
 
 
Bar engaged with 
printer lid sensor 
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Figure 2-13: The printer’s lid sensor extended 
The paper feed sensor is close to the rear access door below the main roller 
axle. Caution was taken when dislodging this sensor and its associated cabling 
from underneath the roller axis to an accessible area. 
 
Figure 2-14: The printer’s paper feed sensor extended to the back of the printer. 
Printing with the modified printer was done onto a stage mounted underneath 
the cartridge printhead when printing. The stage was positioned as close to 
the main rollers’ edge as possible without touching it; this enabled solutions to 
be easily deposited on the substrate on the stage (Figure 2-15). 
Lid sensor 
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Figure 2-15: The printer with stage positioned. 
The distance between the cartridge printhead and the stage was kept fixed 
with the aid of a height-controllable platform (Figure 2-16). 
 
 
Figure 2-16: The stage on a height adjustable platform. 
The cartridges used were HP black ink cartridges number 337 (Figure 2-17). 
These cartridges were modified by carefully separating the cartridge cap from 
the body with a sharp knife. Fragments were removed from the edges of the 
cap and the body. The plastic tape located on the nozzle plate was kept 
covering the nozzles to protect them (Figure 2-17).  
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Figure 2-17: Images of HP 337 black cartridge (left) and a highlight of plastic tape covering 
nozzles (right). 
The foam in the cartridge was removed, exposing the ink reservoirs 
underneath the permeable membrane which was removed with a pair of 
tweezers. Before cleaning the cartridge, the plastic tape protecting the nozzle 
plate was removed. The ink solution in the cartridge was flushed out with 
deionised water several times until it was clear. The nozzles of the cartridge 
were submerged in a deionised water: ethanol solution (2:1) for 5 minutes. The 
cartridge was then submerged in deionised water and sonicated for 15 minutes 
afterwards. The cartridge was finally dried in a convection oven at 40 ºC for 30 
minutes and was ready for use (Figure 2-18). 
 
Figure 2-18: Modified cartridge 
 
protective 
tape 
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The software used in issuing commands to the printer was Microsoft Word 
2010, part of the Office 2010 suite. Once a printing command has been issued 
to the printer, the printhead is usually wiped by nozzle plate wipers as a purging 
mechanism. The cradle then moves toward the stage and rollers become 
activated at which point the paper feed sensor needs to be activated. The 
timing of these events is important because should the sensor not become 
activated, the printer will assume unavailability of paper, trigger a paper jam 
warning, and stop working until this warning is addressed. This is resolved by 
manually pressing the resume button. All printing was done using normal print 
quality settings. 
 
2.3.3 Measuring diameter of cartridge nozzle  
Scanning electron microscopy (SEM) was used to measure the diameter of the 
cartridge nozzles. The cartridge nozzles were prepared by sputter coating with 
gold for 3 minutes (Quorum model Q150). The images were then obtained with 
the scanning electron microscope (SEM, Quanta 200 FEG, FEI, Netherlands).  
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2.3.4 Bacterial culture preparation 
Lactobacillus acidophilus (LA - 5) from the Christian Hansen culture collection 
(Reading, UK) was the micro-organism used. L. acidophilus was grown on de 
Man, Rogosa and Sharpe (MRS) agar and incubated under anaerobic 
conditions for 48 hours at 37 ºC. A few colonies were taken and used to 
inoculate 7 ml of MRS broth to create a starter culture and incubated for 24 
hours. 99 ml of fresh MRS broth was inoculated with 1 ml of the starter culture 
to create a 1: 100 dilution. This was incubated for another 24 hours, at which 
point the bacteria were in the stationary phase. The culture was then mixed 
using a magnetic stirrer to ensure an even mixture and then dispensed into 
falcon tubes. Centrifugation was done at 9500 rpm and 4 ºC for 10 minutes 
using a Sigma 3-16KL centrifuge (Germany) to harvest the cells after which 
supernatant was removed carefully by suction. The cells were washed with 
phosphate-buffered saline (PBS) and centrifuged at 9500 rpm and 4 ºC for 10 
minutes. The supernatant was removed by suction and the washing process 
repeated. The cells were resuspended in ¼ Ringer’s solution made up with 
15% v/v glycerol, acting as a cryoprotectant. The bacterial cultures were mixed 
continuously using a magnetic stirrer and 1.8 ml of the culture was rapidly 
dispensed aseptically into 2 ml cryovials (Nunc). Sealed vials were immersed 
gently into liquid nitrogen for 10 minutes after which the frozen vials were 
removed and stored in a freezer at – 80 ºC. Post-freezing enumeration was 
approximately 107 CFU/ml representing 97% recovery. 
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2.3.5 Print substrate (bio-paper) preparation  
Agar-coated glass slides (Figure 2-19) were chosen as the print substrate. 
Unless otherwise stated, this was the substrate used in this chapter. This was 
chosen to provide nutrients for cell growth and to enable work to be carried out 
with a minimum distance between stage and printhead. Microscope glass 
slides (Thermo Scientific, UK) frosted at one end were used to prepare print 
substrates. This type of slide was chosen to make room for holding the slide 
without touching the agar. Before use, the glass slides were sterilised by 
rinsing with 70% ethanol and dried. 1 ml of sterilised agar (50 ⁰C) was pipetted 
onto the end of the sterilised glass slide closer to the frosted end. The glass 
slide was held at an acute angle during the process to allow the agar to flow 
gently towards the other end. This created an even thin film of agar on the 
slide. The agar was allowed to set and the procedure was repeated such that 
each slide had two 1 ml MRS agar films on the surface. The agar-coated glass 
slides were then stored in sterile petri dishes. 
 
 
Figure 2-19: Agar-coated glass slide 
 
2.3.6 Protocol for cartridge sterilisation  
Autoclaving - saturated steam under pressure - was one of the sterilisation 
techniques investigated. Modified cartridges were wrapped in aluminium foil 
prior to autoclaving at 121 ⁰C and 100 KPa for 15 minutes. The effectiveness 
of the procedure was then determined. 1 ml of sterile deionised water was 
loaded into the ink channel of the sterilised cartridge and used to deposit a 2 
Frosted end of slide 
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cm x 2 cm square template onto Iso-sensitest agar–coated glass slides. A 
control was also run by pipetting 20 µl of the sterilised water directly onto the 
slide. The experiment was done in triplicate and the slides were incubated 
overnight at 37 ⁰C.  
70% ethanol was evaluated as an alternative sterilisation technique. The inner 
chamber and outer part of cartridges were initially rinsed repeatedly with sterile 
deionised water, then sprayed with 70% ethanol with greater attention given to 
the nozzles. Cartridges were dried completely under aseptic conditions and 
effectiveness determined as above.  
 
2.3.7 Evaluating robustness of modified printer 
These series of experiments were conducted to evaluate any potential inter- 
or intra-cartridge variations due to the modification. Three modified HP 337 
black cartridges were used for this experiment. 1 mg/ml solution of Fast Green 
dye was used as the “ink” for printing. 1 cm x 1 cm squares were printed in 
triplicate for each cartridge onto the clear acetate sheets. The print-outs were 
then carefully cut and immersed in 1 ml deionised water to dissolve dye. The 
dye solutions were vortexed to ensure complete dissolution after which high-
performance liquid chromatography (HPLC) analysis was conducted using the 
conditions described below. Statistical analyses were conducted afterwards 
using a Student's t-test with a significance level of 0.05. 
 
2.3.7.1 High-performance liquid chromatography 
The liquid chromatographic system used was Agilent Technologies 1200 
series with quaternary pump and degasser. The column used was a 
Phenomenex C18 column (150 mm x 3.90 mm, 5 µm). A gradient system 
(Table 2-1) was adopted with acetonitrile HPLC grade as the organic phase 
and 55 mM acetate buffer (pH = 5 ± 0.02) as the aqueous phase. A flow rate 
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of 1 ml/min was used for 10 minutes and the injection volume was 10 µl. A 
wavelength of 600 nm was used and the column temperature set at 30 ⁰C. 
 
Table 2-1: Gradient system used in HPLC 
Mobile phase Time (minutes) 
0 5 6 7 
Acetonitrile 15% 60% 15% 15% 
55 mM 
Acetate buffer 
85% 40% 85% 85% 
 
 
2.3.8 Effect of autoclaving on cartridge function 
This experiment was conducted to evaluate the impact of one autoclaving 
cycle on the efficiency of cartridges. Three modified HP 337 cartridges were 
used for this experiment. 1 mg/ml solution of Fast Green dye was used as the 
“ink” for printing.  
1 cm x 1 cm squares were printed in triplicate on clear acetate sheets for each 
cartridge. The print-outs were then carefully cut and dissolved in 1 ml deionised 
water. The solutions were vortexed to ensure complete dissolution and HPLC 
analyses conducted using the conditions described in section 2.3.7.1. The 
cartridges were then autoclaved and the procedure repeated. Statistical 
analyses were conducted afterwards using a Student's t-test with a 
significance level of 0.05. 
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2.3.9 Effect of thermal ink jetting on bacterial cell  
Three tests were conducted to evaluate the effect of thermal ink jetting on 
bacterial cells, i.e., colony plate counting, measuring the absorbance of 
bacterial suspension, and Gram-staining.  
2.3.9.1 Colony plate counts 
0.5 ml of L. acidophilus (107 CFU/ml) - from the bacterial stock prepared - was 
added to 4.5 ml of PBS to create a 106 CFU/ml bacterial culture. 1 ml was then 
put into the ink chamber of a sterilised cartridge for printing. The printing 
template used was a 2 cm x 20 cm rectangle. Printing was done repeatedly 
into a sterile petri dish until the volume of liquid in the petri dish was enough to 
enable withdrawal of 50 µl. This was then serially diluted (1 in 10), plated out 
onto MRS agar, and incubated for 48 hours under anaerobic conditions. Two 
cartridges were used and the experiment was done in triplicate. The initial 
number of bacteria in the sample was also determined simultaneously for each 
experiment. 
2.3.9.2 Measuring absorbance of bacterial suspension 
0.5 ml of L. acidophilus (108 CFU/ml) was put into the ink chamber of a 
sterilised cartridge and used for printing. Printing was done as above (2.3.9.1).  
50 µl was then diluted to 500 µl using PBS. A further 1 in 10 dilution was done 
(300 µl to 3 ml using PBS as diluent). 
200 µl was then transferred to 8 bijous and each diluted to 2 ml using MRS 
broth. A pipetted control experiment was also run. Both control and test bijous 
were kept at 37 °C. 1 ml from both control and test bijous was pipetted hourly 
from corresponding bijou into clean cuvettes and examined using a 
spectrophotometer (Thermo Scientific, USA) to measure the absorbance. The 
experiment was conducted in triplicate. 
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2.3.9.3 Gram-staining 
20 µl of L. acidophilus was pipetted onto a sterile glass slide and used as a 
control. 2 cm x 10 cm template was also used to deposit bacterial solution (107 
CFU/ml) onto sterile glass slides. Both samples were heat-fixed and gram-
staining experiments performed (McClelland, 2001). Slides were viewed 
afterwards using Zeiss light microscope (Germany) fitted with a camera. 
 
2.3.10 Optimising printing by modified printer 
A series of experiments were conducted to optimise the ink jetting technique. 
The bacterial concentrations used were 107, 106, 105, 104, and 103 CFU/ml. 
The print templates used were a set of 1 cm x 1 cm squares, greyscale, 2 cm 
x 2 cm square, and two rows of dots (Figure 2-20 - Figure 2-23).  To further 
test the precision and to highlight controlled delivery, a text (DODOO) using 
Calibri (font size 36) (Figure 2-24) was printed using 107, 106, 105, and 104 
CFU/ml. 1 ml of each bacterial concentration was put into a sterilised black 
cartridge and used to print the templates onto separate MRS agar-coated 
slides. After printing, the slides were incubated for 48 hours under anaerobic 
conditions. 
 
 
Figure 2-20: Image of template for set of 1 cm x 1 cm squares. 
 
   73 
 
Figure 2-21: Image of template for 2 cm x 2 cm square. 
 
 
Figure 2-22: Image of template for greyscale. 
 
 
Figure 2-23: Image of template for two rows of dots. 
 
 
Figure 2-24: Image of template for text. 
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2.3.11 Use of thermal ink jetting in antimicrobial susceptibility testing 
With the concept of MIC determination as discussed in the introduction (2.1.1), 
a model was designed whereby varying amounts of antibiotics could be applied 
to a standard bacterial population such that the lowest amount of the antibiotic 
that inhibits the visible growth of microorganisms after incubation could be 
identified. To achieve varying concentrations using IJP, a concept known as 
‘Y-value’ was introduced.  
The term ‘Y-value’ was used to represent a series of rectangles of fixed width 
but varying height (conventional Y-axis). An example of the effect of varying 
the Y-value is shown in Figure 2-25, where three rectangles have the same 
shade of black (100%) and width (0.5 cm) but the Y-value (i.e., height) changes 
from 0.5 cm to 1.5 cm. Printing these templates onto a fixed area results in a 
linear increment in the volume of solution deposited and the amount of material 
per unit area. 
 
 
Figure 2-25: Illustration of Y-value concept 
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2.3.11.1 Standardisation of cartridges 
The objective of standardising cartridges was to know the quantity of “ink” the 
cartridges jetted out for each Y-value. Y-values with a height of 0.5, 1, 2, and 
3 cm and a constant width of 0.2 cm were printed individually onto clean 
acetate sheets using 1 mg/ml Fast Green dye in the modified HP 337 black 
cartridges. The acetate sheets were carefully cut into bijous and 1 ml of 
deionised water added to dissolve the dye. The resulting solutions were then 
transferred into HPLC vials for analysis using the HPLC conditions detailed in 
Table 2-1. A calibration curve for Fast Green dye in the range 0.0625 –  2 µg/ml 
was also obtained.  
 
2.3.12 Protocol for determining minimum inhibitory concentrations  
After standardising cartridges, a model was developed whereby each print 
template had two strips with different Y-values (0.5 and 1 cm), (1.5 and 2 cm), 
and (2.5 and 3 cm) and a constant width of 0.2 cm as demonstrated in Figure 
2-26. An interval of 2.5 cm between the different Y-values was used to prevent 
cross-interaction between different Y-values. L. acidophilus was used as test 
organism and ampicillin, tetracycline, doxycycline, and amoxicillin were the 
antibiotics used. 
 
 
Figure 2-26: Illustration of MIC determination template for printing antibiotics 
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2.3.12.1 Procedure 
1 ml of known antibiotic concentration was put into the ink compartment of a 
sterilised black cartridge. This was used to print the Y-value set (0.5 and 1 cm), 
(1.5 and 2 cm), and (2.5 and 3 cm) onto MRS agar-coated slides as shown in 
Figure 2-27 on a stage, 2 mm from cartridge head. Each Y-value set was 
duplicated. The cartridge was then removed and the main parts of the printer 
that encountered the cartridge were sprayed with 70% ethanol and allowed to 
dry. 1 ml of L. acidophilus (105 CFU/ml) was put into another sterile cartridge 
and used to print an even film (1 cm x 5 cm rectangle) of bacteria across all 
the slides. A control was also set up which had just bacterial film with no drug. 
The experiment was repeated with varying antibiotic concentrations and each 
concentration triplicated. The slides were then incubated under anaerobic 
conditions for 48 hours. Broth microdilution was simultaneously performed 
using 96-well microtitre plates and results used to validate IJP results 
(Andrews, 2001). All triplicates were conducted on separate days with freshly 
prepared antimicrobial dilutions. 
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Figure 2-27: Illustration of designed MIC determination model, 0.5 cm and 1 cm Y-value (A), 
1.5 cm and 2 cm Y-value (B), 2.5 cm and 3 cm Y-value (C). 
 
2.3.13 Effect of varying contact time between bacteria and drug on MIC 
In the model designed, the bacteria and drug were placed into separate black 
cartridges and investigations were carried out to determine whether the time 
involved in changing cartridges and disinfecting parts of the printer in contact 
with cartridge influenced the MIC. Three different sets of experiments were 
conducted using the protocol (2.3.12.1) with tetracycline as the test drug. In 
the first set, tetracycline was printed first and a period of 20 minutes allowed 
before the bacteria were printed. 20 minutes was chosen because it was 
sufficient time for cartridge change and complete drying of 70% ethanol. In the 
second set, the bacteria were printed first then tetracycline immediately 
afterwards. In this instance, the jetted antibiotics encounter bacteria right after 
A B 
C 
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printing. A third set was conducted whereby an interval of 48 hours (duration 
of incubation) was allowed between drug deposition and bacterial printing.  
 
2.3.14 Effect of varying inoculum density 
The protocol for MIC determination as detailed in section 2.3.12.1 was followed 
with one set having an inoculum density of 105 CFU/ml and another set having 
an inoculum density of 106 CFU/ml. The experiment was carried out using 
ampicillin and tetracycline against L. acidophilus. 
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2.4 Results and Discussion 
The printer was functional after modification, however, with the substrate being 
stationary, templates approximately over 1 cm in length were continuously 
jetted onto a fixed area. These templates were printed onto an area with the 
length limited by the length of the nozzle plate of the cartridge. Print-outs were 
also laterally inverted. Black cartridges were used and not tricolour cartridges 
because tricolour cartridges produce droplets of different sizes from the 
different compartments of the tricolour cartridge. These droplet sizes are not 
user controllable, however, with black cartridges, droplets of the same size are 
produced and therefore presents a better option in assay development (Buanz 
et al., 2013). 
 
 
2.4.1 Measuring diameter of cartridge nozzle  
SEM images highlighted unblocked nozzles; with an average diameter of 
19.17 ± 0.1 µm (Figure 2-28). This diameter confirmed the possibility of ink 
jetting bacteria which generally have diameters in the range 0.5 – 2 µm (Jiang 
and Chen, 2016). 
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Figure 2-28: Electron micrographs of HP 337 cartridge nozzles at different magnifications  
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2.4.2 Sterilisation technique 
Sterilisation by autoclaving and the alternative sterilisation procedure, i.e. 
using 70% ethanol both proved to be effective. Most of the cartridges used 
could withstand one autoclaving cycle, however, the efficiency of some 
cartridges started declining after three cycles of autoclaving and some failed 
completely after five cycles. Thus, an alternative sterilisation protocol needed 
to be adopted. It is worth noting that cartridges are manufactured to be used 
as disposable consumables; however, in this work as with most research and 
developments, they had to be re-used a few times (Ihalainen et al., 2015). 
Autoclaving is a reliable and easily controlled process for decontamination. It 
was appropriate to evaluate the impact of an autoclaving cycle on cartridges 
whilst maintaining a milder, yet, effective alternative protocol for sterilisation of 
cartridges (Lauer et al., 1982). The results of evaluating the impact of an 
autoclaving cycle on cartridge efficiency can be found in next section. None of 
the agar-coated slides had bacterial colonies growing on them after overnight 
incubation. There was no growth on the agar-coated slides for the control as 
well, confirming sterility of the deionised water used.  
 
2.4.3 Evaluating robustness of modified printer and effect of an 
autoclaving cycle 
Printers, by their design, are robust devices, however, it was imperative to find 
the impact of the modification process on this robustness. The area under the 
curve (AUC) obtained by HPLC analysis of Fast Green dye ink jetted before 
and after autoclaving is indicated in Table 2-2. 
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Table 2-2: Area under curve obtained via HPLC before and after autoclaving (n=3). 
The relative standard deviation (RSD) was used as a means of quantifying the 
robustness of the modified printer. Prior to autoclaving, RSD values of 2.17%, 
0.25%, and 0.87% were obtained for the three cartridges and after autoclaving, 
RSD values of 0.86%, 0.42% and 0.62% respectively were obtained. These 
low values (less than 5% RSD) indicated the repeatability and precision of the 
procedure, highlighting the robust nature of the modified inkjet. Statistical 
analyses performed with a Student's t-test showed the average AUC values 
before and after autoclaving were not significantly different (p > 0.05); 
confirming that a single autoclaving cycle did not have a negative impact on 
the cartridges. In instances where the experimenter prefers to use autoclaving 
as a sterilisation technique, it will be prudent to perform just one autoclaving 
cycle.  
  
 
 
Cartridge Average 
Area Under 
Curve 
Standard 
Deviation 
Relative 
Standard 
Deviation 
 
Before 
Autoclaving 
1 232.33 5.03 2.17 % 
2 232.33 0.58 0.25 % 
3 239.33 2.08 0.87 % 
     
After  
Autoclaving 
1 242.67 2.08 0.86 % 
2 238.00 1.00 0.42 % 
3 246.67 1.53 0.62 % 
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2.4.4 Effect of thermal ink jetting on bacterial cell 
Colony plate counting – a conventional bacterial enumeration technique – was 
used to evaluate bacterial viability. Analysis of bacterial cells after thermal ink 
jetting showed the cells were intact and viability was comparable to the control. 
This evaluation revealed that the printing procedure did not have any 
deleterious effect on bacterial viability. The bacterial population after ink jetting 
was similar to that of control (pipetted); approximately 107 CFU/ml in all 
instances (Figure 2-29).  
 
Figure 2-29: Effect of thermal ink jetting on bacterial viability (y-axis, cell number expressed 
as Log CFU/ml; x-axis, a triplicate sampling of two independent cartridges and control which 
represents the original cell number before printing). 
Bacterial absorbance at 600 nm is a technique used for bacterial enumeration. 
Absorbance at this wavelength is directly proportional to bacterial population 
as it gives an indication of the turbidity of the medium. Bacterial growth can be 
categorised into lag, log, and stationary phases (Braissant et al., 2013). These 
are characteristic of any bacterial species. The lag phase characteristics of 
thermal ink jetted L. acidophilus was, therefore, monitored using absorbance 
at 600 nm. The absorbance of both the thermal ink jetted and pipetted (control) 
bacterial species were almost superimposable in the lag and early log phases 
of bacterial growth, (Figure 2-30), indicating no significant change in growth 
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characteristics. This further highlighted the negligible effect of the thermal ink 
jetting procedure on bacterial viability. 
 
Figure 2-30: Bacterial absorbance at 600 nm comparing thermal ink jetted (TIJ) and pipetted 
(control) bacteria, showing almost superimposable values with error bars representing 
standard deviation from mean values. 
The final assessment conducted was the Gram-staining experiment. This is a 
simple albeit useful technique to differentiate bacteria into two large groups, 
Gram-positive and Gram-negative. The basis for this differentiation is the 
physical and chemical composition of the cell wall of bacteria which helps to 
retain and release stains (McClelland, 2001, Bartholomew and Mittwer, 1952). 
Gram-staining was key in evaluating any potential damage the thermal ink 
jetting procedure may have caused to bacterial cell wall integrity. Visualisation 
by light microscopy after Gram-staining revealed that both the ink jetted and 
pipetted bacteria gave the same outcome, i.e., adsorbed primary dye (Figure 
2-31). This implied the cell wall integrity of bacterial species were still intact 
with no damage to the cell wall incurred during droplet formation. A live/dead 
staining technique could also have been performed to ascertain the viability of 
the ink jetted cells (Green et al., 2011). 
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Figure 2-31: Light microscope images after Gram-staining pipetted (left) and ink jetted (right) 
L. acidophilus. 
In bio-printing, it is important that the selected printing method is neither toxic 
nor irreversibly damaging for cells and their DNA (Mironov et al., 2006). The 
primary concern when using thermal inkjets to print bacteria is whether cell 
viability will be maintained after transit through the printhead because the 
heating elements can reach a significantly high temperature (about 200 ºC) 
during droplet formation. This is a major reason why most bioprinting work is 
usually conducted with piezoelectric printers (Allain et al., 2004). Although the 
temperature at the surface of the heating element increases during droplet 
formation, the actual temperature rise in the printing solution is significantly 
smaller; the heat acts to create expanding gas bubbles that drive the droplet 
from the nozzle and the bubbles effectively insulate the solution. Xu et al. 
(2005) showed that viable Chinese hamster ovary cells (mammalian cells) 
could be printed with a viability of 90% and that the effective temperature of 
the solution (bio-ink), does not rise more than 10 ºC above ambient conditions. 
Since mammalian cells can be successfully printed, bacterial cells should in 
principle be unaffected by the process of inkjet printing since these are 
relatively tougher organisms as demonstrated here. Merrin et al. (2007) have 
demonstrated bacterial viability after printing with piezoelectric printers. Zheng 
et al. (2011) have used fluorescence to ascertain viability after ink jetting.  
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2.4.5 Optimising ink jetting by the modified printer 
Post-incubation images when a set of 1 cm x 1 cm squares was the template 
for ink jetting 107, 106, 105, 104 and 103 CFU/ml bacterial concentrations are 
shown in Figure 2-32. 107 and 106 CFU/ml (A and B), showed clearly defined 
squares of bacterial colonies, however, there were some colonies observed 
outside the designed template (satellite growths). 105 CFU/ml (C) resulted in 
bacterial growth with a defined outline representative of the template with no 
satellite growth. For 104 CFU/ml (D), although there were no satellite growths, 
a lower bacterial density was visible relative to 105 CFU/ml. Colonies observed 
for 103 CFU/ml (E) had no resemblance to the print template used. 
 
      
      
 
Figure 2-32: Post-incubation images for the set of 1cm x 1cm squares (107 CFU/ml (A), 106 
CFU/ml (B), 105 CFU/ml (C), 104 CFU/ml (D), and 103 CFU/ml (E)). 
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When ink jetting was done with a 2 cm x 2 cm square, the print-outs had the 
horizontal element of the square being longer than the vertical (Figure 2-33). 
This was expected as the modification of the printer had restricted print-outs 
to a maximum vertical element equivalent to the length of cartridge nozzle 
hence, any shape with a vertical element greater than the length of the 
cartridge nozzle will be printed repeatedly onto the same area. The trends of 
the print-outs were like the earlier images (Figure 2-32). 107, 106, 105, and 104 
CFU/ml showed clearly defined shapes of bacterial colonies (A-D), with 107 
and 106 CFU/ml having satellite growths. 103 CFU/ml showed colonies with no 
resemblance to the template (E). 
 
      
      
 
Figure 2-33: Post-incubation images of 2 cm x 2 cm square (107 CFU/ml (A), 106 CFU/ml 
(B), 105 CFU/ml (C), 104 CFU/ml (D), and 103 CFU/ml (E)). 
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A greyscale template with black at one end decreasing gradually in intensity to 
white at the other end was used. It was expected that after incubation, a 
densely populated bacterial growth will be observed at the end representing 
black with the bacterial density decreasing gradually to no bacterial growth at 
the end representing white (Figure 2-34). 107 CFU/ml showed a very densely 
populated strip and the gradual reduction in bacterial density was not clearly 
observed; satellite growths were also present (A). 106 and 105 CFU/ml showed 
well-defined strips with no satellite growths (B and C), the gradual decline in 
bacterial density was, however, more visible in 105 CFU/ml. 104 CFU/ml 
showed a strip with a decrease in bacterial density across the slide, however, 
the decrease in density was not consistent and representative of the template 
(D). 103 CFU/ml had colonies not consistent with the template (E). 
 
       
      
 
Figure 2-34: Post-incubation images of greyscale (107 CFU/ml (A), 106 CFU/ml (B), 105 
CFU/ml (C), 104 CFU/ml (D), and 103 CFU/ml (E)). 
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Printing was also done with two rows of twenty dots to ascertain the ability of 
the modified printer to transfer images in detail (Figure 2-35). 107, 106, and 105 
CFU/ml showed clearly defined dots with 107 and 106 CFU/ml having satellite 
growths (A and B). 104 CFU/ml had colonies across the length of the agar-
coated slide representative of the entire length of the dots, however, these dots 
were not clearly defined (D). 103 CFU/ml had a few colonies on the slide (E). 
 
    
    
 
Figure 2-35: Post-incubation images of two rows of dots (107 CFU/ml (A), 106 CFU/ml (B), 
105 CFU/ml (C), 104 CFU/ml (D), and 103 CFU/ml (E)). 
To further test the ability of the modified inkjet printer to print in detail, a text 
(DODOO) was used as the template. Post-incubation images for 
concentrations used (107, 106, 105 and 104 CFU/ml) are shown in Figure 2-36. 
Bacterial growth was visible with letters separated; 105 CFU/ml, however, 
produced the most well-defined image without satellite growth (C). 
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Figure 2-36: Post-incubation images of text (107 CFU/ml (A), 106 CFU/ml (B), 105 CFU/ml 
(C), and 104 CFU/ml (D)). 
The satellite growths observed for the various templates can be attributed to 
the aerosols accompanying droplet formation during ink jetting (Iida et al., 
2014, Udey et al., 2013). Since the distance between the printhead and the 
substrate was kept at a permitted minimum, it was inferred that for controlled 
printing, 107 and 106 CFU/ml were not the optimum concentrations to use, due 
to bacterial colonies growing at unexpected regions. 105 CFU/ml produced 
results typical of the print templates used and had no satellite growths. 104 and 
103 CFU/ml produced results with no satellite growths, however, the nature of 
the images produced after incubation were usually not representative of the 
print templates and this can be attributed to the fact that the low bacterial 
concentration resulted in some of the printed droplets not having bacterial cells 
in them. From the above, 105 CFU/ml was chosen as the optimum 
concentration of L. acidophilus to use for controlled delivery under the 
conditions used.  
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2.4.6 Use of thermal ink jetting in antimicrobial susceptibility testing 
Prior to AST, it was imperative to standardise the cartridges. This gave 
information about the jetting characteristics of the cartridge and helped in 
determining the amount of material jetted with a given set of templates. Fast 
green dye was used in the standardisation. Any dye can be used for 
standardisation so long as quantitative analysis can be conducted afterwards. 
Fast Green dye was selected based on availability and the possibility of 
quantifying deposited amounts analytically. HPLC was used to ascertain the 
quantity jetted out as Fast Green absorbs light at 600 nm. Y- values with height 
0.5, 1, 2, and 3 cm with a constant width of 0.2 cm were the dimensions of the 
template used in standardisation. It was necessary to standardise using the 
same Y-values to be used in MIC determination. A calibration curve (Figure 
2-37) for Fast Green dye was obtained with a good linearity (r2 = 0.9999) 
between 0.0625 and 2 µg/ml. The graph of Y-value against area under the 
curve (AUC) (Figure 2-38) was also linear (r2 = 0.9992) validating the Y-value 
concept. The volume of liquid deposited by inkjets usually contains a solute 
which is a fraction of the total solute in the cartridge. This fraction is fixed per 
template; this is denoted here as the characteristic ratio per template. This was 
obtained by expressing the amount of Fast Green dye per Y-value as a fraction 
of the cartridge concentration used in printing Y-values (Equation 2-1). A plot 
of the characteristic ratio against the Y-value for the templates used is shown 
in Figure 2-39.  
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Figure 2-37: Calibration curve for Fast Green dye between 0.0625 – 2 µg/ml. 
 
 
Figure 2-38: Y-value against area under curve (AUC) 
 
Equation 2-1 
𝑐ℎ𝑎𝑟𝑎𝑐𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐	𝑟𝑎𝑡𝑖𝑜 = 	 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑐𝑎𝑟𝑡𝑟𝑖𝑑𝑔𝑒	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  
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Figure 2-39: Y-value against characteristic ratio 
Once the cartridges had been standardised, susceptibility testing could in 
principle be performed with the MIC being the least Y-value at which growth 
was inhibited. Figure 2-40 shows images from MIC determination for ampicillin 
using a concentration of 0.2 mg/ml in the cartridge. Figure 2-40A shows an 
even strip of bacterial colony after incubation, i.e., the control. Figure 2-40B 
shows a similar colony pattern to the control even though an antibiotic solution 
was deposited, indicating that the concentration of antibiotic present was not 
enough to inhibit the growth of L. acidophilus. Two distinct zones were seen in 
Figure 2-40C, representative of growth inhibition, in the areas where the 
antibiotic solution was deposited. Figure 2-40D showed almost no growth on 
the slide. The MIC in this instance was the concentration of drug at a Y-value 
of 1.5 cm; this was the least concentration of antibiotic that inhibited bacterial 
growth after incubation. Figure 2-40C also represents an ideal image for MIC 
determination since the two different concentrations are clearly visible. 
Assuming Figure 2-40D was the first slide to show inhibition, a higher cartridge 
drug concentration would have been used for observation. In Figure 2-40D, it 
is difficult to infer if there had been any interaction between the two Y-values 
due to growth inhibition across the whole slide. 
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Figure 2-40: Illustration of MIC on bio-paper post-incubation; Control (A), 0.5 cm and 1 cm y-
value (B), 1.5 cm and 2 cm y-value (C), 2.5 cm and 3 cm y-value (D). 
Table 2-3 represents results after incubation for the various cartridge 
concentrations evaluated, with ‘+’ indicating growth and ‘-’ representing no 
growth for the indicated Y-values. 
 
 
  
A B 
C D 
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Table 2-3: Results for MICs determined via ink jetting. 
Drug Cartridge 
concentration 
(mg/ml) 
Y-value (cm) 
0.5  1.0  1.5  2.0  2.5  3.0  
Tetracycline 0.1 
0.10.2 
+ + + + + + 
0.2 
0.30.2 
+ + + + + + 
0.3 
0.3 
+ + + + + + 
.6 
0.6 
+ + + + - - 
.7 
0.7 
+ + + - - - 
        
 
Ampicillin 
0.1 
0.100  
+ + + + + - 
0.2 
0.20  
+ + - - - - 
. 5 
0.25  
+ + - - - - 
        
Doxycycline 0.3 + + + + - - 
0.4 + + + - - - 
0.5 + + - - - - 
0.6 + + - - - - 
        
Amoxicillin 0.2 + + + + - - 
0.3 + + + - - - 
0.4 + - - - - - 
0.5 + - - - - - 
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The MIC obtained by the broth microdilution (Table 2-4) was recorded in the 
standard manner; i.e., if growth was observed at 0.5 µg/ml and no growth was 
observed at 1 µg/ml, the MIC was documented as 1 µg/ml. However, with the 
ink jetting technique because the concentration terms were in linear 
increments rather than doubling increments, MIC’s were rounded off to the 
next incremental doubling dilution for comparisons with broth microdilution 
(Table 2-5). A similar approach was adopted when comparing spiral gradient 
endpoints with standard techniques and since the ink jetting model being 
designed is similar to the SGE technique, the same approach of comparison 
was used (Hill and Schalkowsky, 1990). 
 
Table 2-4: Results for MICs determined via broth microdilution. 
Drug MIC 
Tetracycline 2 µg/ml 
Ampicillin 0.25 µg/ml 
Doxycycline 1 µg/ml 
Amoxicillin 0.5 µg/ml 
 
 
A sample calculation for the corresponding MIC value using 0.6 mg/ml 
tetracycline is shown below: 𝑀𝐼𝐶	𝑎𝑡	2.5𝑐𝑚 = 0.6	𝑥	(𝑐ℎ𝑎𝑟𝑎𝑐𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐	𝑟𝑎𝑡𝑖𝑜	𝑎𝑡	2.5	𝑐𝑚) 
From graph (Figure 2-39), 2.5 cm º 0.001 𝑀𝐼𝐶 = 0.6	𝑥	0.001 = 	6	x	10AB	mg/ml	(0.6	µg/ml) 
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Table 2-5: Results for MICs determined via ink jetting (IJP) and broth microdilution. 
 
Antibiotic 
Cartridge 
Concentration 
(mg/ml) 
Inkjet 
printing 
(MIC) (µg/ml) 
Corrected 
IJP MIC 
(µg/ml) 
Broth 
microdilution 
(MIC) (µg/ml) 
 
Tetracycline 
0.60  0.60 1 2  
0.70  0.56  1 2  
     
 
Ampicillin  
0.10  0.12  0.125 0.25  
0.20  0.12  0.125 0.25  
0.25  0.15  0.25 0.25  
     
 
 
Doxycycline 
 
0.3 0.30 0.5 1 
0.4 0.32 0.5 1 
0.5 0.30 0.5 1 
0.6 0.36 0.5 1  
     
 
 
Amoxicillin 
0.2 0.20 0.25 0.5  
0.3 0.24 0.25 0.5 
0.4 0.16 0.25 0.5 
0.5 0.20 0.25 0.5 
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The corrected MIC values from the test concentrations used were all within 
one doubling dilution from the broth microdilution MIC, which were within the 
range of acceptable MIC values when comparing with a standard technique 
(Pong et al., 2010, Wexler et al., 1996, Paton et al., 1990, Andrews, 2001, 
Jorgensen and Ferraro, 2009). As a model still in developmental stages, this 
outcome was considered very promising and a good foundation for further 
optimisation.  
Zheng et al. (2011) attempted to use ink jetting in assessing the susceptibility 
of bacteria to antimicrobial agents. In their approach, a rectangular gradient 
grey strip ranging from pure white at one end to pure black at the other end 
was used to print antibiotic solutions onto the bacterial coating. The gradient 
grey scale was used as a means of delivering antibiotics with a continuous 
concentration gradient. The results obtained were compared with MIC values 
calculated from zones of growth inhibition. 
A major criticism identified with their technique is the possible diffusion of drug 
solution on agar-coated slides which could result in difficulty identifying 
accurately the lowest inhibitory concentration since the concentration 
variations were continuous. The cup plate method used as a standard for 
comparison was also not the best option to use in quantitative MIC 
determinations (Amsterdam, 1996). We consider the use of the Y-value in this 
work as a better approach, as it offers discrete concentrations. 
Smith and Kirby, (2016), demonstrated a more accurate technique in AST via 
ink jetting. With the aid of a commercial digital dispenser, HP D300, they 
deposited antimicrobial stock solutions, in 2-fold serial dilutions, directly into a 
384-well plate for broth microdilution testing. After addition of bacteria and 
incubation, MICs were determined by plate absorbance readings and 
automated data analysis. The cost element of the digital dispenser and plate 
reader is a major limitation with this approach especially, in resource-
challenged regions. 
Investigations conducted to ascertain whether the time of contact between 
antibiotics and bacteria played a role in MIC determinations are shown in Table 
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2-6. Comparable results were obtained when the antibiotic (tetracycline) was 
printed immediately onto bacteria and when an interval of 20 minutes – to 
make up for time used to change cartridges and disinfect vital parts of printer 
– was allowed between antibiotic deposition and bacterial prints. In both 
instances, a cartridge concentration of 0.3 mg/ml yielded no growth inhibition 
whilst 0.7 mg/ml cartridge concentration resulted in growth inhibition at a Y-
value of 2.0 cm equivalent to 0.56 µg/ml. Growth was observed for 0.3 mg/ml 
in both instances and this could possibly be that the effective concentrations 
on the slides were sub-inhibitory. When an interval of 48 hours was allowed 
between printing of drug and antibiotic, growth was observed and the nature 
of bacterial growth on all slides for both 0.3 mg/ml and 0.7 mg/ml cartridge 
concentrations were similar to that of control. This could also be that the 
effective drug concentration on the slides decreased over the duration 
highlighting a possible time dependence nature of this model. 
This implies that unlike other susceptibility testing techniques (agar dilution) 
whereby media with antibiotics incorporated can be stored for future use, it will 
be inappropriate with this technique. This observation could be because the 
volume of antibiotic solution incorporated onto agar-coated slides was very 
small. Hill and Schalkowsky (1990), revealed that MICs don’t vary significantly 
when an interval of interaction up to 7 hours was allowed between drug and 
organism. However, since relatively smaller quantities of antibiotics were used 
here in comparison to the SGE technique, the impact of time on the MIC is 
very significant. Also, in instances where anaerobic species are being 
investigated, it is better to keep the interval of interaction to a minimum as 
these organisms require a longer generation time. It is, therefore, 
recommended that for consistency in MIC results with this model, it is best to 
perform tests within a time frame of 20 minutes.  
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Table 2-6: Results showing the effect of contact time on MIC values 
 
Time 
 
 
 
Cartridge 
concentration 
(mg/ml) 
 
Y-value (cm) 
  
0.5  
 
1.0  
 
1.5  
 
2.0  
 
2.5  
 
3.0  
 
 
0 mins 
 
0.3  
+ + + + + + 
 
0.7  
+ + + - - - 
        
 
 
20 mins 
 
0.3  
+ + + + + + 
 
0.7  
+ + + - - - 
        
 
 
48 hours 
 
0.3  
+ + + + + + 
 
0.7  
+ + + + + + 
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When the inoculum density was increased from 105 to 106 CFU/ml, an 
increment of 0.5 cm y-value was observed for all MICs except for 0.7 mg/ml 
tetracycline (Table 2-7). The relatively higher equivalent MIC values for the 106 
CFU/ml inoculum was expected because a slightly greater bacterial population 
was being acted upon by the same amount of antibiotic as used for 105 
CFU/ml. However, when these MIC values were corrected by rounding up to 
the next doubling dilution for comparison with standard techniques; the values 
obtained for ampicillin using 105 CFU/ml inoculum (0.125 µg/ml) and 106 
CFU/ml inoculum (0.25 µg/ml) increased by one doubling dilution. The MIC 
obtained for 106 CFU/ml inoculum was, therefore, equal to that for the broth 
microdilution as seen in Table 2-4. For tetracycline, however, the same MIC 
value was observed for both inoculum densities i.e., 1 µg/ml for both 105 
CFU/ml and 106 CFU/ml inoculum densities. A plausible explanation for this is 
that as the MIC values increased, the range between successive doubling 
concentrations increased correspondingly, resulting in a greater likelihood for 
slightly higher MIC values obtained via ink jetting to be similar when corrected 
to the next doubling concentration irrespective of the change in inoculum 
density. A major drawback with the use of 106 CFU/ml inoculum was the 
satellite drops on the agar- coated slides, hence, 105 CFU/ml would still be 
used for subsequent fine tuning of the model. 
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Table 2-7: Results showing effect of inoculum density on MIC. 
 
Antibiotic 
Cartridge 
concentration 
(mg/ml) 
105 CFU/ml inoculum 
density 
106 CFU/ml inoculum 
density 
  MIC     
Y-value 
(cm) 
Equivalent 
concentration 
(µg/ml) 
MIC     
Y-value 
(cm) 
Equivalent 
concentration 
(µg/ml) 
 
 
 
Ampicillin 
0.10  3.0  0.12  No MIC N/A 
0.20 1.5  0.12  2.0  0.16  
0.25  1.5  0.15  2.0  0.20  
      
 
 
Tetracycline 
0.60  2.5 0.60  3.0  0.72  
0.70  2.0 0.56 3.0  0.84  
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2.5 Conclusion  
A thermal inkjet (HP 5940) was successfully modified, substituting the paper 
feeding mechanism with printing onto a stationary stage, without inhibiting its 
key functionality. An effective sterilisation protocol, whereby, cartridges can be 
sterilised using autoclaving was evaluated. This method is appropriate when 
cartridges are to be used as disposable consumables. When cartridges are 
intended for multiple use, sterilisation with 70% ethanol is a milder and 
effective alternative. The modified printer was also found to maintain its 
robustness, exhibiting insignificant inter- and intra-cartridge variability. 
A model for the determination of MICs using ink jetting was designed and used 
to determine the MIC of ampicillin, tetracycline, amoxicillin, and doxycycline 
against Lactobacillus acidophilus. The MIC values obtained were all within one 
doubling dilution from MIC obtained via a broth microdilution standard. This 
range is considered acceptable when comparing MICs obtained by a different 
technique with a standard technique.  
With antimicrobial resistance being a global issue and the rapid emergence of 
multidrug-resistant bacteria, there is often a need to perform susceptibility 
testing for less commonly used or newer antimicrobial agents. The automated 
susceptibility testing model described here, aims to address the heavy 
workload of manual testing and to bridge the cost element of automated 
susceptibility testing to make this accessible irrespective of the availability of 
funds.   
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Chapter 3 Formulating Probiotics for Oral Delivery using 
Thermal Ink Jetting 
3.1 Introduction 
Dairy products supplemented with probiotics are a natural means of probiotics 
administration. However, for the purposes of prevention or treatment of 
diseases, specifically targeted applications, formulae, devices, or carriers with 
a slow release of probiotics might be needed (Meurman and Stamatova, 2007). 
As detailed in the chapter 1, current techniques for the formulation of probiotics 
mainly involve microencapsulation via spray-drying or freeze-drying. There 
are, however, contrasting reports on the effect of microencapsulation on 
bacterial cell viability upon storage and protection from harsh conditions. Some 
researchers have found the process to have significant effects on bacterial 
viability and tolerance to gastric acids; others have reported no significant 
improvement after microencapsulation (Guerin et al., 2003, Iyer and 
Kailasapathy, 2005, Sun and Griffiths, 2000, Sultana et al., 2000). 
Due to the harshness of these manufacturing process, excipients are added. 
Pharmaceutical formulations are generally made up of two main parts, the 
active ingredient and the excipients. Excipients are added to enhance product 
performance by providing a more efficacious product as well as improve 
stability and patient compliance. An ideal excipient aids in maintaining product 
uniformity and stability throughout the manufacturing process to administration 
by the consumer (Elder et al., 2016, Abrantes et al., 2016). 
In a probiotic formulation, excipients are mainly needed to maintain the viability 
of cells throughout the formulation process and upon storage. Most probiotic 
formulations are made by drying the bacterial cells as such the excipients often 
used are mainly to enable cells to withstand elevated temperatures and 
maintain viability during storage. These excipients are generally known as 
protectants. Microorganisms usually survive better in low water activity, 
however, over-drying results in severe often lethal stress; protectants tend to 
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create a balance with optimum water activity to maintain viability (Carvalho et 
al., 2004, Desmond et al., 2001, Wang et al., 2004, Potts, 2001). 
A variety of protectants have been used including carbohydrates (especially 
the sugars, e.g., trehalose, sucrose, lactose, and glucose), amino acids 
(sodium glutamate), polymers (dextran and polyethylene glycol), polyols 
(glycerol and mannitol) as well as complex mixtures like non-skimmed fat milk 
(Efiuvwevwere et al., 1999, Costa et al., 2000).  
Due to the challenges encountered with current formulation strategies, the 
potential of ink jetting – which has been demonstrated in the previous chapter 
not to have any damaging effect on bacterial cells – in formulating probiotics 
was investigated. L. acidophilus (LA 5), an aero-tolerant organism, was chosen 
as the model probiotic species rather than a Bifidobacterium spp. since it 
presents greater flexibility in these initial stages of formulation development. 
Lactobacilli are also the most common probiotic bacteria associated with the 
human GIT (Caglar et al., 2005). The tolerance of the formulated probiotic to 
gastrointestinal fluid was evaluated. To target these formulated probiotics to 
the intestines, the ink jetted formulation was encapsulated into ready-to-use 
capsules coated with Phloralâ. Phloralâ is a coating technology – developed 
at University College London – that targets the release of drugs to the colon. 
It consists of a blend of bacteria-activated (resistant starch) and pH-activated 
(Eudragitâ S) components. The independent triggers of a bacterially-triggered 
component within a pH-responsive polymer are effective, complementary, and 
act as failsafe mechanisms for each other in drug delivery (Ibekwe et al., 2008, 
McConnell et al., 2008). The ability of the formulated probiotic to adhere to 
intestinal cells was also ascertained in vitro using Caco-2 cells. The 
antibacterial property of the formulation was finally assessed against E. coli. A 
major analytical technique, isothermal calorimetry, which was used is 
elaborated further upon. 
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3.1.1 Isothermal microcalorimetry 
Microcalorimetry is a non-invasive and non-destructive technique which works 
on the basic principle that all physical and chemical processes are 
accompanied by heat exchange between a system and the surrounding. The 
resulting heat flow is measured as a function of time. Isothermal 
microcalorimetry (IMC) involves measurement under isothermal conditions in 
the microwatt range. Other types of calorimeters are differential scanning, 
adiabatic, constant-volume, and constant-pressure calorimeters (Zhao et al., 
2013, Braissant et al., 2010c, von Ah et al., 2009, Phipps and Mackin, 2000).  
All living systems produce heat; therefore, physiological activity can be 
monitored by calorimetry with measurements being proportional to the rate at 
which a given chemical or physical process takes place. Physiological studies 
using IMC is not a new concept; studies date back to the 18th century where 
scientists used an ice calorimeter to monitor heat released by small animals 
(Braissant et al., 2010a).  
Isothermal microcalorimeters (Figure 3-1) are often employed in 
thermodynamic investigations; they are also useful as general analytical 
instruments, for example, in the characterisation of stability and incompatibility 
of materials of pharmaceutical and technical importance (Johansson and 
Wadso, 1999). 
IMC possesses varied advantages, one of which is the inherent sensitivity of 
the technique. With sensitivity as low as 0.2 µW, a wide range of processes 
can be monitored. Isothermal microcalorimeter thermostats can be set at any 
temperature within an instrument’s performance range (e.g. 15 - 300°C) with 
a high accuracy, typically within 0.02 °C. IMC being a passive and non-
destructive method does not require much sample preparation and allows 
subsequent evaluations of any kind on the undisturbed sample. IMC also 
imposes no requirements on the physical nature of the sample under 
investigation (the sample can be solid, liquid, or inhomogeneous). In addition, 
rate processes involving samples that are difficult to monitor in real-time using 
other methods - e.g., those taking place on opaque solids or in porous samples 
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- can be monitored easily using microcalorimetry (Said et al., 2015, Braissant 
et al., 2010a, Braissant et al., 2010c, Koenigbauer, 1994).  
 
Figure 3-1: Image of thermal activity monitor (TAM 2270) 
IMC, notwithstanding its advantages, has some limitations and challenges. A 
major limitation with IMC is the non-specific nature of the heat signal. Heat 
arises as a result of physical or chemical processes in the system. A 
calorimetric signal will not identify a measured process or its different phases. 
Another drawback with the use of IMC especially when biological systems are 
involved is oxygen depletion and the build-up of metabolic waste due to a 
closed system being employed. These challenges must be considered during 
data analysis. Also, most IMC experiments require a period of equilibration 
during which the sample and reference attain the same temperature. In 
instantaneous processes, data are lost during this period; however, this can 
be reduced by using flow systems. It has also been noted that IMC offers lower 
throughput as compared to other analytical techniques (Wadso, 2002, 
Johansson and Wadso, 1999, Braissant et al., 2010c). 
   108 
IMC is an extremely versatile technique and has been applied in many fields 
including clinical and pharmacological analyses, ecology, agriculture, forestry, 
and biotechnology (Johansson and Wadso, 1999). Some medical and 
pharmaceutical applications are highlighted below. 
IMC can be used as an appropriate tool for detection of infections or microbial 
contamination of clinical products. Bacterial contamination of platelet products 
remains one of the most important causes of transfusion-related morbidity and 
mortality (Trampuz et al., 2007). IMC has been used for the rapid detection of 
platelet contamination by microorganisms. IMC is also effective in monitoring 
in real-time slow growing organisms. Contamination by Mycobacterium 
tuberculosis, for instance, can be detected using this technique within hours to 
a few days (Braissant et al., 2010b). 
IMC is a useful tool with potential in AST. With bacterial metabolism being 
accompanied by heat, the susceptibility of microorganisms can be determined 
readily as the rate of metabolism is directly proportional to the number of viable 
organisms. von Ah et al. (2009) used IMC to determine minimum inhibitory 
concentrations of antibiotics against microorganisms. IMC has been used to 
evaluate the efficacy of silver wound dressings against common wound 
bacteria (Said et al., 2014b). 
IMC has been used in solid state characterisation to investigate properties like 
crystallisation. IMC can detect very low levels of amorphicity which is not 
possible with conventional techniques like x-ray powder diffraction. This makes 
it a useful analytical instrument after processes (e.g., milling, compaction) that 
may impart degrees of amorphicity to crystalline products (Phipps and Mackin, 
2000).  
IMC can be applied in the study of dissolution properties of solids in simple 
and, more importantly, complex media (Buckton et al., 1991, Ashby et al., 
1989). Buckton and colleagues (1989) used this technique to study the 
dissolution of tetracycline hydrochloride from a commercial sustained-release 
product and from a dispersion of the drug in a semi-solid matrix.  
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Microcalorimetry being a direct measurement of reaction processes occurring 
within a sample can be used to investigate physical and chemical stability of 
materials. This has been used in emulsion technology to study the physical 
stability of components and the surfactants (Fubini et al., 1988, Fubini et al., 
1989). 
Just as IMC can be useful in studying antimicrobial susceptibility, it can be 
used in investigating probiotics, where real-time data can be obtained. This 
technique can be used to evaluate the behaviour of microbes to varying 
environmental conditions in GIT as well as the comparison of formulations. 
With the rise in health claims of probiotics, IMC can be used to evaluate 
interactions between probiotics and potentially pathogenic bacteria that exist 
within the microbiota. The technique has been used to compare some probiotic 
products on the market (Fredua-Agyeman and Gaisford, 2015, Fredua-
Agyeman et al., 2017).    
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3.2 Aims 
• To design an appropriate probiotic bio-ink for ink jetting. 
• To evaluate the recovery of ink jetted probiotics from a substrate. 
• To assess the viability and stability of the probiotic formulation with time. 
• To evaluate the tolerance of the probiotic formulation to gastrointestinal 
fluid.  
• To overcome any potential barriers to delivering viable strains to the 
intestines. 
• To evaluate adhesion of L. acidophilus to intestinal cells. 
• To evaluate the antibacterial properties of the probiotic formulation. 
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3.3 Materials and Methods 
3.3.1 Print substrate 
Edible starch paper (Lakeland, UK) was the print substrate used in this 
chapter. 
 
3.3.2 Growth media and reagents 
Sodium hydroxide pellets, sodium chloride, and glacial acetic acid were 
purchased from Fisher Scientific, UK. Sodium dihydrogen phosphate dihydrate 
and hydrochloric acid were purchased from VWR, UK. The simulated intestinal 
fluid powder used was from Biorelevant, UK. Pepsin, dimethylsulphoxide, 
trehalose, xylitol, sucrose, glucose, and triton X-100 were purchased from 
Sigma-Aldrich, UK. Dulbecco’s Modified Eagle Medium, heat-inactivated foetal 
bovine serum, 1% non-essential amino acid, trypsin-ethylene diamine 
tetraacetic acid, and trypan blue dye were from Gibco, UK.  Cooked meat 
medium, nutrient agar, and MRS agar were from Oxoid, UK. 
 
 
3.3.3 Bio-ink formulation 
The bacterial stock prepared in section 2.3.4 was used. This was to prevent 
batch-to-batch variability observed with freshly prepared daily cultures. 
Depending on the intended cell density, a few frozen vials were centrifuged 
and concentrated. Frozen cells were thawed in a water bath at 40 °C for 3 
minutes (Said et al., 2014a). The bio-ink was then made by suspending 
bacteria in phosphate-buffered saline (PBS). 
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3.3.4 Evaluating recovery from substrate 
Calorimetry and colony plate counting were the techniques used for this 
evaluation. The bio-ink was composed of 107 CFU/ml bacterial population 
suspended in PBS. A 1 cm x 2 cm rectangular template was used for ink jetting 
onto edible starch paper. 
Calorimetric readings were conducted by carefully inserting the imprinted 
starch paper into sterile 3 ml calorimetric ampoules filled with 3 ml of pre-
warmed (37 °C) MRS broth. The ampoules were then hermetically sealed as 
shown in Figure 3-2 by crimping and vortexed for 10 seconds. Calorimetric 
readings were then taken over a period of 40 hours. 
 
 
Figure 3-2: A hermetically sealed glass ampoule filled with MRS broth 
All calorimetric experiments were conducted using a 2277 Thermal Activity 
Monitor (TAM, TA Instruments Ltd., UK) operated at 37 ± 0.1 °C. Prior to data 
recordings, samples were placed into the thermal equilibration position of the 
calorimeter for 29 minutes then lowered into calorimeter and data collection 
started exactly 30 minutes after inoculation. A software package, Digitam 4.1, 
which records 1 data point every 10 seconds was used to record data. A purity 
plate was set up for each ampoule after the experiment by streaking a loopful 
of culture onto MRS agar plate. Subsequent growth of colonies of a single type 
and morphology confirmed purity of the culture. As a control, calorimetric data 
of pipetted L. acidophilus concentrations was also taken. Final ampoule 
concentrations of 105 CFU/ml, 104 CFU/ml, and 103 CFU/ml L. acidophilus 
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were used. To ensure accuracy in calorimetric results, the calorimeter was 
calibrated periodically. 
Colony plate counts were conducted by suspending imprinted templates in 2 
ml PBS for 20 minutes. Two sets of 30-second vortexing were done at 0 and 
20 minutes. 1 in 10 serial dilutions were then conducted after which plating out 
onto MRS agar was done. The agar plates were then incubated under 
anaerobic conditions for 48 hours.  
 
 
3.3.5 Evaluating effect of protectants on bacterial viability 
Bio-inks were composed of 107 CFU/ml bacterial concentration in 10% 
sucrose, 10% trehalose, or PBS (control). The three bacterial solutions were 
printed onto edible starch paper using a 1 cm x 2 cm template. These were 
then inserted into a 3 ml calorimetric glass ampoule and 3 ml of pre-warmed 
(37 °C) MRS broth added. The ampoules were hermetically sealed and 
vortexed afterwards. Calorimetric readings were taken as above (section 
3.3.4) for a period of 40 hours. Another set of imprinted starch paper was kept 
at 2 - 8 °C and on the 7th day, calorimetric readings repeated.  
For colony plate counts, the same template dimensions (1 cm x 2 cm) were 
used to print the three bacterial solutions onto edible starch paper. The 
imprinted starch paper was then stored at 2 - 8 °C for a period of 7 days and 
daily enumeration conducted as above (section 3.3.4).   
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3.3.6 Evaluating tolerance of imprinted Lactobacillus acidophilus to 
simulated gastrointestinal fluids 
Five different types of simulated gastrointestinal fluids were investigated; 
fasted state simulated gastric fluid (FaSSGF), fed state simulated gastric fluid 
(FeSSGF), fasted state simulated intestinal fluid (FaSSIF), fed state simulated 
intestinal fluid (FeSSIF), and pig small intestinal fluid (PIF) (Fredua-Agyeman 
and Gaisford, 2015, Wang et al., 2015, Aburub et al., 2008).  
3.3.6.1 Sourcing and preparation of simulated gastrointestinal fluids 
The composition of the artificial fluids used is indicated in Table 3-1.  
Table 3-1: Composition of artificial gastrointestinal fluids in 100 ml medium. 
Property FaSSGF FeSSGF FaSSIF FeSSIF 
pH 1.2 4.0 6.5 5.0 
Sodium chloride 0.2g 1.187g 0.62g 1.187g 
Sodium hydroxide pellets - 0.404g 0.04g 0.404g 
Sodium dihydrogen 
phosphate dihydrate 
- - 0.45g - 
Glacial acetic acid - 0.865g - 0.865g 
Biorelevant simulated 
intestinal fluid powder 
- - 0.224g 1.12g 
Pepsin 0.32g 0.32g - - 
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3.3.6.1.1 Fasted State Simulated Gastric fluid (FaSSGF)  
100 ml of sodium chloride and hydrochloric acid (HCl) mixture was first 
prepared by dissolving 0.2 g of sodium chloride in 90 ml purified water. The pH 
was adjusted to 1.2 with HCl and volume made up to 100 ml. 0.32 g of pepsin 
was then added to 50 ml of the sodium chloride and HCl solution and stirred 
until complete dissolution. The volume was adjusted to 100 ml afterwards. The 
solution was filter-sterilised and used within 48 hours of preparation. 
 
3.3.6.1.2 Fed State Simulated Gastric Fluid (FeSSGF) 
100 ml of buffer was first prepared by dissolving 0.404 g of sodium hydroxide 
(pellets), 0.865 g of glacial acetic acid, and 1.187 g of sodium chloride in 90 ml 
of purified water. The pH was adjusted to 4.0 and volume increased to 100 ml 
with purified water at room temperature. 0.32 g of pepsin was then added to 
50 ml of buffer and stirred until complete dissolution. The volume was then 
adjusted to 100 ml. The solution was sterilised by filtration and used within 48 
hours of preparation. 
 
3.3.6.1.3 Fasted State Simulated Intestinal Fluid (FaSSIF)  
100 ml of buffer was first prepared by dissolving 0.04 g of sodium hydroxide 
pellets, 0.45 g of sodium dihydrogen phosphate dihydrate, and 0.62 g of 
sodium chloride in 90 ml of deionised water. The pH was adjusted to 6.5 and 
volume was increased to 100 ml with deionised water at room temperature. 
0.224 g of simulated intestinal fluid powder was then added to 50 ml of buffer 
and stirred until complete dissolution; additional buffer solution was added to 
100 ml. The solution was left for 2 hours at which point the solution became 
slightly opalescent and was ready to use. The solution was sterilised by 
filtration using a membrane filter of 0.22 μm pore size (Millex, UK) and used 
within 48 hours of preparation. 
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3.3.6.1.4 Fed State Simulated Intestinal Fluid (FeSSIF).  
100 ml of buffer was first prepared by dissolving 0.404 g of sodium hydroxide 
(pellets), 0.865 g of glacial acetic acid, and 1.187 g of sodium chloride in 90 ml 
of deionised water. The pH was adjusted to 5.0 and volume increased to 100 
ml with deionised water at room temperature. 
1.12 g of simulated intestinal fluid powder was then added to 50 ml of buffer 
and stirred until complete dissolution; additional buffer solution was added to 
100 ml. The solution was sterilised by filtration using a membrane filter with 
0.22 μm pore size and used within 48 hours of preparation. 
 
3.3.6.1.5 Pig Small Intestinal Fluid 
Pig gastrointestinal tracts were obtained from a cross-breed of large white and 
landrace pigs (n = 3) at an abattoir (Cheale Meats, Essex, United Kingdom). 
The gastrointestinal tracts from pigs were then dissected to collect the fluid 
from the small intestine. The fluid was collected within 5 hours at 4 °C following 
sacrifice into multiple aliquots and immediately stored at −80 °C. Prior to use, 
the fluid was centrifuged at 10,000 rpm (Eppendorf Mini spin, Germany) for 10 
minutes at 25 °C. The supernatant obtained was sterilised by filtration 
afterwards. The pH of the small intestinal supernatants was 6.6 ± 0.2. 
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3.3.6.2 Tolerance testing 
Three different bio-inks were prepared using the bacterial stock suspended in 
10% sucrose, 10% trehalose, and PBS (control) to produce a 107 CFU/ml 
bacterial population. A 1 cm x 2 cm template was used to deposit solutions 
onto edible starch paper and suspended correspondingly into simulated 
intestinal fluid (FaSSGF, FeSSGF, FaSSIF, or FeSSIF) for 2 hours at 37 °C; 
vortexing was done for 30 seconds before and after incubating. Sterile 
ampoules were filled with 2970 µl of pre-warmed (37 °C) MRS broth and 30 µl 
of resultant simulated fluid was added. The ampoules were then hermetically 
sealed and vortexed. Calorimetric readings were taken over a period of 40 
hours. A purity plate was set up for each experiment by taking a loopful of 
culture and streaking out onto an agar plate. The experiment was also done 
using filtered supernatant from PIF and bio-ink composed of 10% trehalose. 
The sterility of the filtered supernatant was also confirmed by plating out.  
Colony plate counting was also conducted to further support calorimetry 
determinations using the same bio-inks. A 1 cm x 2 cm template was used to 
deposit bio-inks onto starch paper and suspended correspondingly in 
FaSSGF, FeSSGF, FaSSIF, FeSSIF, and PIF (only 10% trehalose) for 2 hours 
at 37 °C. Vortexing was done for 30 seconds before and after incubating. Serial 
dilutions and subsequent plating out onto MRS agar were done. The agar 
plates were then incubated under anaerobic conditions for 48 hours. The 
experiment was repeated for FaSSGF and FeSSGF with enumeration at 0, 5, 
10, 20, 30, 60, 90 and 120 minutes with a higher dosing of 15 cm x 2 cm.  
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3.3.7 Overcoming the gastric environment 
Capsule coating was used as a means of protection against the gastric 
environment. An evaluation of the effect of pre-coating capsules before filling 
with active (opened coating) and then filling with active before coating (closed 
coating) was conducted first.  
 
3.3.7.1 Capsule coating  
Capsules were coated using Phloral®. The coating medium was prepared 
using the ingredients in Table 3-2.  
 
Table 3-2: Recipe for Phloral® coating  
Ingredients  Quantity (mg/cap) 
Eudragit® S 28 
Starch 12 
Triethyl citrate 8 
Glycerol monostearate 2 
Butanol 27.5 
Tween 80 0.8 
Deionised water 357.14 
Ethanol 96% (w/w) 421.12 
Total solids 50.8 
The coating was performed with a Caleva Mini Coater (UK), a fluidised bed 
coater. The parameters used for coating are indicated in Table 3-3. The 
duration of the coating varied based on the target weight gain. 
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Table 3-3: Coating conditions 
Parameter  
Spray rate  0.4 g/min 
Temperature 25 ⁰C 
Atomising pressure  0.2 bar 
Pump  35 % 
Fan speed (m/s) 9 - 11 m/s 
 
 
3.3.7.2 Effect of opened and closed capsule coating techniques 
Paracetamol was used as the active ingredient to evaluate the differences 
between opened and closed capsule coating techniques. Two types of 
capsules were used; gelatin and hydroxypropyl methylcellulose (HPMC) 
capsules (size 0) (QualicapsÒ, USA).  
For the closed capsule coating, capsules (total surface area of 500 mm2) were 
filled with 30 ± 2 mg paracetamol powder and closed tightly. The capsules 
were then coated with Phloral® with a target weight gain of 5 mg/cm2. The 
coated capsules were dried at room temperature afterwards.  
For the opened capsule coating, the capsule head and body were coated 
separately with Phloral®; the number of caps or bodies to be coated was 
chosen to equal the total outer surface as used in the closed coating process. 
Coating was done with a target weight gain of 5 mg/cm2 and the capsules were 
then dried at room temperature. 30 ± 2 mg of paracetamol powder was loaded 
into capsules and closed tightly. To determine the pH dissolution profile of the 
coated capsules, dissolution testing was conducted. 
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3.3.7.3 Dissolution testing 
Dynamic dissolution testing method using USP-II apparatus (Model PTWS, 
Pharmatest, Hainburg, Germany) was carried out as detailed in Goyanes et 
al., (2015b). Capsules were initially put into 750 ml of 0.1 M HCl for 2 hours to 
mimic fasted gastric conditions and residence time. The capsules were then 
transferred into 950 ml of modified Hank’s buffer (Table 3-4) for 35 minutes. 
50 ml of pre-Kreb’s solution (400.7 mM sodium bicarbonate and 6.9 mM 
potassium hydrogen phosphate) was added to produce a modified Kreb’s 
buffer in situ. The pH was then modified with time to mimic intestinal transit in 
the fasted state; sink conditions was attained in all instances. Modifications 
used as indicated in Table 3-5 were achieved with the aid an Auto pH System®. 
The paddle speed was set at 50 rpm and the tests were conducted at 37 ± 0.5 
⁰C (n = 6). Paracetamol release was determined using an in-line UV 
spectrophotometer (Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) at the 
wavelength of 243 nm. Data were processed using Icalis software (Icalis Data 
Systems Ltd., Berkshire, UK). 
 
Table 3-4: Composition of modified Hank’s buffer 
Ingredient Ionic composition (mM) 
Sodium chloride 136.9 
Potassium chloride 5.37 
Magnesium sulphate heptahydrate 0.812 
Calcium chloride 1.26 
Sodium hydrogen phosphate 
dihydrate 
0.337 
Potassium dihydrogen phosphate 0.441 
Sodium bicarbonate 4.17 
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Table 3-5: pH scheme mimicking intestinal transit 
Time pH 
0 min 5.6 
5 min 6.0 
10 min 6.5 
20 min 6.8 
At 35 min 
 
Add 50 ml of pre-Krebs solution to each vessel. 
This will produce a litre of Krebs buffer in each 
vessel. 
36 min 7.0 
50 min 7.2 
80 min 7.4 
210 min 6.5 (a higher carbon dioxide, CO2, flow is 
necessary to drop the pH rapidly; it will take 
about 15 min to attain the set point). 
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3.3.7.4 Encapsulating ink jetted probiotics 
Based on the outcome of the dissolution testing, probiotics were formulated 
using the opened capsule coating method. Both gelatin and HPMC capsules 
were used. Different target weight gain was investigated initially (5, 8, 10 
mg/cm2) to find the maximum permissible coating that did not hinder capsule 
closure. 5 mg/cm2 was chosen as suitable capsule weight gain afterwards. L. 
acidophilus (107 CFU/ml) suspended in 10% trehalose was used as bio-ink. 
Probiotics were formulated by ink jetting 2 cm x 15 cm black rectangular 
template onto starch paper. This was then inserted into the capsule body which 
was then closed with a cap before dissolution testing was conducted. 
  
3.3.7.4.1 Dissolution testing 
With this formulation intended for site-specific delivery, an improvised 
dissolution testing system was used, mimicking the United States 
Pharmacopoeia’s (USP) standard dissolution testing for such formulations as 
closely as possible. Capsules were immersed in three consecutive media for 
2 hours each i.e., 0.1 M HCl, phosphate buffer at pH 6.8, and phosphate buffer 
at pH 7.4. All the media used were pre-warmed to 37 ⁰C prior to use. Bacterial 
enumeration was conducted at hourly intervals in all media. To ensure the 
process was carried out at 37 ⁰C with 50 rpm paddle movement as observed 
in USP dissolution testing; a modified dissolution testing was carried out in an 
incubator shaker at 37 ⁰C with shaking set to 50 rpm. 5 ml media were used 
and capsules were completely immersed with the aid of sinkers.  
Another set of capsules were immersed into above media separately, i.e., 
either 0.1 M HCl, phosphate buffer (pH 6.8), or phosphate buffer (pH 7.4) for 
2 hours and enumeration conducted for all three media afterwards. Based on 
the outcome, the dissolution testing was modified with the duration in 0.1 M 
HCl reduced to 30 mins whilst all other tests and conditions maintained.  
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3.3.8 Evaluating adhesion of L. acidophilus to intestinal cells in-vitro  
To evaluate the ability of probiotics to adhere to intestinal cells, an in-vitro test 
was conducted using Caco-2 intestinal cells. Caco-2 intestinal cells were 
obtained as a gift from Department of Pharmaceutical & Biological Chemistry 
in University College London. 
3.3.8.1 Cell culture 
3.3.8.1.1 Growth medium  
The growth medium used was Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% of heat-inactivated foetal bovine serum (FBS) and 1% 
non-essential amino acid. The prepared medium was used to routinely grow 
Caco-2 cell lines in cell culture flasks (Nunc) with surface area 75 cm2 or to 
seed cells in a well-plate (Nunclon). All cells were incubated at 37 ⁰C in a 
humidified atmosphere of 5% CO2 (NuAireÔ Autoflow CO2 Air-Jacketed 
Incubator, NuAir Inc.). 
3.3.8.1.2 Cell sub-culturing 
Caco-2 cells were sub-cultured every 2-3 days when the cells were 
approximately 70 - 80% confluent. The spent culture medium was aspirated 
and discarded. The cells were rinsed by gently adding 10 ml PBS to the side 
of the vessel opposite the attached cells (to prevent disturbance to cells) and 
the vessel rocked back and forth several times to remove traces of serum, 
calcium, or magnesium that can potentially inhibit the dissociation reagent. The 
wash solution was then aspirated and discarded after which 1.2 ml of pre-
warmed 0.25% trypsin-ethylene diamine tetraacetic acid (trypsin-EDTA) was 
added as a dissociation reagent. The vessel was then rocked gently to 
completely cover cell monolayer. The flask containing the cell lines was 
incubated for 5 minutes at 37 ⁰C in 5% CO2. The cells were then observed with 
an inverted microscope (Evos FL, UK) for confirmation of cell detachment. 3 
ml of pre-warmed growth medium was added to halt the activity of trypsin-
EDTA. The cells were then transferred into 15 ml centrifuge tubes and 
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centrifuged at 1000 rpm for 10 minutes at 20 ⁰C. The cell pellets were 
resuspended in 3 ml of pre-warmed medium. Using a split ratio of 1:3, the cells 
were resuspended in fresh 20 ml pre-warmed medium in cell culture flask. The 
flask was then labelled with the cell name, passage number and date and 
placed in an incubator with humidified atmosphere of 5% CO2 at 37 ⁰C. 
3.3.8.1.3 Cell cryopreservation 
The Caco-2 cells were cryopreserved for long-term storage. The freezing 
medium was composed of the growth medium with 10% dimethylsulphoxide 
(DMSO) kept at 2 – 8 ⁰C. 
Cryopreservation of cells was preceded by steps similar to the cell sub-
culturing (section 3.3.8.1.2). The adhered cells were dissociated with trypsin-
EDTA and resuspended in growth medium. The total number of cells and 
viability was determined. A viability over 90% was obtained prior to cryo-
freezing. The suspension was centrifuged and cell pellets resuspended in 3 ml 
freezing medium. 1.2 ml was then aliquoted into sterile cryovials. The cryovials 
were labelled and transferred into a cryo-freezing container, Mr. Frosty™ 
Freezing Container (Thermo Scientific, UK), containing 250 ml isopropanol 
and stored at -80 ⁰C. The cryo-freezing container reduces the temperature at 
approximately 1 ⁰C per minute. The vials were then transferred into a liquid 
nitrogen dewar and stored until needed. 
3.3.8.1.4 Cell recovery 
A cryovial was removed from liquid nitrogen and immediately thawed in a water 
bath at 37 ⁰C with gentle swirling for about 1 minute. The thawed content was 
then transferred into an appropriate volume of pre-warmed medium and 
centrifuged at 1000 rpm for 10 minutes at 20 ⁰C. The supernatant was then 
aspirated and the cell pellet resuspended in 3 ml growth medium. Using a split 
ratio of 1: 3, 20 ml of pre-warmed growth medium in cell culture flask was 
inoculated with cells. The flask was then labelled and incubated at 37 ⁰C with 
humidified atmosphere of 5% CO2. The cells were then sub-cultured 
accordingly.  
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3.3.8.1.5 Enumeration of cells and viability   
Cell enumeration and viability were determined with the aid of a 
haemocytometer and the trypan blue dye exclusion test. 50 µl of trypan blue 
dye was added to 50 µl of Caco-2 cell suspension and mixed thoroughly. This 
was then loaded onto a haemocytometer (Fortuna, Germany) with a clean 
cover slip placed on. The haemocytometer was mounted on an inverted light 
microscope and cells counted with magnification (x 10). Dead cells were 
stained as these picked up the colour of dye whereas live cells remained 
unstained. Cells in the outer 4 quadrants were counted and an average 
determined. Total cell count and percentage viability were computed as shown 
in equations below. 
 
 
Equation 3-1 𝑐𝑒𝑙𝑙𝑠 𝑚𝑙 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒	𝑐𝑜𝑢𝑛𝑡 ∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝑓𝑎𝑐𝑡𝑜𝑟 ∗ 10B 
 
 
Equation 3-2 𝑡𝑜𝑡𝑎𝑙	𝑐𝑜𝑢𝑛𝑡 = 𝑐𝑒𝑙𝑙𝑠 𝑚𝑙 ∗ 𝑡𝑜𝑡𝑎𝑙	𝑣𝑜𝑙𝑢𝑚𝑒 
 
 
Equation 3-3 
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒	𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑢𝑛𝑠𝑡𝑎𝑖𝑛𝑒𝑑	𝑐𝑒𝑙𝑙𝑠	𝑡𝑜𝑡𝑎𝑙	𝑐𝑜𝑢𝑛𝑡	(𝑠𝑡𝑎𝑖𝑛𝑒𝑑	𝑎𝑛𝑑	𝑢𝑛𝑠𝑡𝑎𝑖𝑛𝑒𝑑) ∗ 100 
 
 
  
   126 
3.3.8.2 In vitro adhesion testing  
The evaluation done here was similar to work carried out by Forestier et al. 
(2001). A bacterial suspension of known concentration in 10% trehalose was 
ink jetted onto edible starch paper using a 1 cm x 2 cm template. This was then 
suspended in 2 ml of PBS at 37 ⁰C to disintegrate starch paper.  
Caco–2 monolayers were seeded at a concentration of 2 x 105 cells per well 
in 12-well plates and incubated at 37 ⁰C with humidified atmosphere of 5% 
CO2. Caco–2 cells were used in the late post-confluence state with passage 
numbers between 39 and 54. Prior to adhesion testing, Caco–2 monolayers 
were washed twice with 1 ml PBS and 1 ml of the cell culture growth medium 
added to each well. 1 ml of the disintegrated ink jetted starch paper in PBS 
was also added. The plate was then incubated at 37 ⁰C for 1 hour after which 
medium was aspirated. The monolayers were then washed three times with 1 
ml PBS to remove any non-adhered bacterial cells. The cells were lysed by 
addition of 1 ml 0.1% triton X-100 solution and the number of viable adhering 
bacteria determined by plating out serial dilutions onto MRS agar. The number 
of adhered cells were then expressed as a percentage of the initial number. 
An estimate of Caco–2 cells in wells was conducted each time adhesion tests 
was done. This was to ensure the available Caco-2 cells was not less than 
bacterial cells being added. The Caco-2 cells used for these tests were 
between 2.9 x 105 – 1 x 106 cells per well.  
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3.3.9 Evaluating the antibacterial properties of Ink jetted formulation 
The antibacterial property of probiotic formulation was investigated against 
Escherichia coli (NCTC 10418). Antibacterial activity was monitored using 
calorimetry.  
Cooked meat medium supplemented with 2% glucose (CMMg) was used as 
the growth medium. A power-time curve of E. coli (104 CFU/ml) co-incubated 
with ink jetted L. acidophilus formulation (equivalent to 2.8 x 103 CFU per 
template) was obtained. Plate counts for both organisms were conducted at 
24 and 48 hours.  As a control, power-time curves were also obtained for 
individual species and plate counts conducted at 24 and 48 hours. E. coli 
enumeration was conducted on nutrient agar plates and L. acidophilus 
enumeration on MRS agar plates. 
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3.4 Results and Discussion 
3.4.1 Evaluating recovery from substrate 
Ink jetting of pharmaceutical actives has received much attention recently, 
however, relatively limited information on ink jetting of live bio-actives exists in 
the literature. Biological materials are naturally delicate with viability easily 
subject to change; hence, it was vital to assess recovery of ink jetted 
formulation from the substrate. 1 cm x 2 cm template dimension albeit small 
was used as a dimension in this developmental phase. Plate counting to 
enumerate microorganisms in the deposited template indicated bacterial 
numbers of 2.8 x 103 CFU per template. Calorimetry was used to monitor 
bacterial growth because it gives real-time data on bacterial growth (Fredua-
Agyeman et al., 2017). Use of isothermal calorimetry to study L. acidophilus 
dates as far back as 1978, when Fujita and colleagues studied pure lactic acid 
species under limiting substrate conditions. In recent times, a few studies have 
been done using this technique to monitor lactic acid bacteria (Fredua-
Agyeman and Gaisford, 2015, Stulova et al., 2015, Kabanova et al., 2009, 
Fujita et al., 2009).  
Data from calorimetry are usually represented as power against time, known 
as a thermogram (Braissant et al., 2010a). The power signal in this instance 
arises due to metabolic heat in the system which is directly proportional to the 
bacterial population in the system. The area under the curve (AUC), hence, 
represents heat energy (Joules) and gives an indication of the number of 
organisms in the system. The thermogram, as indicated in Figure 3-3, showed 
an onset of activity at approximately 15 hours and a peak intensity between 
0.35 mW and 0.45 mW at 10 hours after onset. Such peaks (Figure 3-3) are 
typical of microbial growth in static ampoules, i.e., an initial rise to a maximum 
then drop to baseline after some time (Braissant et al., 2013, Wadso, 2001, 
Kabanova et al., 2009).  
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Figure 3-3: A thermogram illustrating growth of ink jetted L. acidophilus from substrate.  
When microbes are inoculated into an ampoule with an appropriate culture 
medium, there is an initial lag period which is dependent on the cell density 
and age of cells (Belaich, 1980). The calorimeter although very sensitive has 
a limit of detection of about 105 - 106 active cells; any cell density below this 
limit contributes to the lag time (Gaisford et al., 2009, Braissant et al., 2010c, 
Kabanova et al., 2009). With continuous bacterial metabolism and utilisation 
of the nutrients in the medium for growth, cell density increases and a 
corresponding heat production results in signals being obtained. These signals 
increase proportionally to metabolic activity in the medium to the maximum 
after which the signal returns to baseline. This drop in signal occurs because 
of utilisation of all nutrients in the medium. A return to baseline, however, does 
not correspond to death of cells but rather a halt in metabolic activity as cells 
are usually in the stationary phase of growth. Microbes have been shown to 
be viable over long hours even after the stationary phase of growth and this 
has been confirmed by viable counts being obtained after plating out at such 
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periods. This is demonstrated further in subsequent sections in this chapter 
(Braissant et al., 2013, Hrenovic, 2009, Stulova et al., 2015). 
The initial 15-hour lag phase was, therefore, mainly attributable to the fact that 
the cell population introduced was below the limit of detection and cells were 
also adapting to their new environment (Stulova et al., 2015). This is visible in 
the reduction of lag time when a higher inoculum was used to inoculate (Figure 
3-4). 
 
 
Figure 3-4: A thermogram comparing different concentrations of L. acidophilus. 
Incubation of lactobacilli was done between 40 – 48 hours rather than 
overnight since these, like most probiotic species, are slow growing anaerobic 
organisms (Juturu and Wu, 2015). To further highlight the precision of the ink 
jetting procedure and its null effect on bacterial viability, thermograms were 
obtained for pipetted 103 and 104 CFU/ml bacteria and compared with ink 
jetted bacteria. The initial rise in the signal obtained for the ink jetted template 
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(2.8 x 103 CFU per template) was between that of 103 and 104 CFU/ml (Figure 
3-5). 
 
Figure 3-5: A thermogram comparing (2.8 x 103 CFU per template) ink jetted (IJP) and 
pipetted (103 and 104 CFU/ml) L. acidophilus. 
Integration of power-time plots resulted in graphs representative of typical 
bacterial growth curve highlighting more clearly the various phases (i.e., lag, 
log, and stationary phases) of bacterial growth. These integrals are also 
representative of cumulative heat energy at any given time point (Braissant et 
al., 2010c, Stulova et al., 2015, Belaich, 1980). The graph comparing integrals 
of 103,104 CFU/ml, and ink jetted population (2.8 x 103 CFU per template), 
Figure 3-6, translates the same set of data as observed in Figure 3-5, with an 
onset of bacterial activity earlier for 104 CFU/ml followed by the ink jetted then 
103 CFU/ml. It can, however, be noticed that the IJP integral (19.36 ± 1.27) 
was slightly higher than that for 104 CFU/ml (18.86 ± 1.54) at the time of 
stopping the experiment (Figure 3-7).  
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Figure 3-6: An illustration of cumulative heat output comparing (2.8 x 103 CFU per template) 
ink jetted (IJP) and pipetted (103 and 104 CFU/ml) L. acidophilus. 
 
 
Figure 3-7: A bar chart of the cumulative heat output comparing (2.8 x 103 CFU per template) 
ink jetted (IJP) and pipetted (103 and 104 CFU/ml) L. acidophilus. 
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A plausible reason could be that with the ink jetted bacteria, the substrate 
(starch paper) on which the bacteria were deposited albeit small, could be 
serving as an additional nutrient source as compared to the 104 CFU/ml hence, 
the slightly higher cumulative metabolic heat energy. This implies that in 
addition to depositing live bacterial cells, ink jetting bacteria onto starch paper 
could potentially be serving as an additional nutrient supply to the organisms.  
 
3.4.2 Evaluating effect of protectants on bacterial viability  
With knowledge of the fact that inkjet droplets are deposited in the picolitre (10 
-12 L) range (Allain et al., 2004), it was imperative to evaluate how best to 
optimise as well as preserve bacterial viability upon storage. The ink jetted 
formulation was rehydrated in PBS; other media like deionised water and 
skimmed milk have been used for rehydration, with no significant differences 
being observed between these and PBS (Teixeira et al., 1995). Dehydration is 
known to be a major stressor when probiotics are dried under 45 °C (Broeckx 
et al., 2016). It was, therefore, important to incorporate an excipient to alleviate 
this. Trehalose and sucrose have previously been shown to offer good 
protection during the storage of lactic acid bacteria, as such, these were 
chosen as additives (Strasser et al., 2009, Leslie et al., 1995, Sun and 
Davidson, 1998).  
When the bio-ink was composed of L. acidophilus suspended in 10% trehalose 
or 10% sucrose, a higher loading, 3.96 ± 0.06 and 4.01 ± 0.18 Log CFU per 
template (i.e., 9.1 x 103 and 1.0 x 104 CFU per template) respectively, was 
observed relative to control, 3.45 ± 0.1 Log CFU per template (2.8 x 103 CFU 
per template) (Figure 3-8). This was an interesting observation as the initial 
aim for sugar addition was to help organisms survive dehydration over time. 
Also, the sugars were added to modify the viscosity of the bio-ink to prevent 
dripping of the bio-ink from the cartridge nozzles. An ideal viscosity range of 2 
– 20 mPas is recommended for ink jetting. The addition of 10% sucrose or 
trehalose produced bio-inks with viscosities of 3.7 ± 0.3 and 3.8 ± 0.4 mPas 
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respectively, which were within the ideal range. High viscosities lead to 
decreased speed and accuracy of the expelled droplet, printing fails at 
extremely high viscosities if the ink cannot flow into the liquid chamber rapidly 
enough to refill it (Daly et al., 2015, Ihalainen et al., 2015). A student’s t-test 
revealed a significant difference (p < 0.05) between the effect of both sugars 
on bacterial loading and the control. When the effect of 10% sucrose and 10% 
trehalose on bacterial loading was compared no significant difference (p > 
0.05) was obtained. This highlighted the importance of the sugars on the 
formulation and the similarity in activity between them. Trehalose and sucrose 
have been shown to have similar protectant effects during drying; a superiority 
of trehalose over sucrose during storage over long periods has, however, been 
reported (Tymczyszyn et al., 2007b, Crowe et al., 2001, Leslie et al., 1995, 
Sun and Davidson, 1998). 
 
 
Figure 3-8: An illustration of L. acidophilus enumeration after ink jetting formulation 
composed of 10% trehalose, 10% sucrose, or control (no sugar, i.e., PBS). 
In this case, considering how delicate and fundamental this model for probiotic 
formulation was, the only excipient introduced was a sugar, i.e., 10% sucrose 
or 10% trehalose. The major stress anticipated here was osmotic stress as a 
result dehydration of cells (Desmond et al., 2001, Potts, 2001). Both trehalose 
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and sucrose have been previously documented to offer protection to bacterial 
cells under high temperatures and other stresses (Strauss and Hauser, 1986, 
Costa et al., 2000, Zhao and Zhang, 2005, Rumian et al., 1993, Sun and 
Davidson, 1998, Strasser et al., 2009). A few hypotheses have been proposed 
for the mechanism of sugar protection, the most popular of these hypotheses 
is the water replacement hypothesis. This suggests that the replacement of 
water by sugars between the lipid headgroups of membranes via the formation 
of hydrogen bonds helps stabilise native structures in a dry state (Crowe et al., 
1987, Palmfeldt et al., 2003, Crowe et al., 2001, Tymczyszyn et al., 2007a). 
Thermograms obtained indicated a similar trend whereby the formulation with 
10% sucrose had a faster onset of activity relative to 10% trehalose and control 
(Figure 3-9). The AUCs were 23.00 ± 0.85 J, 21.73 ± 2.22 J, and 19.36 ± 1.27 
J for sucrose, trehalose, and control respectively (Figure 3-10 and Figure 
3-14). This could lead to the assumption that these sugars were being 
metabolised hence, the resulting increased population. However, considering 
the short time (less than 30 minutes) between preparation and ink jetting any 
sugar entering the bacterial cells may not be lost in metabolism thereby making 
this assumption null (Zayed and Roos, 2004). This phenomenon could be 
attributed to the fact that these sugars have the potential to form hydrogen 
bonds with the polar head groups in phospholipids in the cell membrane of 
bacterial cells (Crowe et al., 1987). It is, therefore, likely that for each droplet 
being jetted out, sugar molecules could have interacted with bacterial cells to 
have more bacterial cells together resulting in the differences noted for the 
loading. Another possible explanation is that, the removal of water from 
bacterial cells causes these to contract, thereby, reducing the cell volume and 
drawing the bilayers close together to form a gel-like phase and in the process 
more cells being entrapped within each droplet (Broeckx et al., 2016, Garvey 
et al., 2013).   
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Figure 3-9: A thermogram showing effect of protectant on L. acidophilus viability. 
 
Figure 3-10: Cumulative heat output illustrating effect of protectant on L. acidophilus viability. 
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The immediate application for such a formulation will be as an 
extemporaneous formulation at point of care (i.e., under hospital settings or in 
the local pharmacy); the stability was therefore studied over a 7-day period at 
2 - 8 ⁰C during which daily enumeration of the formulation was conducted. This 
temperature range was chosen as the stability of dried samples decreases 
during storage with higher survival rates usually being recorded at lower 
storage temperatures (Carvalho et al., 2004, Wang et al., 2004, Meng et al., 
2008). It was during this period that the effect of the sugars was more evident. 
From the graph, Figure 3-11, it can be observed that there was a reduction in 
L. acidophilus numbers in all formulations, however, this reduction was 
greatest for the control (1.27 Log cycle) with reductions of 0.86 and 0.88 Log 
cycles obtained for sucrose and trehalose respectively. 
 
 
Figure 3-11: An illustration of L. acidophilus colony plate counts showing effect of protectants 
over 7 days. 
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Thermograms obtained on Day 7 of storage (Figure 3-12), correlated with data 
obtained for plate counts with trehalose and sucrose almost superimposable 
and an onset of activity around 15 hours. Integration of these showed growth 
curves highlighting a similarity between sucrose and trehalose as protectants 
(Figure 3-13).  
 
 
Figure 3-12: A Thermogram for L. acidophilus formulated with 10% trehalose, 10% sucrose, 
and control on day 7. 
Comparing the cumulative heat outputs on Days 0 and 7, Figure 3-14, shows 
relatively higher values for sugars as compared to the control, a similar trend 
to the colony plate counts observed in Figure 3-11. Further exploration to 
optimise viability upon storage is required despite the relatively higher 
numbers when sugars were added to the formulation. By using a higher 
printing concentration, the impact of this decrease in numbers upon storage 
can be minimised as long as relatively higher numbers are still available at the 
time of consumption. 
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Figure 3-13: An illustration of cumulative heat output for L. acidophilus formulated with 10% 
trehalose, 10% sucrose, and control on day 7. 
 
 
 
Figure 3-14: Bar graph comparing cumulative heat output on days 0 and 7 for L. acidophilus 
formulated with 10% trehalose, 10% sucrose, and control. 
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3.4.3 Evaluating tolerance of imprinted Lactobacillus acidophilus to 
simulated gastrointestinal and pig small intestinal fluids 
In conventional drug design with chemotherapeutic agents, dissolution tests 
are conducted to evaluate product release at target sites. The formulation 
design in this instance involved live cells; it was, therefore, imperative to 
ascertain the tolerance of this formulation to gastrointestinal fluids. Relevant 
gastrointestinal media (i.e., media with physiological pH and salt 
concentrations) were used to mimic gastrointestinal conditions (Aburub et al., 
2008). Once ingested, probiotics descend into the stomach for a period 
depending on the presence or absence of food and then into the upper small 
intestine and eventually into the lower small intestine and colon where most 
probiotic activity originates. These different parts of the GIT have different 
characteristics and interact differently with the probiotics. Gastrointestinal 
tolerance testing is a common assay in probiotic formulations to assess any 
influence of gastrointestinal fluid on cell viability (Teoh et al., 2011, Liong and 
Shah, 2005, Fredua-Agyeman and Gaisford, 2015, Charteris et al., 1998).  
Simulated gastro-intestinal media were all freshly prepared to prevent any 
degradation, especially, pepsin in simulated gastric fluid (Aburub et al., 2008). 
A baseline signal observed after the formulation was exposed to FaSSGF 
highlighted the absence of any viable cells (Figure 3-15). This implied that the 
cells after being exposed to FaSSGF for 2 hours were non-viable. FaSSGF 
has a pH of 1.2, typical of a strong acid and kills most organisms when in 
contact (Klayraung et al., 2009). It is usually assumed that because these 
probiotics are acid-producing organisms, they should be able to withstand the 
gastric conditions. Probiotic organisms, however, produce lactic acid, which is 
a weak acid with a pH that is mild thus allowing the probiotic strains to tolerate 
them. Govender et al., (2014) reported that bacterial viability can drop by about 
60% after exposure to gastric fluids.  
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Figure 3-15: Thermogram obtained after exposing L. acidophilus to FaSSGF.  
When the formulation was exposed to FeSSGF, FaSSIF, and FeSSIF, signals 
were, however, obtained (Figure 3-16 - Figure 3-18). One attribute of these 
media is their relatively higher pHs as compared to FaSSGF. The pHs of the 
FeSSGF, FaSSIF, and FeSSIF used were 4 ± 0.1, 6.5 ± 0.1, and 5 ± 0.1 
respectively. It was noted that the peaks for the FeSSGF had a longer lag 
phase relative to FeSSIF and FaSSIF highlighting the delay in adapting to the 
growth medium. Despite these organisms being acid-producing they clearly 
preferred the close-to-neutral pH values. This observation was noted during 
the development of a general non-selective growth medium to support 
lactobacilli with an ideal pH between 6.2 and 6.5 being suggested (de Man et 
al., 1960).  
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Figure 3-16: Thermogram obtained after exposing L. acidophilus to FeSSGF. 
 
Figure 3-17: Thermogram obtained after exposing L. acidophilus to FaSSIF.  
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Figure 3-18: Thermogram obtained after exposing L. acidophilus to FeSSIF.  
The data obtained for the FaSSIF and FeSSIF were not surprising. 
Colonisation of the small intestines by gut microbiota is known; hence, L. 
acidophilus was expected to withstand exposure to simulated intestinal fluids 
better than stomach fluids (O'Hara and Shanahan, 2006). Closer mimicking of 
in-vivo conditions using PIF (Figure 3-19) revealed probiotic species being 
even more tolerant of this medium relative to the biorelevant intestinal fluids. 
PIF was a more natural medium and could possibly have contained nutrients 
from food ingested by the pig prior to sacrifice. This nutrient-rich medium could 
have supported bacterial metabolism and growth compared to the biorelevant 
media which were composed mainly of salts and surfactants.  
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Figure 3-19: Thermogram obtained after exposing L. acidophilus to PIF. 
Another phenomenon observed from the thermograms was the lower intensity 
of the PIF signal as compared to the biorelevant fluids. The signal for the PIF 
had a relatively earlier onset and prolonged signal as compared to biorelevant 
fluids resulting in a comparable AUC to FeSSIF and FaSSIF as shown in 
Figure 3-20. Computing the AUC for the signals of other simulated 
gastrointestinal fluids confirmed the greater tolerance to the biorelevant 
intestinal and pig small intestinal fluids relative to the biorelevant gastric fluids 
(Figure 3-20). A similar trend was obtained for the plate counts (Figure 3-21), 
with the intestinal fluids having higher numbers relative to FeSSGF, with no 
bacterial growth being observed in FaSSGF.  
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Figure 3-20: An illustration of cumulative heat output for L. acidophilus after exposure to 
simulated gastrointestinal fluids. 
 
 
 
Figure 3-21: An illustration of colony plate counts for L. acidophilus after exposure to 
simulated gastrointestinal fluids. 
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The comparable plate count data with the calorimetry data further highlight the 
importance of calorimetry as a useful tool in pre-formulation and formulation. 
With these data, it was evident that to deliver the formulation in a viable form 
into the lower small intestines there was the need to overcome the gastric 
environment. Strategies to overcome this are explored in the next section. 
The loading dose was increased by modifying the template dimensions (2 cm 
x 15 cm) to evaluate any improvement in gastric tolerance over 2 hours. There 
was no improvement in tolerance to FaSSGF with a loss of viability within 5 
minutes (Figure 3-22).  
 
 
Figure 3-22: An illustration of bacterial enumeration at different times over 2 hours after 
exposure to FaSSGF and FeSSGF. 
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Most of the commercial probiotic formulations available are released in the 
stomach after intake and expected to travel down to the small intestines or 
colon with gastrointestinal motility. Few products have ‘to be taken with meals’ 
indicated on their packages. The science behind this is understandable as the 
pH of the stomach after a meal can rise to between 4 and 5. This pH is tolerable 
to probiotics hence, viability can be maintained; however, there is the 
possibility of these organisms staying in the stomach for a longer time and 
being exposed to fasted state pH. Gastric emptying after food intake is a 
complex process which can be further complicated by consumption of snacks 
in between meals. Gastric emptying is of fundamental value to ensuring that 
the supply of nutrients and fluid to the body is maintained (Varum et al., 2013, 
Newton, 2010). Other probiotic products don’t have the inscription ‘to be taken 
with meals’ on their packages and the claim of probiotics especially, lactobacilli 
being gastric acid resistant is usually cited. This claim, as demonstrated here 
and by other researchers, is not entirely true. There is the possibility of certain 
strains having greater tolerance, but this cannot be applied as a generalisation 
to all lactobacilli (Douglas and Sanders, 2008).  
 
3.4.4 Overcoming the gastric environment  
The Phloralâ coating technology could theoretically be adapted to any drug 
and used for a variety of disease states. With the main components, Eudragitâ 
S which is a synthetic polymer that dissolves at pH > 7 and resistant starch 
which is not digested by mammalian amylase enzymes secreted by the 
pancreas but by colonic bacterial enzymes, this technology is useful in drug 
targeting (Ibekwe et al., 2008, McConnell et al., 2008). The interest in dosage 
forms, where the release of the active substance can be controlled and 
modulated – prolonged-release or site-specific delivery – to optimise its 
therapeutic effect, has increased steadily during the last 50 years (Conti et al., 
2013, Tonnesen and Karlsen, 2002). The need to protect probiotics was 
emphasised recently by Caillard and Lapointe when they evaluated some 
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commercial probiotics and found that only the enteric coated formulations had 
resistance after exposure to gastric acid at fasting and all the unprotected 
formulations had high drops in numbers after exposure to gastric media 
(Caillard and Lapointe, 2017). 
Based on the results from the tolerance testing, it was necessary to overcome 
the barrier created by gastric fluid.  The process of coating capsules can be a 
major challenge when heat and moisture sensitive materials are involved 
(Huyghebaert et al., 2004). Since viability of probiotic formulation was key, 
open capsule coating was the intended coating technique but the effect of 
coating technique on dissolution testing needed to be verified; this was done 
using paracetamol. The dissolution profile of paracetamol was similar for both 
opened and closed capsule coating techniques for gelatin and HPMC (Figure 
3-23 and Figure 3-24). Both capsules showed no release after 2 hrs in acid in 
agreement with the United States and European Pharmacopoeia requirements 
for such formulations (i.e., less than 10% release after 2 h in 0.1 M HCl). A 
sharp burst of release was then observed from approximately 150 minutes to 
175 minutes. It was during this period that the pH increased above 7, the 
threshold pH for dissolution of Eudragitâ S (Ibekwe et al., 2008). This agreed 
to work done by Huyghebaert et al. (2004) whereby a similar evaluation was 
conducted with no difference in the coating techniques being observed.  
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Figure 3-23: Percentage release of paracetamol using PhloralÒ-coated gelatin capsules 
comparing opened and closed capsule coating. 
 
 
 
Figure 3-24: Percentage release of paracetamol using PhloralÒ-coated HPMC capsules 
comparing opened and closed capsule coating. 
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Based on the results obtained, pre-coated capsules were used for the probiotic 
formulation, capsule coating is generally independent of capsule content. This 
form of capsule coating has potential applications in other drug development 
and formulation, especially, for heat and moisture sensitive materials. This 
technique can also be used in retail or hospital pharmacy, and research and 
development sections of the pharmaceutical industry where enteric coating of 
capsules offers a problem due to lack of appropriate equipment and training 
(Huyghebaert et al., 2004, Cole et al., 2002). 
The dissolution properties of the encapsulated probiotics after 2 hours in 0.1 
M HCl and subsequent transfer into pH 6.8, then 7.4 did not yield promising 
results (Figure 3-25). No viable bacteria were obtained after enumeration at 
various time points. No viable counts were expected in pH 1.2 and 6.8 as the 
coating properties implied an intact polymer since threshold pH for dissolution 
was not reached, but after pH 7 when capsules had disintegrated, viability was 
expected. Due to the same reason, an intact capsule, similar outcomes were 
expected when the capsules were placed individually in these media without 
subsequent transfer (Figure 3-26 and Figure 3-27). However, when the 
capsules were placed in pH 7.4, the viable bacteria released were about 90% 
(Figure 3-28). Of the three media used, based on the tolerance testing and 
literature, 0.1 M HCl is noted to be the main challenging medium (Govender et 
al., 2014, Klayraung et al., 2009).  
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Figure 3-25: Graph illustrating no viable counts after capsules were immersed consecutively 
for 2 hours in 0.1 M HCl, pH 6.8, and pH 7.4.  
 
Figure 3-26: Graph illustrating no viable counts after capsules were immersed in 0.1 M HCl 
for 2 hours. 
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Figure 3-27: Graph illustrating no viable counts after capsules were immersed in pH 6.8 for 2 
hours. 
 
Figure 3-28: Graph illustrating percentage viability after capsules were immersed in pH 7.4 
for 2 hours. 
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With the gastric environment known to be the harshest of the three media, the 
2-hour duration in the simulated gastric medium was, therefore, reduced to 30 
minutes as this is a reasonable in vivo gastric residence time whilst maintaining 
the duration for the subsequent media (Troncon et al., 1994). This yielded 
some positive results, 100% and 44.58% recoveries were obtained for gelatin 
and HPMC respectively (Figure 3-29). 
 
Figure 3-29: Graph illustrating percentage viability after capsules were immersed 
consecutively for 30 mins in 0.1 M HCl, then for 2 hours each in pH 6.8 and pH 7.4. 
There is no standard dissolution test for probiotics in the literature. However, 
there is the likelihood of conducting dissolution testing for modified-release 
formulations using the USP standard dissolution testing. With the possibility of 
estimating bacterial numbers using UV spectrophotometers, the opacity of the 
medium containing bacterial cells released from capsules can, in theory, be 
estimated. However, the challenge of contamination and cross-contamination 
or a very stringent sterilisation process must be in place. Also, the line used 
for liquid transfer must be disposable since bacterial biofilms could potentially 
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build up in these (Said et al., 2015). These challenges do not make such an 
approach commercially attractive.  
With gradual advancements in probiotic science, hopefully standards similar 
to dissolution testing for probiotic formulations will be a reality in future. The 
dissolution testing method used here was to simulate as closely as possible 
the USP standard of dissolution testing for modified release dosage forms. The 
use of the incubator shaker to mimic temperature conditions as well rotor 
speed has been demonstrated previously (Liserre et al., 2007).  
In this instance, however, phosphate buffers were used albeit the advantages 
of bicarbonate buffers due to the challenge of keeping carbon dioxide evolution 
under control. The volume of medium used was 5 ml because the objective 
was to completely immerse capsules which was achieved using sinkers. 
Secondly, considering the number of organisms deposited on the substrate, a 
volume that would permit detection of any organisms released was needed. 
Although large volumes have been recommended for dissolution testing in the 
pharmacopoeia, in reality volumes as low as 20 ml have been observed in the 
small intestine after feeding (Schiller et al., 2005). The same group also noted 
a mean fasted stomach volume of 45 ± 18 ml for 12 individuals. These volumes 
are very variable, however, with further optimisation of this formulation, greater 
volumes would be used in analyses.  
Protection of these organisms is challenging; in the current formulation using 
ink jetting, the starch paper used was very hygroscopic, therefore, it could 
attract fluid upon the least contact. The loss of viability after 2 hours in gastric 
pH could potentially be due to penetration of the gastric fluid into capsules 
through the bridge where capsule cap meets the body. In probiotic 
encapsulation, the objective is not only to protect the cells against adverse 
environment, but also to allow their release in a viable and metabolically active 
state in the intestine (Picot and Lacroix, 2004). The results obtained upon 
reduction of time in the gastric pH clearly indicated the duration of exposure 
as a critical factor here. Poelvoorde et al. (2008) also demonstrated the release 
of probiotics from an enteric coated formulation, whereby, probiotics were 
   155 
loaded onto pellets using skimmed milk as a protectant and subsequently 
enteric coated the formulation. After 2 hours in 0.1 M HCl, only 1% viable 
bacteria were obtained. The difficulty of maintaining the viability of gastro-
resistant coated probiotics after successive transfer from simulated gastric 
fluid to intestinal fluids has been observed by other researchers  (Huyghebaert 
et al., 2005, Poelvoorde et al., 2008). 
Although USP standards indicate a 2-hour gastric acid immersion, a median 
gastric transit time of 37 minutes in the fasted state has been reported  in 
human studies (Ibekwe et al., 2008). The improved viability obtained after 
capsules had been immersed in the gastric medium for 30 minutes was quite 
promising although improvements to formulation are still needed to meet the 
2-hour USP standard. HPMC is usually preferred to gelatin as pre-coating 
material due to its rough surface which promotes adhesion of coating material 
(Cole et al 2002). Both materials were successfully coated with Phloralâ and 
all coated capsules exhibited good integrity. The difference in viability obtained 
was because all the gelatin capsules used demonstrated good bacterial 
viability when capsules coating dissolved; however, with the HPMC capsules, 
some exhibited very low viability which resulted in the relatively lower average 
obtained. It must be noted that comparing individual capsules, some HPMC 
capsules had similar bacteria released as gelatin capsules.  
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3.4.5 Testing in vitro adhesion of Lactobacillus acidophilus to intestinal 
cells 
The Caco-2 cell density available for adhesion was 2.9 x 105 – 1 x 106 cells 
per well. Bacterial enumeration after adhesion to Caco-2 cells was 78.3% of 
the administered bacteria (Figure 3-30).  
 
Figure 3-30: An illustration of bacterial population post-adhesion in comparison to initial 
numbers, error bars represent the standard deviation from mean. 
The ability of probiotic strains to adhere to the mucosal surfaces of the intestine 
and the subsequent long or short-term colonisation is an important criterion for 
the selection of probiotic strains. Non-adhered bacterial cells usually travel 
through the intestinal system and are subsequently eliminated from the body 
before any health benefits are imparted to the individual (Govender et al., 
2014, Maragkoudakis et al., 2006, Forestier et al., 2001). One of the proposed 
mechanisms of probiotic action is the ability to compete with pathogens for 
adhesion sites in the GIT. A probiotic strain demonstrating good adhesion has 
the propensity to compete for adhesion sites with pathogenic species 
(Sanders, 2009, Verna and Lucak, 2010, O'Hara and Shanahan, 2006). 
Dissolution analysis data are unable to give any information about the 
effectiveness of probiotic bacteria to adhere to the intestinal wall and to 
simulate competition with the natural intestinal flora of the human intestinal 
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system (Govender et al., 2014). Many in vivo studies use probiotic cells in 
faecal matter as an indication of adhesion with the assumption that once viable 
cells have been excreted, then a proportion would have adhered to the 
intestines in the process. Cells in faecal matter are cells that have not adhered 
to the intestinal wall; hence, they are not ideal to use as an indication of 
adhesion (Govender et al., 2014). The difficulties in performing adhesion 
testing in vivo, especially in humans, have led to the development of in vitro 
models (Greene and Klaenhammer, 1994). Simple models have been 
developed to estimate probiotic adhesion whereby probiotic numbers after 
addition to intestinal cells are estimated in vitro (Tuomola and Salminen, 1998, 
Forestier et al., 2001, Maragkoudakis et al., 2006, Gopal et al., 2001). The 
adhesion of the L. acidophilus was performed using Caco-2 intestinal cells, a 
human colon carcinoma cell line that expresses several markers characteristic 
of normal small intestinal villous cells (Greene and Klaenhammer, 1994).  
Caco-2 cells were sub-cultured every 2-3 days when the cells were 
approximately 70 - 80% confluent and in the exponential phase of growth. The 
78.3% adhesion obtained was promising. Maragkoudakis et al. (2006), using 
a similar technique for L. plantarum ACA-DC 146, obtained a maximum 
adhesion of 25.5%. The adhesion obtained here was almost three times that 
obtained Maragkoudakis and colleagues. A possible reason could be the 
differences in bacterial species used. Some species and specifically strains 
naturally adhere better than others (Tuomola and Salminen, 1998, 
Maragkoudakis et al., 2006, Forestier et al., 2001, Gopal et al., 2001). The 
adhesion obtained highlights the high adhesion propensity of the strain of 
probiotic used. It also further confirms the absence of loss of cell properties 
after ink jetting.  
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3.4.6 Evaluating the antibacterial properties of Ink jetted formulation. 
Thermograms for E. coli and IJP L. acidophilus were obtained individually as 
well as when co-incubated. Signals for E. coli control were seen relatively 
earlier (less than 2 hours) due to its high rate growth rate; that for the ink jetted 
L. acidophilus was, however, seen after about 10 hours. When these 
organisms were co-incubated, two independent peaks were obtained, the first 
peak was almost superimposable to the E. coli control. The second peak, 
however, was not similar to the ink jetted L. acidophilus formulation (Figure 
3-31). With just two organisms present in the growth medium, the second 
signal was most likely a growth signal from L. acidophilus metabolism. The 
difference in onset and peak height for L. acidophilus could be due to reduced 
nutrient availability from initial metabolism by E. coli. The plate counts were 
quite interesting; the numbers obtained at 24 hours for E. coli when co-
incubated with the formulation were very similar to that of E. coli control at 24 
hours. However, when the same enumeration was conducted at 48 hours, 
during which time growth of L. acidophilus would also be in stationary phase, 
no viable cells were obtained for E. coli in the co-incubated test as compared 
to the over 7 Log CFU/ml (107 CFU/ml) counts in the control. Plate counts for 
L. acidophilus over 48 hours was similar i.e., over 8.5 Log CFU/ml (3.2 x 108 
CFU/ml) in both the co-incubated and control test (Figure 3-32). 
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Figure 3-31: Thermograms after co-incubation of ink jetted (IJP) L. acidophilus and E. coli 
and their respective controls. 
 
 
Figure 3-32: Plate counts at 24 and 48 hours after the co-incubation of ink jetted (IJP) L. 
acidophilus LA 5 and E. coli and their respective controls. 
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Intestinal Infectious diseases caused by pathogenic organisms are major 
causes of mortality in both developed and developing countries. Organisms 
like Shigella spp., Vibrio cholerae, pathogenic E. coli, Campylobacter spp., and 
rotavirus are the usual organisms involved in such cases (Nomoto, 2005). E. 
coli was therefore chosen as the test organism for the probiotic formulation. 
CMMg, a growth medium that supports the growth of both organisms was used 
for analyses. Calorimetry was used to monitor in real-time the interactions 
between these organisms. Other complicated methods are available which 
mimic closely the current commensal microbiota in the intestinal system for 
studying interactions between an organism and the microbiota. An example of 
such a model is the Simulator of the Human Intestinal Microbial Ecosystem 
(SHIME) (Molly et al., 1993, Alander et al., 1999).  
The growth rate and the generation time are often used to indicate how fast a 
bacterial culture grows. A change in these two parameters can indicate a 
positive or negative effect of a treatment on cultures and can be useful when 
investigating new antimicrobial compounds (Braissant et al., 2013). Among the 
proposed mechanisms of probiotic activity include the release of chemicals or 
substances with antibacterial activity, competition for adhesion sites and 
available nutrients, and production of acids which make the milieu 
unfavourable for pathogenic bacterial growth (Sanders, 2009, Govender et al., 
2014, Verna and Lucak, 2010). In this instance, however, since growth 
occurred in a liquid medium, no competition for adhesion sites occurred. 
Competition for nutrients can be a major factor here; L. acidophilus, being a 
slow growing organism, attained its exponential growth phase when the E. coli 
was already in its stationary phase. This scenario makes competition for 
nutrients a very difficult mechanism for L. acidophilus to antagonise E. coli 
growth. Microorganisms are known to stay in the stationary for a very long time 
even without nutrients (Juturu and Wu, 2015). It was, therefore, expected that 
E. coli numbers would be maintained over the 48-hour period as obtained with 
plate counts for the E. coli control. This was not the case when the L. 
acidophilus growth was complete; no E. coli colonies were obtained from the 
medium after enumeration. This could be that L. acidophilus may have 
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released antibacterial substances into the growth medium during its growth 
and/or produced a very unfavourable medium for E. coli from acid released 
during growth (Forestier et al., 2001). E. coli generally adapts well to acidic 
environments; as such release of acid by L. acidophilus did not cause the 
complete elimination of E. coli population (Gomez Zavaglia et al., 2003, 
Benjamin and Datta, 1995). The release of antibacterial substances by L. 
acidophilus could, therefore, be the major reason for the elimination of E. coli 
population. Another possibility could be that the E. coli organisms had entered 
a viable but non-culturable (VBNC) state which could have resulted in no 
colonies being obtained after enumeration (Bogosian and Bourneuf, 2001, Su 
et al., 2013). Polymerase chain reaction assays could be useful in deducing 
whether the E. coli cells were dead or in a VBNC state. A live/dead staining 
technique could also have helped ascertain the state of E. coli cells (Willenburg 
and Divol, 2012, Wu et al., 2015, Green et al., 2011). The scenario observed 
here, whereby, pathogen growth was established before that of the probiotics 
is the exact opposite of what was observed by Fredua-Agyeman and 
colleagues evaluating the activity of probiotics against Clostridium difficile. The 
inhibition of C. difficile growth by probiotics that they observed was attributed 
to the fact that probiotic population was well established before pathogenic 
species. Hence, in addition to reduced nutrients being available for growth of 
C. difficile, production of growth-inhibitory substances from probiotic 
metabolism could have contributed to the inability of C. difficile to establish 
(Fredua-Agyeman et al., 2017). In this scenario, the pathogenic species, E. 
coli, had an established population before probiotic growth began yet, total 
elimination of E. coli was observed after 48 hours. This brings a new dimension 
to probiotic activity in that, most of the recommendations of probiotics are as 
preventive therapies, however, in instances where an infection is already 
established there could be a potential of using probiotics as effective means of 
eliminating some pathogenic species.  
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3.5 Conclusion 
After demonstrating the null effect of ink jetting on bacterial cell viability in the 
previous chapter, the potential of ink jetting in formulating probiotics on-
demand was explored in this chapter. With several studies confirming reduced 
viability in some commercial products and even total absence of viable 
organisms in certain products; this model will allow clinicians to formulate their 
own probiotics for trials. The ease of formulation will also promote further 
research and development in probiotic science and aid verification of some of 
the health claims attributed to probiotics.  
The bio-inks used in ink jetting were formulated using 10% trehalose or 10% 
sucrose as excipients to protect the bacterial cells from dehydration. Both 
sugars proved beneficial, with higher bacterial loading and bacterial viability 
over 7 days relative to a control with no sugar. These cells were ink jetted onto 
starch paper as a substrate which was also found to serve as an additional 
nutrient source for these probiotics.  
An evaluation of the ink jetted formulation to gastrointestinal fluids revealed a 
lack of tolerance to gastric acid despite, the model probiotic organism being a 
lactobacillus. To overcome this, the probiotic species were encapsulated in 
Phloral® coated capsules for delivery into the lower small intestines and colon. 
The Phloral® -encapsulated probiotics could withstand 30 minutes in 0.1 M 
hydrochloric acid and subsequent 2-hour transfers into pH 6.8 and 7.4 with 
viable bacterial obtained after capsule dissolution. To further evaluate probiotic 
properties of the formulation, the ability of ink jetted probiotic to adhere to 
intestinal cells was demonstrated with 78.3% of delivered organisms adhering 
to Caco-2 cells.  
The antibacterial property of the probiotic formulation was evaluated against 
E. coli. It was observed that although E. coli was a relatively faster growing 
organism compared to L. acidophilus, when co-incubated, no E. coli colonies 
were obtained upon plate counting. This demonstrated the potential of using 
probiotics not only as preventive remedies but the possibility in treatment.  
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Chapter 4 Probiotic Oral Films 
4.1 Introduction 
The oral cavity is anatomically connected to the nasopharynx, the larynx, the 
tonsils, the middle ear through the Eustachian tube, and the gastrointestinal 
tract. Therefore, it influences, and is influenced by, general human health 
(Teughels et al., 2011). The mouth is continuously washed with saliva, 
producing warm (35 – 36 °C) and moist conditions with a pH range of 6.75 – 
7.25, which favours microbial growth (Marsh, 2003). The oral cavity is a 
complex ecosystem of rich and diverse microbiota. These organisms have 
differing nutritional, atmospheric, and physicochemical (pH) requirements 
which influence the composition of the microbiota. Other parameters like 
shedding and non-shedding surfaces, salivary, and crevicular fluids also 
influence composition; homeostasis is, however, often attained in the healthy 
host. These organisms are usually present either in the planktonic state or 
integrated into biofilms (Caglar et al., 2005, Bizzini et al., 2012). Various 
lactobacilli and a few bifidobacteria and Streptococcus strains have been 
shown to inhabit the healthy mouth (Hojo et al., 2007, Rastogi et al., 2011).  
The normal microbiota is recognised to protect the oral cavity from infections 
(Haukioja, 2010). Infections and diseases of the oral cavity constitute some of 
the commonest and costly forms of human infections. In the UK, the National 
Health Service spends over £1.6 billion per annum on dental treatment (Marsh, 
2003). These usually occur due to changes in the resident oral microbiota 
resulting in the dominance of potential pathogens. Dental caries and 
periodontal diseases are globally considered the most important oral health 
problems (Caglar et al., 2005, Bizzini et al., 2012). Dental plaque – a biofilm of 
microorganisms on the tooth surface – is an aetiological factor in the 
development of these oral diseases (Dhawan and Dhawan, 2013). 
Dental caries is one of the most prevalent chronic diseases worldwide and 
individuals are susceptible to this throughout their lifetime. Streptococcus 
mutans has been identified as the main causative organism; Streptococcus 
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sobrinus is also known to be a causative agent in some instances. In dental 
caries, the production of organic acid together with rapid sugar metabolism 
results in a low pH environment and eventual demineralisation of the tooth 
structure. Inhibiting colonisation of S. mutans is reported to have a role in 
preventing the formation of dental plaque and development of dental caries 
(Dhawan and Dhawan, 2013, Yao and Fine, 2014, Bizzini et al., 2012, Cagetti 
et al., 2013). 
Periodontal disease is a chronic, inflammatory disease affecting the supporting 
structures of the teeth. It results from bacterial infections and may cause bone 
loss, bleeding and erythema of the gingival tissue, and mobility of the teeth. 
Periodontal disease may at times be preceded by inflammation of the gums 
(gingivitis). Periodontal diseases in comparison with caries has less 
information available regarding the effects of beverages/foods on disease 
aetiology (Marsh, 2003, Spratt et al., 2012, Yao and Fine, 2014, Yanine et al., 
2013).  
Another condition arising due to bacterial imbalance is halitosis, an unpleasant 
odour emanating from the breath which can significantly impact social 
interactions. Halitosis is not a disease but a discomfort, although some oral 
diseases including periodontitis may be the underlying cause. Oral 
microorganisms, especially those on the tongue and in periodontal pockets, 
are suspected to be the primary cause of halitosis and it can occur in all ages. 
Volatile sulphur compounds (e.g. hydrogen sulphide and dimethyl sulphide) 
which are by-products of metabolism by certain oral microorganisms are 
among the common malodourous substances released (Haukioja, 2010, 
Bizzini et al., 2012, Burton et al., 2005). 
The impact of these on individuals is significant, the pain and impairment of 
function accompanying dental caries and periodontal disease is considerable 
(Bizzini et al., 2012). The best approach to managing oral infections is to 
prevent initial occurrence. Good oral hygiene, a reduction in intake of sugary 
foods, and a stop to habits like smoking are ways to prevent the initial 
occurrence (Cagetti et al., 2013, Spratt et al., 2012). Traditional treatments of 
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oral diseases are considered very expensive (Bizzini et al., 2012). Other 
methods of treatment often involve mechanical removal (brushing, tongue 
cleaner, dental floss) of the bacteria/plaque with or without antibiotics (Yao and 
Fine, 2014). However, it is difficult to achieve complete eradication with most 
of these organisms repopulating quickly and recolonising the oral surfaces 
once antimicrobial use is stopped. These agents also stay in the mouth at 
effective doses only for a short period (minutes) and are mainly below MIC 
levels for prolonged periods (hours) (Cagetti et al., 2013, Marsh, 2003, Burton 
et al., 2005, Heinemann et al., 2013). Fluoride is also known to reduce 
occurrence in dental caries, although, it has limited ability when there is an 
infection (Caglar et al., 2005). Plant and fungal extracts like mushroom and 
chicory homogenates, and quinic acid (also found in mushrooms) have shown 
promising results as anti-caries or anti-gingivitis agents but require further 
studies to evaluate effectiveness (Spratt et al., 2012, Conti et al., 2013).   
An ecological approach to treatment has been proposed involving the 
administration of non-virulent bacteria (i.e. probiotics) to prevent recolonisation 
of these pathogenic species after antimicrobial therapy. These can also be 
adopted for use after rinsing with oral antiseptics, such as chlorhexidine. 
Treating oral infections by reducing the pathogenic bacterial population and 
facilitating a favourable environment that allows tooth remineralisation has 
been suggested to halt disease progression (Bizzini et al., 2012, Dhawan and 
Dhawan, 2013, Wescombe et al., 2012, Tagg and Dierksen, 2003). There are 
numerous commercial products that have probiotics incorporated in different 
formulations for promoting oral health. ProBiora3Ò from Oragenics – a probiotic 
mouthwash which contains Streptococcus oralis, Streptococcus uberis, and 
Streptococcus rattus – is reported to promote fresh breath, whiter teeth, and 
gum and tooth health. PerioBalanceÒ lozenges (which are reported to promote 
healthy teeth and gums, reduce plaque, and fight bad breath); KForce Breath 
GuardÒ mouthwash and lozenges; and various probiotic forms of BLIS K12 
utilise Streptococcus salivarius as the main probiotic organism (Yao and Fine, 
2014, Bizzini et al., 2012, Tagg and Dierksen, 2003). 
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The presence of sugars (e.g. sucrose and glucose) increases the risk of dental 
diseases like dental caries. Sugar alcohols especially xylitol, on the other hand, 
have been reported to suppress growth of S. mutans and in effect reduce risk 
of dental caries. Xylitol is a natural sweetener that can be found in foods as 
berries, fruits, vegetables and mushrooms. It, however, has minimal effects on 
the non-pathogenic species like S. salivarius and L. rhamnosus   (Ohshima et 
al., 2016, Cagetti et al., 2013, Marsh, 2003). Xylitol has been considered a 
prebiotic since it is non-fermentable by most oral bacteria. It also stimulates 
saliva secretion thereby aiding in the mineralisation or remineralisation of tooth 
structure  (Kojima et al., 2016, Leepel et al., 2009, Soderling, 2009).  
 
4.1.1 Probiotics and oral health  
Consumer interest in the possible preventive and health maintenance benefits 
of oral probiotics, as well as research into oral health claims, have led to an 
increased interest in the use of probiotics in oral health (Bowen, 2012, Marsh, 
2003). A balance between the beneficial and pathogenic bacteria determines 
the oral health of an individual. The mechanism by which probiotics act in the 
oral cavity is not well understood; it is assumed to be a result of 
immunomodulation as well as non-immunologic defence mechanisms that 
influence the development and stability of the microflora and inhibit 
colonisation by pathogens. Modification of the environmental conditions of the 
oral cavity via pH and/or oxidation-reduction potential is reported to prevent 
stain and plaque formation (Dhawan and Dhawan, 2013). Co-aggregation of 
certain lactobacilli has also been noted to prevent the formation of dental 
plaque. Development of strains which can colonise the oral cavity and stay 
there long enough to produce an effect is paramount in tackling oral infections 
(Twetman et al., 2009, Bizzini et al., 2012, Rastogi et al., 2011, Caglar et al., 
2005, Yao and Fine, 2014). The potential use of probiotics in the management 
of oral diseases may reduce the cost of conventional treatment. The idea of 
replacing pathogenic organisms in the mouth with non-harmful variants is 
considered attractive (Dhawan and Dhawan, 2013).  
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A few organisms have been used experimentally in oral probiotics evaluations. 
Chewing gums made with strains of L. reuteri ATCC 55730/ATCC PTA 5289 
have been shown to significantly reduce levels of S. mutans (Caglar et al., 
2009). L. rhamnosus GG and S. salivarius K12 are also common candidates 
used in oral probiotic formulations. L. rhamnosus strains are reported to offer 
oral health benefits. These have been used extensively as probiotics for 
improving the GIT. These are suggested to antagonise activities of cariogenic 
streptococcus species. L. rhamnosus GG is the most widely used strain 
(Meurman, 2005, Caglar et al., 2005). S. salivarius strains are among the early 
colonisers of the oral cavity and are usually present in high numbers 
throughout the lifetime of the healthy host, with various benefits at any given 
age as shown in Figure 4-1. Although S. salivarius is not normally considered 
a food supplement like other probiotics for improving the GIT; it has a safe 
profile (GRAS) and has been used mainly for consumer oral health products. 
Strain K12 is the most popularly used and thought to produce bacteriocins for 
protection against oral pathogens and throat infections (Wescombe et al., 
2012, Hale et al., 2012, Burton et al., 2005, Haukioja, 2010, Devine and Marsh, 
2009).  
 
Figure 4-1: Diseases that may be alleviated by S. salivarius probiotics and the ages at which 
they generally tend to manifest (adapted from Hale et al., 2012). 
A potential risk from probiotic use is the production of acid from metabolism of 
dietary carbohydrates which could increase the risk of caries formation; 
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however, with the right strain selection, this can be overcome. Also, 
consumption of probiotics with milk as a vehicle is suggested to reduce 
acidogenic properties of probiotics by the buffering action of milk (Meurman, 
2005). Benefits are also known to be derived from the calcium in the milk in 
strengthening teeth (Meurman, 2005, Cagetti et al., 2013, Bizzini et al., 2012). 
Xylitol has been used as a sweetener in chewing gums to prevent plaque 
formation. It has also proved beneficial in preventing biofilm formation. 
Although xylitol has proved to be effective in plaque control, in individuals with 
poor oral hygiene, there is reduced plaque control. Similarly, some strains of 
S. mutans have been reported to be resistant to otherwise effective xylitol 
amounts (Soderling, 2009, Badet et al., 2008).  
An ideal approach in the treatment of oral diseases is to deliver or apply 
formulation directly into the mouth and stay there for an extended period. Oro-
dispersible films are a delivery mechanism that can be used to achieve this. 
 
4.1.1.1 Probiotic oral films 
The use of oro-dispersible films (ODFs) for oral drug delivery is not a new 
concept. Drugs like rasagline mesylate and salbutamol sulphate, have been 
successfully formulated for oral delivery (Genina et al., 2013, Buanz et al., 
2011). There are several commercial products including ListerineÒ Pocket 
Pack/Breath Strips (mouth refresher containing essential oils) by 
Pfizer/Johnson & Johnson, Triaminic Thin StripsÒ (phenylephrine and 
diphenhydramine) by Novartis, prescription medications like SuboxoneÒ 
sublingual films (buprenorphine and naloxone) by Reckitt Benckiser 
Pharmaceuticals, and BreakylÒ Buccal films (fentanyl citrate) by Meda Pharma 
(Preis et al., 2015). 
ODFs allow for suitable delivery of actives in people with swallowing difficulties. 
ODFs, as a drug delivery mechanism, are attractive because they involve a 
cost-effective manufacturing process and are easy to use as a dosage form. It 
is also an innovative way of personalising medicines extemporaneously for 
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both local and systemic delivery. A major drawback is the low drug loading 
which makes ODFs suitable for low-dose and highly potent drugs  (Krampe et 
al., 2016, Preis et al., 2013, Buanz et al., 2015, Heinemann et al., 2013).  
Due to its impact on probiotic viability, it is necessary to impart as little stress 
as possible to these organisms during probiotic formulation. Ideally, a probiotic 
vehicle should be suitable for all ages since early exposure, in the case of 
babies, may facilitate permanent colonisation of health promoting strains 
(Singh et al., 2011). 
Solvent casting and hot melt extrusion (HME) are the main formulation 
approaches adopted; both require the drug to be mixed into the polymer matrix. 
Flexography, a contact printing method that uses rotating rollers to deposit the 
printing solution onto the substrate has also been explored (Krampe et al., 
2016, Buanz et al., 2015). A very high temperature accompanies HME, this 
can lead to a reduction in cell viability when used in formulating probiotics 
(Scarpa et al., 2017, Maniruzzaman et al., 2012). The contact with rotating 
rollers in flexography also has implications of potentially contaminating the 
ODFs. There is also a challenge of cleaning rollers after formulating which 
adds to making flexography an unattractive technique. The impact of organic 
solvents used in solvent casting on bacterial cells is a challenge with this 
technique in formulating probiotics. Although the solvents evaporate, residual 
solvent has been reported to be present (Krampe et al., 2016, Maniruzzaman 
et al., 2012).  
The possibility of formulating probiotic oral films using IJP for the treatment of 
oral infections was, therefore, explored. In addition to this method being a non-
contact technique, it has been proved not to damage bacterial cells in earlier 
chapters. This method has the advantage of tailoring ODF to patients’ needs, 
whether a combination of strains is needed or a probiotic-prebiotic 
combination. The phosphate ion solubilisation by probiotic strains was also 
evaluated. Phosphate plays a significant role in the susceptibility of teeth to 
caries progression and is needed for teeth mineralisation and remineralisation 
(Abou Neel et al., 2016). 
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4.2 Aims 
• To evaluate the suitability of starch paper as an oro-dispersible film 
substrate for printed medicines. 
• To evaluate the phosphate ion solubilising potential of selected probiotic 
strains. 
• To formulate oro-dispersible films of probiotic strains and xylitol. 
• To evaluate the potential of the ink jetted probiotic strains and xylitol in 
treating oral infections. 
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4.3 Materials and Method 
4.3.1 Growth media and reagents used 
Columbia blood agar, MRS (de Man, Rogosa, Sharpe) agar, nutrient agar, 
cooked meat medium, anaerobe basal broth, defibrinated horse blood, and 
mitis salivarius agar were from Oxoid, UK. Phosphate-buffered saline tablets, 
¼ Ringer’s solution tablets, and glycerol were purchased from Fisher 
Scientific, UK. Trehalose, xylitol, and glucose were from Sigma-Aldrich, UK. 
Bacitracin was from the Wellcome Trust, UK. 
 
4.3.2 Organisms 
The microorganisms used were Streptococcus salivarius NCTC 8618, 
Streptococcus mutans NCTC 10449, and Lactobacillus rhamnosus NCIMB 
30174.  
 
4.3.3 Culture stock preparation 
S. salivarius and S. mutans were grown on Columbia blood agar supplemented 
with 5% defibrinated horse blood (CBAhb) and incubated under anaerobic 
conditions for 48 hours at 37 ºC. A few colonies were taken and used to 
inoculate 7 ml of anaerobe basal broth supplemented with 5% horse blood to 
create a starter culture and incubated for 24 hours. 99 ml of fresh anaerobe 
basal broth supplemented with 5% horse blood was inoculated with 1 ml of the 
starter culture to create a 1: 100 dilution and this was incubated for 24 hours. 
The culture was then mixed using a magnetic stirrer to ensure homogeneity 
and dispensed into falcon tubes. Centrifugation was done at 9500 rpm and 4 
ºC for 10 minutes to harvest the cells after which the supernatant was removed 
carefully by suction. The cells were washed with phosphate-buffered saline 
and centrifuged at 9500 rpm and 4 ºC for 10 minutes. The supernatant was 
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removed by suction and the washing process repeated. The cells were 
resuspended in ¼ Ringer’s solution made up with 15%v/v glycerol acting as a 
cryoprotectant. The bacterial cultures were mixed continuously using a 
magnetic stirrer and 1.8 ml of the culture was rapidly dispensed aseptically into 
2 ml cryovials (Nunc). Sealed vials were immersed gently into liquid nitrogen 
for 10 minutes after which the frozen vials were removed and stored in a 
freezer at – 80 ºC. Post-freezing enumeration was 106 CFU/ml for both 
species. 
L. rhamnosus was prepared for storage using same media and procedure for 
L. acidophilus as documented in section 2.3.4. 
 
4.3.4 Substrate characterisation 
Potato starch paper (Lakeland, UK) was used as the substrate. Substrate 
characterisation involved determining its thickness, disintegration, and 
topography using scanning electron microscopy.  
 
4.3.4.1 Substrate thickness 
The thickness of substrates (n=5) was measured using a digital micrometer 
(Fowler, USA). 2 cm x 2 cm substrates were used and the readings taken from 
the four corners and the centre.  
 
4.3.4.2 Disintegration testing 
A method used by Garsuch and Breitkreutz, (2010) was adopted here. The 
substrate (2 cm x 2 cm) was placed in a petri dish containing 2 ml of distilled 
water. The gelation times of the films (n=5) were recorded as the disintegration 
time. 
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4.3.4.3 Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) was used to observe the topography of 
the starch paper. The samples were prepared by sputter coating with gold for 
3 minutes (Quorum model Q150). The images were then obtained with the 
scanning electron microscope (SEM, Quanta 200 FEG, FEI, Netherlands).  
 
4.3.5 Phosphate ion solubilisation assay 
Phosphate ion solubilisation was assessed using in-house prepared 
Pikovskaya agar plates. 10 µl of exponentially grown culture was spot-
inoculated on plates and incubated at 37 °C for 14 days. L. rhamnosus and S. 
salivarius were the organisms tested and S. mutans was used as a positive 
control. The composition of the prepared Pikovskaya agar is indicated in Table 
4-1. 
Table 4-1: Pikovskaya medium composition in 1L 
Ingredient Quantity (g) 
Glucose 10 
Tricalcium Phosphate 5 
Ammonium sulphate 0.5  
Yeast extract 0.5 
Sodium chloride 0.2 
Potassium chloride 0.2 
Magnesium sulphate heptahydrate 0.1 
Manganese sulphate monohydrate 0.002 
Ferrous sulphate heptahydrate 0.002 
Agar 20 
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4.3.6 Optimum concentration of xylitol against S. mutans 
A stock solution of xylitol was prepared. Different volumes were added to 
cooked meat medium supplemented with 2% w/v glucose (CMMg) to give final 
xylitol concentrations of (0.1, 0.5, 1, 5% w/v) in sterile 3 ml calorimetric glass 
ampoules. Thawed culture of microorganisms (S. salivarius and S. mutans) 
were then inoculated separately – 30 µl of 106 CFU/ml – into these ampoules. 
The ampoules were sealed with crimped caps and vortexed for 10 seconds. 
Calorimetric readings were taken afterwards. 
4.3.6.1 Ink jetting optimum xylitol concentration 
Based on the results from section 4.3.6, 0.5% xylitol solution was chosen as 
the optimum xylitol concentration that inhibited S. mutans but was tolerated by 
S. salivarius. The amount of xylitol that had to be ink jetted onto acetate paper 
to give a concentration of xylitol equivalent to 0.5% xylitol solution in a 3 ml 
ampoule was determined. A calibration curve between 0.5 mg/ml and 30 mg/ml 
was obtained using HPLC. A stock solution of xylitol (0.5 g/ml) was prepared 
and used to deposit templates of varying dimensions onto acetate paper. The 
print-outs were then carefully cut and immersed in 1 ml deionised water to 
dissolve the xylitol. The xylitol solution was vortexed to ensure complete 
dissolution after which HPLC analysis for xylitol as described in the USP was 
conducted. 
The liquid chromatographic system used was Agilent Technologies 1200 
series with quaternary pump and degasser. The column used was a 
Phenomenex SCX column (250 mm x 4.60 mm, 5 µm). The mobile phase 
consisted of water: acetonitrile mixture (80:20) with a flow rate of 0.5 ml/min. 
A column temperature of 80 ⁰C and wavelength of 192 nm were used for 
detection. Each assay was run for 10 mins. 
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4.3.7 Evaluating recovery of S. salivarius from oral films  
Frozen cells were thawed in a water bath at 40 °C for 3 minutes. 3 vials were 
concentrated together to give 107 CFU/ml. The bio-ink was then made by 
suspending this population (1 in 10) in either PBS (control) or 10% trehalose. 
A rectangular template (2 cm x 15 cm) was used for ink jetting onto edible 
starch paper. 
Calorimetry was conducted by carefully inserting the imprinted starch paper 
into sterile 3 ml calorimetric ampoules filled with 3 ml of pre-warmed (37°C) 
CMMg. The ampoules were then hermetically sealed by crimping and vortexed 
for 10 seconds. Calorimetric readings were then taken for 20 hours. 
 
4.3.8 Evaluating antibacterial properties of S. salivarius and xylitol 
formulation 
The antibacterial property of the probiotic formulation was investigated against 
S. mutans and monitored using calorimetry with CMMg used as the growth 
medium. A power-time curve of S. mutans (104 CFU/ml) co-incubated with ink 
jetted L. acidophilus (2 cm x 15 cm) and xylitol (2 cm x 16 cm) formulation was 
obtained. Post-calorimetry plating was conducted after 24 hours using mitis 
salivarius agar and mitis salivarius agar supplemented with 15% sucrose and 
0.2 i.u of bacitracin per ml were used to differentiate between the streptococci. 
As a reference, pure cultures of both species were streaked onto both media 
to confirm selectiveness. 
A cell-free supernatant (CFS) of S. salivarius was obtained and used in the 
antibacterial evaluation. CFS was obtained by incubating ink jetted S. 
salivarius in CMMg for 5 days. This was then centrifuged at 9500 rpm and 4 
ºC for 10 mins, the supernatant was then decanted and filtered using 0.22 µm 
diameter filters to obtain the CFS. Varying volumes of the CFS were added to 
ampoules containing CMMg inoculated with S. mutans and the calorimeter 
used to monitor growth.  
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4.3.9 Evaluating tolerance of S. salivarius to artificial saliva 
Artificial saliva was prepared using the recipe for GlaxoSmithKline’s (GSK) 
standard in-house saliva formulation (Table 4-2). The pH was adjusted to 7 
and sterilised by filtration using a membrane filter of 0.22 μm pore size. 
A 2 cm x 15 cm template was used to deposit S. salivarius (107 CFU/ml) onto 
potato starch paper and suspended into 5 ml artificial saliva for 2 hours at 37 
°C. Vortexing was done for 30 seconds before and after incubating. 30 µl of 
the resultant artificial saliva mix was added into 3 ml sterile glass ampoule 
containing CMMg. The ampoules were then hermetically sealed and vortexed. 
Calorimetric readings were taken afterwards for 20 hours. A purity plate was 
set up for each experiment by taking a loopful of culture and streaking out onto 
an CBAhb plate. 
 
Table 4-2: Recipe for artificial saliva (GSK's standard in-house formulation) 
Ingredient Quantity (g) 
Sodium chloride 0.175 
Potassium chloride 0.100 
Calcium Chloride 0.100 
Distilled water 100 
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4.4 Results and Discussion  
4.4.1 Substrate characterisation 
The ODFs presented a mean thickness of 160 ± 3 µm and were very porous 
as shown in Figure 4-2. This value, however, did not meet the suggested 70 
µm thickness reported to be suitable for consumers (Garsuch and Breitkreutz, 
2009). The starch paper was chosen based on it being edible and to 
demonstrate the recovery of organisms after ink jetting onto a substrate.  
For the 5 films tested, the gelation time ranged between 35 to 80 seconds. As 
there is no official test for evaluating disintegration of films, the method used 
by Garsuch and Breitkreuz, (2010) was adopted. Observation of gelation time 
was, however, found to be quite subjective since films did not dissolve. This 
approach will be most suited for fast dissolving films. 
 
 
Figure 4-2: Electron micrograph of starch paper used, showing its porous nature. 
All the tests were done with the plain potato starch with no organisms 
deposited. Since the organisms will be deposited onto substrate rather than 
incorporated into the film forming matrix the properties of the plain substrate 
will be similar to that of the ink jetted substrate (Buanz et al., 2015). 
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4.4.2 Phosphate solubilisation assay  
After incubating organisms on Pikovskaya agar plates under anaerobic 
conditions for 14 days, a phosphate-solubilising organism presents a 
halo/clear zone around the site of inoculum. This was observed for both L. 
rhamnosus and S. mutans whilst no halo was observed for S. salivarius (Figure 
4-3 - Figure 4-5). Pikovskaya medium is used in soil microbiology to evaluate 
phosphate solubilisation of by soil microorganisms (Goteti et al., 2014, Kumar 
Meena et al., 2015).   
 
 
 
Figure 4-3: Image after incubating S. salivarius on pikovskaya agar with no visible halo after 
incubation. 
 
   179 
 
Figure 4-4: Image after incubating L. rhamnosus on pikovskaya agar showing a visible halo 
after incubation.  
 
 
 
Figure 4-5: Image after incubating S. mutans on pikovskaya agar showing a visible halo after 
incubation.  
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A very important, yet omitted, test in most oral probiotics evaluation is the 
phosphate ion solubilising potential of probiotic organisms. Phosphate is an 
important ion needed for teeth mineralisation and remineralisation, and plays 
a significant role in the susceptibility of teeth to caries progression. The teeth 
are also comprised of a phosphate-based mineral, apatite, in the enamel and 
dentine (Abou Neel et al., 2016). Any activity that results in the decrease in 
phosphate amounts has implications on teeth integrity and should not be used 
for oral treatment or be used with caution.  
S. mutans, the primary organism that causes dental caries is a known 
phosphate-solubilising organism. This was, therefore, used as a positive 
control in the evaluation of the two probiotic candidates being evaluated. 
Incubation was done for 14 days since maximum solubilisation would have 
occured during this period (Goteti et al., 2014). After incubation, it was 
observed that both S. mutans and L. rhamnosus had halos indicative of 
phosphate solubilisation whilst S. salivarius did not. The L. rhamnosus strain 
was, as a result, not used for the further formulation of ODFs. This, however, 
does not mean L. rhamnosus is not a suitable candidate for oral formulations. 
As with most probiotics, this activity may be limited to the NCIMB 30174 strain. 
 
4.4.3 Optimum concentration of xylitol against S. mutans 
The effect of varying xylitol concentration on growth and metabolism of S. 
salivarius and S. mutans are shown in Figure 4-6 and Figure 4-7 respectively. 
The AUCs which give an indication of the cumulative heat output are also 
represented in Figure 4-8 and Figure 4-9 for S. salivarius and S. mutans 
respectively. It was observed that increasing xylitol concentrations to 1% did 
not have any significant impact on S. salivarius metabolism. Peaks of similar 
characteristics were obtained for concentrations used except 5% xylitol. A 
different scenario was observed for S. mutans, xylitol concentrations as low 
0.1% were enough to result in delayed metabolism, concentrations of 0.5% 
resulting in the very inhibited onset of metabolism.  
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Figure 4-6: Effect of varying xylitol concentrations on S. salivarius metabolism. 
 
Figure 4-7: Effect of varying xylitol concentrations on S. mutans growth. 
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Figure 4-8: Cumulative heat output representative of total AUC for S. salivarius under 
varying xylitol concentrations. 
 
 
Figure 4-9: Cumulative heat output representative of total AUC for S. mutans under varying 
xylitol concentrations. 
Based on these results, investigations were carried out to print an amount of 
xylitol onto a substrate that will present the same effect as 0.5% xylitol 
concentration in a 3 ml ampoule. With 0.5 % being equivalent to 15 mg xylitol 
in 3 ml. A calibration curve, Figure 4-10, was obtained for xylitol in the range 
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0.5 to 32 mg/ml using HPLC.  Varying template dimensions as indicated in 
Table 4-3 were used to deposit the xylitol concentrations. These dimensions 
were chosen as the amount deposited with these dimensions still maintained 
substrate integrity with no break in the substrate. After obtaining the AUCs as 
indicated in Table 4-3, the AUC that was approximately similar to that of 15 
mg/ml as computed in Equation 4-1 was determined. It was observed that 2 
cm x 16 cm was the dimension with AUC (2830.20 ± 16.46) closest to 2369.70 
representing 15 mg/ml. Hence, this dimension was used to deposit xylitol 
solution for co-incubation with S. mutans in the calorimeter.  
 
 
 
 
Figure 4-10: Calibration curve for xylitol in the range 0.5 to 32 mg/ml 
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Table 4-3: Varying template dimensions used for ink jetting xylitol and corresponding AUC 
(n=3) 
Template Dimension (cm x cm) AUC  
1 x 1 149.10 ± 19.98 
1 x 2 277.00 ± 29.09 
1 x 4 434.87 ± 20.46 
1 x 8 802.13 ± 2.42 
1 x 16 1540.40 ±  14.68 
2 x 1 275.20 ± 7.88 
2 x 2 495.00  ±  12.13 
2 x 4 820.83  ±  17.29 
 
2 x 8 1574.60  ±  41.58 
2 x 16 2830.20 ± 16.46 
 
Equation 4-1: Expected AUC using calibration curve equation 𝑦 = 	157.98𝑥 𝑤ℎ𝑒𝑛	𝑥 = 15 𝑦 = 2369.7 
A signal similar to 0.5% xylitol concentration was obtained when the ink jetted 
xylitol was co-incubated with S. mutans (Figure 4-11). The AUC (Figure 4-12) 
obtained for S. mutans in the presence of the ink jetted xylitol was higher than 
in the presence 0.5% xylitol. Considering that the ink jetted xylitol had slightly 
more than 0.5% xylitol, it was expected to produce greater inhibition with a 
more delayed onset of S. mutans growth or slightly reduced peak intensity. 
This anomaly can be attributed to the fact that with the ink jetted xylitol, the 
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amount of xylitol available was based on release from the substrate as 
compared to the already available 0.5% pipetted xylitol control. Hence, 
although an amount equivalent to 0.5% xylitol was ink jetted, this amount was 
not available until substrate was completely disintegrated. 
Ink jetting of actives onto starch paper for ODF formulation is not a new 
concept. This substrate was used by Buanz et al. (2011) for personalising 
salbutamol. Xylitol is a sugar that has been reported to inhibit the growth of 
pathogenic organisms in the mouth whilst having minimal effects on the 
beneficial organisms. Xylitol, unlike most sugars (sorbitol, fructose, glucose) is 
a 5- carbon sugar and inhibits glycolysis in S. mutans because it is a non-
fermentable sugar (Ohshima et al., 2016, Cagetti et al., 2013, Marsh, 2003). 
Badet et al. (2008) reported on the importance of xylitol in preventing the 
formation of a multispecies biofilm and the relevance of using it for the 
prevention of oral diseases caused by dental plaque. 
 
 
Figure 4-11: Thermogram comparing metabolism of S. mutans in the presence of 0.5 % 
xylitol and ink jetted (IJP) equivalent. 
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Figure 4-12: Cumulative heat output of S. mutans in the presence of 0.5 % xylitol and ink 
jetted (IJP) equivalent. 
Aside its antibacterial properties xylitol is also known to stimulate secretion of 
saliva which helps in teeth mineralisation and remineralisation. Mineralisation 
is the process in which an inorganic substance precipitates onto an organic 
matrix, e.g., biological processes like the formation of hard connective tissues, 
such as bone, dentin, and cementum, in which collagen fibrils form a scaffold 
for a highly-organised arrangement of calcium phosphate crystals.  
Remineralisation is the restoration of minerals after removal from hard tissues. 
This makes xylitol a good additive in the formulation of ODFs for treating dental 
caries. Secretion of saliva can also dilute, neutralise, and buffer organic acids 
formed by biofilm microorganisms (Abou Neel et al., 2016, Hara and Zero, 
2010).  
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4.4.4 Evaluating recovery of S. salivarius from oral films  
To evaluate the recovery of S. salivarius using 10% trehalose as the excipient, 
thermograms, as shown in Figure 4-13, were obtained. The signal obtained 
had a slightly higher albeit similar shape of signal as control.  
 
 
Figure 4-13: Recovery of S. salivarius from starch paper using trehalose as protectant. 
The use of alternative non-cariogenic sweeteners is recommended for oral 
formulations. Trehalose is a natural sweetening agent with good taste and 
thermostable. As demonstrated in chapter 3, trehalose offers advantages to 
bacterial viability after ink jetting. In this scenario, sucrose was not used as a 
protectant due to its role in causing dental caries. Trehalose, however, is 
reported to prevent oral dryness and not to promote the occurrence of dental 
caries (Mori et al., 2010, Neta et al., 2000). Good recovery was obtained for 
the ink jetted S. salivarius as revealed by the thermograms. This suggested a 
high probability that the formulation will exhibit activity when administered. 
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Heinemann et al., (2013) demonstrated recovery of L. acidophilus or 
Bifidobacterium animalis subsp. Lactis from ODFs prepared by casting. With 
the potential of recovery demonstrated, ODF formulation consisting of both ink 
jetted S. salivarius and xylitol was the next objective.  
4.4.5 Antibacterial properties of S. salivarius and xylitol formulation  
To evaluate the usefulness of probiotic formulation – ODFs composed of ink 
jetted S. salivarius and xylitol –  in treating dental caries, it was co-incubated 
with S. mutans. Thermograms obtained, (Figure 4-14), showed that the signal 
obtained after co-incubating ODF had a relatively delayed onset and intensity 
in comparison to S. mutans and ink jetted S. salivarius. Plate counting post-
calorimetry (Figure 4-15) revealed a drop in S. mutans population albeit the 
relatively smaller peak. 
 
Figure 4-14: Thermograms of S. mutans (control), ink jetted (IJP) S. salivarius, and co-
incubation of probiotic oro-dispersible film (ODF) and S. mutans. 
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Figure 4-15: Colony plate counts of S. mutans control and S. mutans after co-incubating with 
probiotic ODF. 
The ODF was composed of two agents suggested to provide oral health 
benefits. Xylitol, as demonstrated in the earlier section, showed inhibition to 
the activity of S. mutans with little effects on S. salivarius. Hence, using an 
effective medium concentration of 0.5% xylitol (ink jetted) with S. salivarius, it 
was expected that a complemented antibacterial activity will be obtained 
against S. mutans. The signals obtained indicated reduced metabolic activity 
in the ampoule. Due to the similarities between individual signals for S. mutans 
and S. salivarius, it was difficult to match the nature of the peak obtained after 
co-incubation to either of the pure cultures. This highlighted a drawback with 
microbial calorimetry, especially, when species under investigation are closely 
related. 
Plate counting data was, therefore, used to ascertain nature of reaction 
occurring in the co-incubation tests. In this instance, a medium that 
differentiates between S. salivarius and S. mutans had to be used. Mitis 
salivarius (MS) agar supports the growth of streptococci, however, when 
supplemented with 15% sucrose and 0.2 i.u of bacitracin per ml (MSBS) it 
selects for growth of S. mutans (Liljemark et al., 1976, Staat, 1976, Kurasz et 
al., 1986). Pure cultures of both species were streaked and/or spread on MS 
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and MSBS agar as references for comparison. S. salivarius on MS agar 
showed large, pale-blue, mucoid colonies that were glistening in appearance 
(Figure 4-16). S. mutans on MS agar showed raised, convex, undulate, 
opaque, pale-blue colonies that were granular in appearance (Figure 4-17)  
(Hamada et al., 1979, Chapman, 1944). When pure cultures of both species 
were streaked on MSBS, no growth was observed for S. salivarius, however, 
characteristic colonies typical of S. mutans was obtained (Figure 4-18).  
    
Figure 4-16: Images of pure colonies of S. salivarius colonies after streaking (left) and plating 
(right) onto mitis salivarius agar. 
    
Figure 4-17: Images of pure colonies of S. mutans colonies after streaking (left) and plating 
(right) onto mitis salivarius agar. 
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Figure 4-18: Images after streaking pure colonies of S. mutans (left) and S. salivarius (right) 
onto MSBS agar. 
With these references, enumeration of S. mutans post-calorimetry was 
conducted on MSBS.  A drop in numbers from 7.9 to 5.04 Log CFU/ml was 
obtained post-calorimetry for S. mutans co-incubated with ODF in comparison 
to S. mutans control. Although there was not complete elimination of the S. 
mutans population, this was promising as it represented a 2.86 Log reduction. 
Generally, when comparing the bactericidal activity of antimicrobials against 
bacteria, a 3 Log reduction is considered to be a significant; the 2.86 Log 
reduction obtained here was, therefore, considered a positive outcome 
(Usacheva et al., 2014, Heffernan et al., 2013, Koh et al., 2013, Sun et al., 
2014).  
A streak out post-calorimetry onto MS agar as shown in Figure 4-19 revealed 
some large, pale-blue, glistening mucoid colonies characteristic of S. salivarius 
also present, however, enumeration was not possible due inability to select S. 
salivarius growth. This implied that S. salivarius was also present in the 
ampoule at the end of the experiment. 
S. mutans and S. salivarius could also have been differentiated using species 
specific PCR assays (Goh et al., 1997, Blaiotta et al., 2005). Species specific 
PCR assays of sodium dismutase genes was used by Blaiotta et al. (2005) to 
differentiate Staphylococcus carnosus and Staphylococcus simulans. The 
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same group used the technique to identify Staphylococcus equorum from 26 
different species of Staphylococcus (Blaiotta et al., 2004). Other approaches 
like the chaperonin 60 gene identification method and reverse checkerboard 
hybridisation were used by Goh et al. (1997) to identify bacterial isolates. 
 
 
Figure 4-19: Image after streaking out ampoule content post-calorimetry onto mitis salivarius, 
showing colonies representative of both S. mutans and S. salivarius. 
To further evaluate antibacterial properties, varying amounts of cell-free 
supernatant (CFS) from S. salivarius was incubated with S. mutans. 
Thermograms obtained, (Figure 4-20), showed a reduction in peak intensity 
with increasing amounts of CFS. This highlighted a reduction in the metabolism 
of S. mutans in the presence CFS from S. salivarius. It must be noted that 
increasing the volume of CFS did not imply a reduction in the growth medium 
available. The growth medium used here, cooked meat medium, unlike other 
media does not dissolve when formulated.  Hence, the same quantity of meat 
pellets was weighed into each ampoule for tests to ensure equal nutrient 
availability.  
Plate counts when conducted at 11 hours, representative of highest signal 
intensity and metabolic activity is showed in Figure 4-21. A gradual decrease 
in S. mutans population was observed with increasing CFS volume. 
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Figure 4-20 Thermogram of S. mutans in varying amounts of S. salivarius cell-free 
supernatant. 
 
 
Figure 4-21: Enumeration of S. mutans population at the highest signal intensity. 
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With probiotics reported to release materials with the ability to inhibit 
pathogenic species during metabolism, the motive of using CFS was to 
investigate any bacteriocin-like activity by the CFS from S. salivarius. 
Increasing the CFS volume was to serve as a means of increasing amounts of 
any bacteriocin-like substance that may be present then monitoring decrease 
in S. mutans numbers and metabolism with time. CFS from S. salivarius have 
been demonstrated to inhibit S. mutans activity and to play a role in preventing 
biofilm formation by S. mutans (Ogawa et al., 2011). In a similar approach, 
Fredua-Ageman et al., (2017) used varying amounts of freeze-dried CFS from 
L. acidophilus and Bifidobacterium lactis against Clostridium difficile. Amounts 
as high as 20-fold freeze-dried CFS from L. acidophilus and 5-fold freeze-dried 
CFS from B. lactis were needed to obtain complete inhibition. The quantity of 
CFS in this work was relatively minimal compared to the high amounts of CFS 
in their work which could be a reason complete inhibition was not obtained 
here. 
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4.4.6 Evaluating tolerance of S. salivarius to saliva 
Thermograms obtained after exposing ink jetted S. salivarius to saliva are 
shown in Figure 4-22, highlighting the tolerance demonstrated by these 
organisms to the artificial saliva. 
 
Figure 4-22: Thermogram obtain evaluating tolerance of S. salivarius to saliva. 
GSK’s recipe for artificial fluid was used in this instance. The European and 
US Pharmacopoeias do not describe artificial salivary fluids. Calls have been 
made for standardisation of artificial saliva that will guarantee a uniform release 
medium to enable comparative studies at different labs. Phosphate buffer at 
pH 6.0 has been used in the pharmacopoeias for dissolution tests of medicated 
chewing gums (Garsuch and Breitkreutz, 2009, Preis et al., 2013). This 
medium, as observed from the thermogram, was not expected to have any 
deleterious effects on S. salivarius. These organisms are naturally resident in 
the mouth constantly bathed with saliva as such the signals obtained were 
expected. The artificial saliva used also had a neutral pH, such pH is well 
tolerated by most organisms.  
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4.5 Conclusion   
The possibility of formulating ODFs using starch paper was evaluated in this 
chapter. Although this substrate served as a good material for deposition of 
probiotics, it had a thickness that is considered unsuitable for consumers. 
Starch paper has, however, been used as substrate in personalising a number 
of medicines. The use of probiotics in oral care applications is increasing, 
however, with information on oral probiotic formulation and supporting science 
being limited, it is paramount that any candidate chosen for such formulations 
should help alleviate dental diseases rather than contribute to them. The 
phosphate solubilisation test used here revealed L. rhamnosus (NCIMB 
30174) as a phosphate solubilising strain and should not be considered for oral 
probiotic formulation.  
ODFs made of S. salivarius and xylitol were prepared and this exhibited some 
potential in the management of dental caries. A reduction in S. mutans 
numbers was observed after co-incubating S. mutans together with ODFs 
made of S. salivarius and xylitol. The challenge in in-vitro evaluation evident 
here was due to these species belonging to the same genera limiting options 
available for differentiating. The model, however, can be adapted in 
formulating probiotic ODFs using a variety of probiotic organisms to investigate 
of other conditions like periodontal disease and halitosis. 
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Chapter 5 General conclusion and future work  
Inkjet printing is a technology anticipated to revolutionise personalised 
medicine and push the innovation portfolio by offering new paths in patient-
specific treatments. With the gradual shift in the paradigm of the 
pharmaceutical and healthcare industries from mass manufacture towards 
personalised medicine, 2D- or 3D inkjet printing could become an integral 
manufacturing platform. This can benefit the consumer by dispensing tailored 
medicines and give solutions to the pharmaceutical industry and pharmacies 
to meet the future needs of making customised medicines optimally at the point 
of care. Aside from customising medicines for consumers, printing 
technologies offer realistic opportunities for manufacturing APIs with poor 
solubility, which is an increasing challenge in the pharmaceutical industry. 
Good quality control and characterisation of printed systems as well as 
regulatory perspectives of flexible manufacturing, however, need to be outlined 
(Preis et al., 2015, Kolakovic et al., 2013, Scoutaris et al., 2016c).  
The printing technology as highlighted in this thesis is useful in research and 
product developments. Printer models especially, relatively older models can 
be easily modified and used for research. The HP 5940 inkjet used was 
modified with the robustness of the modified printer intact. With the right 
expertise, this printer can be further modified such that cartridge motion will 
not be limited to left-right motion but also a front-back motion can be 
incorporated. This will make this printer model useful in various areas of 
research. An assumption with thermal inkjet printers that was addressed was 
the fact that the high temperature involved in droplet formation in these printers 
can lead to damage of materials (both chemical and biological). With ink jetting 
of bacterial cells as a major theme throughout this work, bacterial viability after 
ink jetting was maintained after ink jetting was determined and found to be 
optimal. 
The potential of the modified printer in antimicrobial susceptibility testing (AST) 
was evaluated. With the WHO recently publishing a list of diseases for which 
new antibiotics are needed, it is important to preserve current classes of 
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antibiotics (WHO, 2017). One way of controlling antibiotic resistance is by rapid 
and easy means of performing antimicrobial susceptibility testing, which the 
model described in this work intends to address. 
The minimum inhibitory concentration values obtained using ink jetting were 
comparable to values obtained using standard broth microdilution methods. 
Promising results were obtained after treating L. acidophilus with some 
antibiotics. L. acidophilus was used here due to its GRAS status and the model 
being in a developmental stage. With basic functional parameters now defined, 
this model will be tried with other organisms that have the potential of causing 
diseases. Antibiotics from different classes with different modes of action must 
be tried as well. These tests will serve to further validate the designed model. 
Once validated, this model will offer a cost-effective automated means of 
performing antimicrobial susceptibility testing. 
The potential of the ink jetting technology in probiotic formulation was also 
explored. The potential of the ink jetting technology in aiding the formulation of 
probiotics for targeted delivery and probiotic oral films were explored. Interests 
in probiotics have been growing for some time now, several health benefits 
have been attributed to probiotics. One of such is directly linked to the earlier 
application the ink jet technology was put to, i.e., reducing antimicrobial 
resistance. With antibiotics having been in existence for over half a century, 
and bacteria continuously developing resistance to these; other options of 
addressing this menace are being explored with the use of probiotics as one 
of the alternatives. Probiotic science, however, falls short of adequate 
evidence-based results.  Two major reasons for this is the difficulty in 
maintaining product viability during formulation and a lack of adequate 
numbers reaching the intestines. An on-demand approach of formulation was, 
therefore, demonstrated whereby probiotics can be ink jetted and 
encapsulated using site-specific coating materials for delivery.  The site-
specific encapsulated ink jetted probiotic could withstand an exposure of 30 
minutes in 0.1 M HCl with a relatively higher viability as compared to complete 
loss of viability within 5 minutes for the unprotected organisms. Another 
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outcome from these sets of experiments was the fact that the assumption of 
lactic acid bacteria, especially the lactobacilli, being acid resistant may not be 
entirely true for all strains. The ease of this formulation approach will help 
propel probiotic science and increase consumer confidence in probiotics. 
Some areas that need further work include the exploration of other excipients 
that will optimise bacterial loading after ink jetting. Fat-based excipients need 
to be explored as these have been reported be beneficial in probiotic viability 
and transit through the GIT (Efiuvwevwere et al., 1999, Costa et al., 2000). 
The impact of these on improving the 30-minute tolerance to 0.1 M HCl need 
to be investigated. Although this is a model intended for extemporaneous 
product preparation with a short shelf-life, longer stability studies need to be 
conducted, the outcome of which might be beneficial in using this model in 
mainstream probiotic manufacture. Finally, rat models need to be used to 
evaluate the ability of this formulation approach in treating diseases and 
ascertain some of the health claims of probiotics. 
The use of probiotics in oral health is another area with great consumer 
interest. With inkjets having been utilised in the preparation of oro-dispersible 
films, the potential of formulating probiotic oral films was explored (Buanz et 
al., 2011). Probiotic ODFs made with S. salivarius and xylitol were used 
against S. mutans to ascertain the potential of inkjets in formulating probiotic 
ODFs and the ability of such a formulation in managing dental caries.  An area 
that needs to be explored further in this work is the ability of S. salivarius to 
colonise the mouth. There are lots of uncertainty about the ability of probiotics 
to colonise the mouth. This has led to some researchers suggesting oral 
probiotic be incorporated in products as toothpaste which are used daily. In-
vitro colonisation needs to be evaluated using adhesion to hydroxyapatite 
beads; rat models can then be used to evaluate potential colonisation in 
animals. Animal models will also help understand the mechanisms of action of 
probiotics in the mouth, especially, the suggested role of probiotics in oral 
immunity. The ability of probiotic ODFs to disrupt pre-existing biofilms of the 
target organisms is worth investigating (Cagetti et al., 2013, Spratt et al., 2012, 
Twetman et al., 2009).   
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An important assay highlighted in this work is the phosphate solubilisation 
ability of the probiotic organism. This helps assess the risks and benefits of 
potential probiotic organisms and should be recommended for all probiotic 
ODFs. With the increasing evidence that the use of probiotics can deliver oral 
health benefits, it is important to emphasise that the production of ODFs that 
contain probiotic bacteria is a viable technology – a view shared by Heinemann 
et al., (2013). Other commercial film forming materials need to be investigated 
and inkjets can be useful equipment in the production of probiotic ODFs.  
Probiotics, in general, have massive potential in medicine, care must, 
however, be taken in subjects who are immunocompromised as there have 
been some cases of bacteraemia associated with probiotic use in such 
individuals (Devine and Marsh, 2009). 
The ink jetting technology has been demonstrated both as an analytical and 
formulation tool in this thesis. With further research using inkjets, many 
potential applications will be discovered that will aid the advancement of 
science and quality of life.  
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